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Abstract 
        Hematopoiesis is the process of formation of fully differentiated blood cells from 
hematopoietic stem cells (HSCs). This process is tightly controlled by the integration of 
developmental and homeostatic signals to ensure the generation of an appropriate number of 
each blood cell type. At the molecular level, the regulation of this developmental process is 
mediated by a number of transcription factors, especially by members of the RUNX family, 
and mutations affecting these factors are at the origin of numerous hemopathies, including 
leukemia. Intriguingly, many transcriptional regulators and signaling pathways controlling 
blood cell development are evolutionarily conserved from humans to Drosophila 
melanogaster. Hence, the fruit fly has become a potent and simplified model to study the 
mechanisms underlying the specification of blood cell lineages and the regulation of blood 
cell homeostasis. 
 
        Members of the Myeloid Leukemia Factor (MLF) family have been implicated in 
hematopoiesis and in oncogenic blood cell transformation, but their function and molecular 
mechanism of action remain elusive. Previous work in Drosophila showed that MLF 
stabilizes the RUNX transcription factor Lozenge (LZ) and controls the number of LZ+ 
blood cells. During my PhD, I sought to further decipher the molecular mechanism of action 
of MLF on Lozenge during blood cell development. 
 
        Using a proteomic approach in Drosophila Kc167 cells, we identified the Hsp40 co-
chaperone family member DnaJ-1 and its chaperone partner Hsc70-4 as two partners of 
MLF. These interactions were confirmed by co-immunoprecipitations and in vitro pull-
down assays. Importantly, we found that knocking down DnaJ-1 or Hsc70-4 expression in 
Kc167 cells caused a reduction in the level of Lozenge protein and a concomitant decrease 
in Lozenge transactivation activity, which were very similar to those caused by MLF knock-
down. Similarly, over-expression of two DnaJ-1 mutants that are unable to stimulate the 
chaperone activity of Hsc70-4 also decreased Lozenge level and impaired its capacity to 
activate transcription. These results suggest that MLF could act within a chaperone complex 
composed of DnaJ-1 and Hsc70-4 to control Lozenge stability and activity. Along that line, 
we showed by co-immunoprecipitation that Lozenge interacts with MLF, DnaJ-1 and 
Hsc70-4, respectively. Using various truncated mutants of MLF or DnaJ-1, we showed that 
MLF and DnaJ-1 interact and together with Lozenge through their conserved MLF 
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homology domain (MHD) and C-terminal region, respectively. Furthermore, in vitro GST 
pull-down assays suggested that the interactions between MLF, DnaJ-1 and Lozenge are 
direct. Thus, we propose that MLF and DnaJ-1 control Lozenge protein level by interacting 
with it and by promoting its folding and/or solubility via the Hsc70 chaperone machinery.  
 
        In parallel, we assessed DnaJ-1 function in Drosophila blood cells in vivo using a null 
allele of dnaj-1 generated by CRISPR/Cas9 technique. We found that, like mlf, dnaj-1 
mutation leads to an increase in the number and size of LZ+ blood cells, as well as to an 
over-activation of the Notch signaling pathway in these cells. Moreover, our data suggested 
that high levels of active Lozenge are required to control the number and size of LZ+ blood 
cells, and to down-regulate Notch expression. We propose that the MLF/DnaJ-1 complex 
controls LZ+ blood cell development in vivo by regulating Lozenge protein level/activity 
and thereby Notch pathway activation. 
 
        In sum, our results establish a functional link between MLF, the Hsp40 co-chaperone 
DnaJ-1 and the RUNX transcription factor Lozenge, which could be conserved in other 
species. 
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Résumé 
        L'hématopoïèse est le processus de formation des cellules sanguines différenciées à 
partir de cellules souches hématopoïétiques. Ce processus est étroitement contrôlé par 
l'intégration de signaux de développementaux et homéostatiques pour assurer une 
production équilibrée des différents types de cellules sanguines. Au niveau moléculaire, la 
régulation de ce processus est médiée par un certain nombre de facteurs de transcription, en 
particulier par les membres de la famille RUNX. Ainsi, des mutations affectant les membres 
de cette famille peuvent entrainer une déréglementation du programme de différenciation 
hématopoïétique et causer des hémopathies, dont des leucémies. D'une manière intrigante, 
de nombreux régulateurs de la transcription et des voies de signalisation contrôlant le 
développement des cellules sanguines sont évolutivement conservés des humains à 
Drosophila melanogaster, qui est donc utilisée comme organisme modèle pour étudier les 
mécanismes sous-jacents à la spécification des lignages sanguins et au contrôle de 
l'homéostasie des cellules sanguines. 
 
        Les membres de la famille Myeloid Leukemia Factor (MLF) ont été impliqués dans 
l'hématopoïèse et dans la transformation oncogénique des cellules sanguines, mais leur 
fonction et leur mécanisme d'action moléculaire restent insaisissables. Des travaux 
précédents chez la Drosophile ont montré que MLF stabilise le facteur de transcription de 
type RUNX Lozenge (LZ) et contrôle le nombre de cellules sanguines LZ+. Au cours de ma 
thèse, j’ai cherché à déchiffrer le mécanisme moléculaire d'action de MLF sur Lozenge dans 
les cellules sanguines. 
 
        Par une approche protéomique puis par des expériences de co-immunoprécipitation 
dans les cellules de Drosophile Kc167, nous avons identifié le co-chaperon de type Hsp40 
DnaJ-1, et son partenaire le chaperon Hsc70-4, comme deux partenaires de MLF. De façon 
importante, nous avons montré que l’inhibition de l’expression de DnaJ-1 ou de Hsc70-4 
dans les cellules Kc167 induit une réduction du niveau de protéine Lozenge et une 
diminution de sa capacité à activer la transcription très semblable à celles observées suite à 
l’inhibition de l’expression de MLF. De plus, la sur-expression de mutants de DnaJ-1 
incapables d’activer le chaperon Hsc70-4 entraîne aussi une réduction du niveau de Lozenge 
et de sa capacité de transactivation et des expériences de coimmunoprécipitation montrent 
que Lozenge interagit avec MLF, DnaJ-1 et Hsc70-4. Nos résultats suggèrent donc que 
MLF agit au sein d’un complexe chaperon composé de DnaJ-1 et Hsc70-4 pour contrôler le 
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niveau de Lozenge. En utilisant différents mutants de MLF ou DnaJ-1, nous avons montré 
que MLF et DnaJ-1 interagissent ensemble et avec Lozenge via des domaines 
phylogénétiquement conservés. D’autre part, des expériences de GST « pull down » in vitro 
suggèrent que ces trois protéines peuvent interagir ensemble directement. Nous proposons 
donc que MLF et DnaJ-1 contrôlent le niveau de protéine Lozenge en interagissant avec elle 
et en favorisant son repliement et/ou sa solubilité via l’activité chaperon de Hsc70-4. 
 
        En parallèle, nous avons étudié la fonction de DnaJ-1 in vivo dans le développement 
des cellules sanguines de la Drosophile. Nos résultats montrent que, comme mlf, la perte de 
dnaj-1 s’accompagne d’une augmentation de la taille et du nombre des cellules sanguines 
LZ+, ainsi que d’une hyperactivation de la voie de signalisation Notch dans ces cellules. Nos 
résultats suggèrent que des hauts niveaux de Lozenge sont nécessaires pour contrôler le 
nombre et la taille des cellules LZ+ et pour inhiber l’expression de Notch. Nous proposons 
que le complexe MLF/DnaJ-1 contrôle le développement du lignage LZ+ en régulant le 
niveau de protéine Lozenge, et ainsi le niveau d’activité de la voie Notch. 
 
        En conclusion, nos résultats ont mis à jour un lien fonctionnel entre MLF, le co-
chaperon de type Hsp40 DnaJ-1 et un facteur de transcription de type RUNX, qui pourrait 
être conservé dans d’autres espèces.  
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Foreword 
        Cancers are a large family of diseases that involve abnormal cell growth with the 
potential to invade or spread to other parts of the body. They have some common hallmarks, 
including continuous cell growth and division absent the proper signals, limitless number of 
cell divisions, avoidance of programmed cell death, and invasion of tissue and formation of 
metastases. It is estimated that there are over 100 types of cancers that affect human health, 
with signs and symptoms including a lump, abnormal bleeding, prolonged cough, 
unexplained weight loss and a change in bowel movements. Many factors could contribute 
to the emergence of cancers, such as tobacco use, which accounts for about 22% of cancer 
deaths, and obesity, poor diet, excessive drinking of alcohol, exposure to ionizing radiation, 
environmental pollutants. At the molecular level of pathophysiology, cancers are driven by 
progressive genetic or chromosomal abnormalities and epigenetic alterations. In genetic 
abnormalities, two broad categories of genes that regulate cell growth and differentiation are 
affected, which are oncogenes and tumor suppressor genes. Malignant transformation can 
occur through the formation of new oncogenes, the inappropriate over-expression of normal 
oncogenes, or the under-expression or disabling of tumor suppressor genes. Epigenetic 
alterations are functionally relevant modification to the genome, such as changes in DNA 
methylation, histone modification or changes in chromosomal architecture. They don’t 
change the underlying DNA sequence, but regulate the expression of some particular genes, 
for instance, DNA repair genes, whose reduced expression disrupts DNA repair. 
 
        Similarly, leukemia is a group of cancers that usually start in the bone marrow of 
human beings and other warm-blooded animals. It is characterized by an abnormal increase 
in the number of immature white blood cells in the tissues and often in the blood. According 
to how quickly the disease develops and which type of blood cells is affected, there 
provides a total of four most common types of leukemia, which are acute myeloid leukemia 
(AML), chronic myeloid leukemia (CML), acute lymphoid leukemia (ALL) and chronic 
lymphoid leukemia (CLL). Among them, acute myeloid leukemia is the most common 
malignant myeloid disorder in adults, which frequently results in hematopoietic 
insufficiency, such as anemia, thrombocytopenia and granulocytopenia and other 
symptoms. Chromosomal translocations, for instance, t(8;21) translocation in core-binding 
factor RUNX or t(3;5) translocation in myeloid leukemia factor, have been believed to be 
involved in the pathogenesis of AML. The t(8;21) translocation produces a fusion protein 
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RUNX1-ETO, and the t(3;5) translocation produces a fusion protein NPM1-MLF. Although 
the properties and function of RUNX1 have been studied extensively, the function and 
mode of action of MLF have been remained rather elusive. Recently, it was shown that 
MLF is a conserved regulator of RUNX transcription factor activity in a Drosophila model, 
which sheds a new light on the relationship between MLF and RUNX in AML as well as in 
other cancers 
 
        In this PhD thesis, I first made a brief introduction to the hematopoiesis in human and 
in Drosophila melanogaster and its associated three families of genes, which are RUNX, 
MLF and DnaJ families. Then I presented the results of my PhD project that is entitled 
Regulation of Lozenge transcription factor activity and blood cell development by MLF and 
its partner DnaJ-1. Finally, I discussed the significance of this study and made a 
perspective about the future research on this topic. 
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1. A general description of hematopoiesis and leukemia 
1.1. Hematopoiesis in mammals 
1.1.1. Ontogeny of the mammalian hematopoiesis 
        Blood is a bodily fluid in animals that delivers necessary substances to the cells and 
transports metabolic waste products away from those same cells, which is considered as one 
of the most highly regenerative tissues with approximately one trillion cells producing daily 
in adult bone marrow. It performs many important functions within the body, including 
supply of oxygen and nutrients to tissues, removal of carbon dioxide, immunological 
functions such as detection of foreign materials by antibodies, regulation of body pH and 
temperature, coagulation and so on. In vertebrates, blood is mainly composed of blood cells 
suspended in blood plasma. The cellular components of the blood can be roughly classified 
into three types, which are red blood cells (RBCs), white blood cells (WBCs) and platelets 
(Figure 1). These three highly specialized cell types are involved in gas transport, immune 
responses, and blood clotting, respectively. In a word, blood and its cellular components are 
essentially vital for human health and normal life, so it is of much significance to determine 
where these blood cells come from and how they are generated. 
 
        To answer these important questions, the concept of hematopoiesis would be 
introduced formally: hematopoiesis is the process of the generation and formation of 
appropriate numbers of fully differentiated blood cells, which is controlled by the 
integration of developmental and homeostatic signals (Orkin et al., 2008). In mammals, 
A                                                          B 
    
 
Figure 1. The cell types in blood  
(A) Blood is composed of red blood cells, white blood cells and platelets suspended in blood 
plasma. (B) A scanning electron microscope (SEM) image of a normal red blood cell, a platelet, 
and a white blood cell. 
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diverse types of blood cells are produced from rare hematopoietic stem cells (HSCs) that 
reside in adult bone marrow. This blood cell development occurs in at least two distinct 
waves in mammals, which are called primitive hematopoiesis for the first wave and 
definitive hematopoiesis for the second wave (Jagannathan-Bogdan et al., 2013). The 
primitive hematopoiesis takes place within the blood islands of the yolk sac (YC) at 
embryonic day 7.5 in the mouse (Figure 2.A) and gives rise to primitive erythrocytes, 
           A                  


           B 


Figure 2. A summary of the process of hematopoiesis in the mouse 
(A) Hematopoiesis occurs first in blood islands of the yolk sac (YS) and later at the aorta-gonad-
mesonephros (AGM) region, and fetal liver (FL) in the mouse. (B) The hierarchical tree model 
for the lineage commitment of hematopoietic stem cells (From Orkin et al., 2008). 
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megakaryocytes and macrophages (Dzierzak et al., 2008). The primary purpose of this 
primitive hematopoiesis is the production of erythrocytes that can facilitate tissue 
oxygenation as the embryos grow very rapidly (Orkin, 2000). This primitive hematopoietic 
wave is transient and it is rapidly replaced by the second adult-type wave of hematopoiesis. 
By contrast, the definitive hematopoiesis first occurs in the aorta-gonad-mesonephros 
(AGM) region during later embryonic development (Figure 2.A) with multipotent 
hematopoietic stem cells (HSCs) arising (Dzierzak, 1999). These definitive HSCs can give 
rise to all blood cell lineages of the adult organism and subsequently they migrate to the 
fetal liver and thymus as the embryo develops. At the end of fetal development, 
hematopoietic stem cells migrate to the bone marrow, which is the major site of postnatal 
hematopoiesis in adults. Of note, it is now established that some of the adult macrophages 
are derived from the primitive wave of hematopoiesis (Perdiguero et al., 2016). 
 
        HSCs in the bone marrow ensure continuous hematopoietic cell production throughout 
life thanks to their dual capacities: they have the capacity to self-renew to maintain their 
number, and the potential to differentiate into all cell lineages of the blood and immune 
system. HSC differentiation is a complex and dynamic hierarchical process (Figure 2.B) 
(Orkin et al., 2008). The hematopoietic stem cells first give rise to two distinct groups of 
multipotent progenitors: the common myeloid progenitors (CMPs) and the common 
lymphoid progenitors (CLPs). Then common myeloid progenitors further differentiate into 
megakaryocyte/erythrocyte progenitors (MEPs) and granulocyte/macrophage progenitors 
(GMPs). From these progenitors, committed precursors for the various lineages arise and 
can be further specified into diverse mature myeloid blood cells with different specific 
functions, including erythrocytes, megakaryocytes, granulocytes, monocytes/macrophages. 
Similarly, common lymphoid progenitors will give rise to B lymphocytes, T lymphocytes, 
and natural killer cells. 
 
        This hierarchical tree model assumes that hematopoiesis is usually governed by binary 
cell fate choices, in which the lymphoid system is completely separated from the myeloid 
system (Ceredig et al., 2009). However, some evidence suggests that under some special 
conditions, lymphoid progenitors retain their ability to give rise to myeloid lineage cells, 
and thymic progenitors have both lymphoid and myeloid potentials. So this separation may 
not be as absolute as thought earlier, and a need for new models is in demand. Some years 
ago, a simple pairwise relationships model of hematopoiesis emerged, which depicts 
 6 
hematopoiesis as a continuum of lineage relationships between hematopoietic stem cells and 
their oligopotent progeny (Ceredig et al., 2009). For instance, dendritic cells could be 
derived from both megakaryocyte-monocyte progenitors and B-cell-T-cell progenitors. This 
reflects that a final cell fate could be reached through more than one type of intermediate 
progenitor as well as the high complexity of the hematopoietic system. More recently, 
single cell-based gene expression profiling analyses have suggested a much revised version 
of the hematopoietic tree and have questioned the existence of several previously described 
‘common progenitors” (Moignard et al., 2016). Thus, although mammalian blood cell 
differentiation has been extensively studied and considered as a paradigmatic differentiation 
process, much remains to be discovered in this field.   
 
 
        In addition, a close relationship between vascular endothelium and hematopoietic stem 
cells during ontogeny provides us more insights into the origin of blood cells. It has been 
proposed that during primitive hematopoiesis, blood cell progenitors arise from 
hemangioblast, a common mesodermal progenitor for both endothelial and hematopoietic 
cells (Figure 3.). However, most recent studies rather suggest that it is a hemogenic 
endothelium (i.e. an endothelial cell that has the potential to give blood cells) that give rise 
to blood cell progenitors in the yolk sac and to definitive HSCs (Lacaud et al., 2017). For 
instance, in the aorta-gonad-mesonephros (AGM) region, the endothelium in the ventral 
wall of the aorta undergoes an endothelial to hematopoietic transition to produce HSCs. All 
together, the origin of hematopoietic development can be depicted as a single linear 
developmental process, which originates from mesoderm, through stages of hemangioblast 
and/or hemogenic endothelium, hematopoietic stem cells, multipotent progenitors, 
committed precursors, and finally mature blood cells (Cumano et al., 2007). 


Figure 3. Schematic representation of the progressive evolution of blood island 
mesodermal cells to a functional vascular network and primitive erythroid cells 
(From Cumano et al., 2007) 
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1.1.2. Functions of mature blood cells 
        The different mature blood cell types produced in the bone marrow then leave this 
hematopoietic organ and enter into the blood circulatory system, performing several 
specialized functions (Hartenstein, 2006; Orkin, 2000). 
 
        Erythrocytes (also called red blood cells) are the most common blood cell type and 
occupy 40% to 45% of the blood volume. In humans, mature erythrocytes look like small 
flexible and oval biconcave disks lacking nucleus and most organelles, but are rich in 
hemoglobin, an iron-containing protein that reversibly binds oxygen and greatly increases 
its solubility in blood. They take up oxygen in the lungs and deliver it to the body tissue via 
blood flow through the circulatory system. 
 
        Thrombocytes (also called platelets) are cytoplasmic fragments without nucleus that 
are derived from the megakaryocytes, giant and polyploid cells from the bone marrow. 
Their main function is to stop bleeding at the site of interrupted endothelium by clumping 
and clotting blood vessel injuries through the three steps of adhesion, activation and 
aggregation. 
 
        Granulocytes are a category of white blood cells that have a segmented nucleus with 
varying shapes and are packed with granules filled with a variety of enzymes in their 
cytoplasm. Distinguished by their appearance under Wright’s staining, granulocytes are 
classified into three principal types, which are neutrophils, eosinophils and basophils. These 
cells are professional phagocytes that are dedicated to the ingestion and destruction of 
bacteria and other pathogens invading the body, and they release their granule contents to 
these pathogens by exocytosis to help fight infection and inflammation.  
 
        Monocytes are mononuclear professional phagocytes like granulocytes that invade the 
tissue at the infection sites. They undergo further differentiation into macrophages that can 
divide and multiply at the needed sites. Macrophages respond to foreign materials (such as 
bacteria, protozoa or tumour cells) and phagocytose them. Besides their role in phagocytosis 
and thus in the innate immune response, macrophages process proteins of the pathogens to 
present them to T lymphocytes that help initiate the adaptive immunity. 
 
        Lymphocytes are one of the subtypes of white blood cells in a vertebrate immune 
system, including B-lymphocytes, T-lymphocytes and natural killer cells (NK cells). B-
lymphocytes and T-lymphocytes constitute the major cellular components of the adaptive 
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immunity while natural killer cells play a role in the cell-mediated cytotoxic innate 
immunity. B-lymphocytes are primarily responsible for humoral immunity and they respond 
to a specific pathogen by producing large quantities of antibodies that then neutralize these 
foreign substances. T-lymphocytes are involved in cell-mediated immunity and they 
recognize antigen/major histocompatibility complex (MHC) complexes presented by 
macrophages with the receptors on their surfaces, which triggers direct cytotoxic effects on 
the recognized infected cells. 
1.1.3. Genetic control of the mammalian hematopoietic system 
1.1.3.1. The hematopoietic niches 
        Based on numerous studies on hematopoiesis in mammals, including the successful 
detection of hematopoietic stem cells in the bone marrow of live mice using real-time 
imaging technology (Xie et al., 2009), it has been showed that there are two subpopulations 
of hematopoietic stem cells, one that is quiescent and the other that is more active. The 
decisions of hematopoietic stem cells to become quiescent or differentiate further are tightly 
controlled by their microenvironment that is termed as niche. The concept of the niche was 
first proposed in the late 1970s by Schofield who proposed that the fate of a blood stem cell 
itself is controlled by its interaction with other cells/a particular microenvironment 
(Schofield, 1978). The niche is composed of subsets of cells and extracellular substrates that 
can provide structural and trophic support as well as appropriate signals to regulate stem cell 
functions. This model gained solid experimental and conceptual support from Drosophila 
germ-line stem cell studies. Over the years, a body of experimental evidence revealed that 
there are three main niches regulating hematopoietic stem cells: the osteoblastic niche, the 
vascular niche and the perivascular niche (Nakamura-Ishizu et al., 2013). Osteoblasts that 
align bone surfaces (the osteoblastic niche) interact with hematopoietic stem cells in vivo 
and influence their functions notably through the activation of the Notch signalling pathway 
to maintain their long-term quiescence. The sinusoidal endothelial cells that align the lumen 
of sinusoid in the central bone marrow (the vascular niche) can express Notch ligand 
Jagged-1 and Jagged-2 to control the proliferation of hematopoietic stem cells, which is 
similar to the osteoblasts. Besides, two perivascular cell groups that possess mesenchymal 
cells properties also function as niche cells (the perivascular niche). A study on deletion of a 
chemokine Cxcl12 in mice revealed that hematopoietic stem cells occupy a perivascular 
niche whereas early lymphoid progenitors occupy an endosteal niche, suggesting different 
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stem and progenitor cells reside in distinct cellular niches in the bone marrow (Morrison et
al., 2014). 
         
        The osteoblastic niche and the vascular niche have different roles in the maintenance 
and differentiation of hematopoietic stem cells in mouse bone marrow, which might be 
related to oxygen availability. The osteoblastic niche is hypoxic, a low oxygen 
microenvironment essential for the maintenance and survival of hematopoietic stem cells 
and their protection from the harmful reactive oxygen species (ROS) accumulation
(Crozatier et al., 2011). Meanwhile, the distinct metabolic profile of hematopoietic stem 
cells also reflects their location in a hypoxic niche, which is revealed by the observation that 
long-term hematopoietic stem cells utilize glycolysis instead of mitochondrial oxidative 
phosphorylation to meet their energy demands. Notably, by regulating the response to 
physiological oxidative stress, the ataxia telangiectasia mutated (ATM) gene and the 
forkhead O (FoxO) gene play pivotal roles in the maintenance and survival of hematopoietic
stem cells in bone marrow (Morrison et al., 2014). Furthermore, similar to normal tissue 
stem cells, cancer stem cells (CSCs) in some tumours also contain low ROS levels and 
enhanced ROS defences, which may contribute to the resistance of tumours to radiation 
therapy. Therefore, the link between the survival of hematopoietic stem cells and ROS 


Figure 4. The model of ecological hematopoietic stem cell niche 
HSC homing, maintenance, and differentiation depend on their specific microenvironment (or 
niche). In the bone marrow, there are at least two major HSC niches, the vascular niche and the 
osteoblastic niche. In addition, there are growing indications that other types of cells. (From 
Shiozawa et al., 2012) 
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levels can improve our understanding of the resistance and therapy failure of tumours in the 
clinical treatments. However, different from the osteoblastic niche, the vascular niche 
probably has higher oxygen levels that could favour the proliferation and differentiation of 
hematopoietic stem cells. 
1.1.3.2. Lineages specific transcription factors and signaling pathways controlling 
blood cell differentiation 
        Genetic and molecular studies in a mouse model have uncovered several signaling 
pathways that are involved in the communication between hematopoietic stem cells and 
their niches as well as in the subsequent stages of blood cell proliferation and 
differentiation, such as Notch, Hedgehog, Wnt or JAK/STAT signaling pathways. Similarly, 
a plethora of transcription factors and co-factors are involved in the combinatorial 
transcriptional control of the self-renewal or lineage commitment of hematopoietic stem and 
progenitor cells, including GATA binding factor (GATA), Friend of GATA co-factors 
(FOG), runt-related binding factor (RUNX), or Early B-cell factor (EBF) (Orkin et al., 
2008). Notably, the development of differentiated blood cells involves a series of alternate 
cell fate decisions that are driven by the antagonistic activity of “lineage restricted” 
transcription factors. For example, during primitive hematopoiesis, the transcription factors 
GATA-1 and Pu.1 exhibit a cross-inhibitory relationship to regulate erythroid versus 
myeloid cell fate choice: the erythroid factor GATA-1 activates the erythroid program and 
inhibits myeloid cell fate by interacting with the myeloid factor Pu.1, and conversely, Pu.1 
activates the myeloid program and represses the erythroid cell fate (Cantor et al., 2002).  
 
        Interestingly, most of these transcription factors and signaling pathways are conserved 
through evolution and also control blood cell fate in other organisms, as shown by studies in 
Zebrafish or Drosophila (Hartenstein, 2006). Thus, studies in model organisms like 
Drosophila, which exhibit a simpler hematopoietic system and less genetic redundancy, can 
help to understand some important conserved aspects of the control of blood cell 
development.   
 
        Importantly, the deregulation of these transcription factors and signaling pathways that 
control normal blood cell development is often at the origin of blood cell cancer (and other 
hemopathies) in human (Orkin et al., 2008). Accordingly, a number of transcription factors 
or signaling pathways implicated in hematopoiesis are the targets of recurrent chromosomal 
translocations or of point mutations that alter (inhibit or activate) their functions. A better 
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understanding of the normal functions and mode of action of these genes is thus of utmost 
importance. 
1.2. Leukemia in human 
        Leukemia is a group of cancers that usually start in the bone marrow of human beings 
and other warm-blooded animals, which is characterized by an abnormal increase in the 
number of white blood cells in the tissues and often in the blood. These white blood cells 
are not fully developed and are called leukemic cells. Unlike normal blood cells, leukemic 
cells don’t die when they become old or damaged, so they can build up and crowd out 
normal blood cells. Due to the low level of normal blood cells, some typical symptoms will 
appear, including bleeding, bruising problems, feeling tired, fever and an increased risk of 
infections. So far, the etiology of leukemia remains unknown, but both inherited and 
environmental factors are believed to be involved in these malignancies. Some risk factors, 
including smoking, ionizing radiation, chemicals (such as benzene), prior chemotherapy, 
could contribute to leukemia. 
1.2.1. Classification of leukemia 
        Based on different criteria, leukemia can be subdivided into a variety of large groups. 
According to how quickly this disease develops, leukemia can be classified into acute 
leukemia and chronic leukemia clinically and pathologically. Acute leukemia usually 
develops quickly and is characterized by a rapid increase in the number of leukemic cells. 
This rapid progression and accumulation of leukemic cells, which then spill over into the 
bloodstream and spread to other organs of the body, out compete normal blood cells, 
making the bone marrow unable to produce healthy normal blood cells. Chronic leukemia 
usually develops slowly and is characterized by the excessive build up of relatively mature 
but still abnormal white blood cells. Typically, these cells are produced at a higher rate than 
normal blood cells, resulting in many abnormal white blood cells over months or years. It is 
often asymptomatic but if not treated, chronic leukemia can progress into a blast phase, 
which resembles acute leukemia. 
 
        In addition, according to which type of blood cells is affected, leukemia can be 
classified into myeloid leukemia and lymphoid leukemia, in which the leukemic cells are 
either derived from a myeloid or a lymphoid cell lineage, respectively. Combining these two 
classifications, one can distinguish four most common types of leukemia: acute myeloid 
leukemia (AML), chronic myeloid leukemia (CML), acute lymphoid leukemia (ALL) 
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and chronic lymphoid leukemia (CLL). And within each of these four main types, there 
are typically several subtypes. 
1.2.2. Acute myeloid leukemia 
        Acute myeloid leukemia (AML) is a heterogeneous clonal disorder of hematopoietic 
progenitor cells, which is the most common malignant myeloid disorder in adults. These 
hematopoietic progenitor cells are designated as AML blasts that have lost the ability to 
differentiate normally and to respond to normal proliferation regulators. AML is 
characterized by the infiltration of the bone marrow, blood and other tissues by clonal, 
proliferative, abnormally differentiated AML blasts of the hematopoietic system and the 
interference with the production of normal blood cells, frequently resulting in hematopoietic 
insufficiency, such as anemia, thrombocytopenia and granulocytopenia, and other 
symptoms including fatigue, shortness of breath and increased risk of infections. 
1.2.2.1. Classification of acute myeloid leukemia 
        As studies on AML progress, it is revealed that AML has several subtypes based on the 
diagnostic procedures, such as morphologic assessment of bone marrow specimens and 
blood smears, analysis of the expression of cell-surface or cytoplasmic markers, 
identification of chromosomal abnormalities or screening for selected molecular genetic 
lesions; subsequently, treatment and prognosis vary among these subtypes. There are two
common classification systems for AML according to different criteria, which are the 
French-American-British (FAB) classification and the World Health Organization (WHO) 
classification. The FAB classification system was introduced in 1976 and defines AML into 
eight subtypes that are from M0 to M7 based on the morphological and cyto-chemical 
characteristics of the leukemic cells (Löwenberg et al., 1999). The WHO classification 
system was introduced in 2001 and revised in 2008 and in 2016 and defines AML into six 
major subtypes (Table 1.) by incorporating genetic information with morphology, 
immunophenotype and clinical presentation (Kouchkovsky et al., 2016). These AML 
classifications provide useful information about the biology and clinical features of this 
malignancy, also are helpful for assessing treatment options to the patients with AML.





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1.2.2.2. Pathophysiology of acute myeloid leukemia
        AML is a highly heterogeneous disease that appears as a de novo malignancy. The 
abnormal proliferation and differentiation of a clonal population of myeloid stem cells are 
believed to be involved in the pathogenesis of AML. Recurrent chromosomal translocations, 
such as t(8;21) translocation in AML or t(15;17) translocation in acute promyelocytic 
leukemia (APL) as well as point mutations affecting key genes that control normal blood 
cell development, have been implicated in the development of AML (Rowley, 2009). 
 
        The most common targets of AML-associated chromosomal translocations are the 
genes encoding DNA-binding transcription factors or the regulatory components of 
transcriptional complexes, and the fusion proteins generated from these chromosomal 
translocations interfere with the functions of the wild-type proteins in a dominant manner. 
For instance, the RUNX transcription factor AML1 (Acute Myeloid Leukemia 1/RUNX1) 
and its heterodimerisation partner CBFβ, which regulate many hematopoietic-specific genes 
and are essential for the normal development of the hematopoietic system, are the target of 
the t(8;21) and inv(16) translocations, respectively, making this complex the most frequent 
target of chromosomal rearrangements in human leukemia (see below, 3.2.5) (Speck et al., 
2002). These mutations or translocations impair blood cell differentiation, but are not 
Table 1. WHO classification of AML and related neoplasms  
(From De Kouchkovsky et al., 2016) 
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sufficient to cause leukemia. It is usually considered that leukemia development requires a 
second mutation, which will give a growth advantage to the blood cells. These mutations 
often target components of signaling pathways controlling blood cell proliferation or 
survival such as c-Kit, Flt3 or Ras (Kelly et al., 2002). The cooperation between these two 
classes of mutations eventually leads to AML.  
 
        Of note, AML is often preceded by a pre-leukemic condition called “myelodysplastic 
syndrome” (MDS), a chronic disease that progresses to AML upon acquisition of new 
mutations. 
1.2.2.3. Current therapy of acute myeloid leukemia 
        The primary purpose of treating patients with AML is to induce remission and 
thereafter prevent relapse. Initially, intensive chemotherapy is the main treatment for 
patients with AML who can tolerate it, and additional chemotherapy or allogeneic 
hematopoietic stem cell transplantation could follow. The drugs used in treatments include 
cytarabine, anthracycline, gemtuzumab ozogamicin, and novel agents under test, such as 
sarafenib, midostaurin, quizartinib, crenolanib. 
 
        While much progress has been made in our understanding of the molecular nature of 
the events leading to AML and in the refinement of therapeutic strategies, this disease 
remains of bad prognosis. Thus a better characterization of the function and mode of action 
of the genes mutated in MDS and AML is of prime interest to be able to develop innovative 
therapeutic approaches. Besides the study of human blood samples or mouse models, simple 
genetic model organisms such as Drosophila can help not only to decipher the basic 
principles underlying blood cell development across species but also to better understand 
the mode of action of conserved genes implicated in AML. 
 
 
 
 
 
 





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2. Drosophila: a simplified model to study the mammalian hematopoiesis 
 
        Drosophila melanogaster is a species in the family Drosophilidae of the order Diptera, 
which has multifaceted brick red eyes, a tan thorax studded with arched black bristles, a 
striped abdomen and a pair of translucent wings (Figure 5.A). Since the serendipitous 
discovery of the white mutation and recognition of its linkage to the X chromosome by 
Thomas Hunt Morgan in 1910, D. melanogaster has been a central model organism in the 
study of transmission genetics, as well as the study of development, physiology and 
behaviour. This tiny insect has numerous practical advantages, such as rapid life cycle (ten 
days for one generation, Figure 5.B), low chromosome number, small genome size with 
low redundancy, easy and cheap stock management, convenient experimental manipulations 
and observations of cells and tissues, availability of a huge body of knowledge and a rich 
resource of genetic tools. The conservation of basic signalling pathways and key 
transcription factors controlling the development and functions of blood cells from 
Drosophila to human, makes D. melanogaster a simplified and interesting model to 
decipher the fundamental mechanisms governing hematopoietic system formation and 
homeostasis.  



 
  A                                                                              B 
  

Figure 5. Drosophila melanogaster and its life cycle 
(A) An adult Drosophila melanogaster. (B) At 25°C, fertilized females lay hundreds of eggs 
over several days and embryonic development lasts for ~21hr. 1st instar larvae take 2 days to 
molt into 2nd then 3rd instar larvae. 3rd instar larvae continue feeding for one more day and 
eventually pupariate (prepupa then pupa). 10 days after egg-laying, adult flies emerge from the 
pupal case. 
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2.1. Ontogeny of Drosophila hematopoietic system 
        Over the last several decades, due to its apparent simplicity, such as an open 
circulatory system, fewer blood cell types and significant similarities in blood cell 
development shared with mammals, Drosophila melanogaster has emerged as a powerful 
genetic model for studying the molecular process that controls hematopoiesis under normal 
conditions or in pathological situations (Letourneau et al., 2016). These studies notably 
highlighted how intricate cell communication networks and microenvironment cues regulate 
blood cell homeostasis and helped revealed the mode of action of key conserved regulators 
of hematopoiesis. 
 A                                                                                  B 
   
 C                                                                                  D 
  
Figure 6. Drosophila hematopoiesis during development  
(A) Overview of Drosophila hematopoiesis during development. (B) Embryonic hematopoiesis. 
(C) Larval hematopoiesis. (D) Adult hematopoiesis. (From Letourneau et al., 2016 (A, C); 
Bataillé et al., 2005 (B); Ghosh et al., 2015 (D)) 
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2.1.1. Embryonic hematopoiesis 
        Similar to the two waves of the vertebrate hematopoiesis, Drosophila hematopoiesis 
takes place in two spatially and temporally distinct waves (Figure 6.A). The first wave, 
which is often compared to the primitive hematopoiesis in vertebrates, occurs in the early 
embryonic development, when prohemocytes (or hemocyte/blood cell precursors) emerge 
from the head mesoderm (Figure 6.B). These cells are first identified during embryonic 
stage 5 by the expression of Serpent (Srp), a GATA transcription factor required for 
hematopoietic development (Rehorn et al., 1996). After four rounds of division, these 
hemocyte precursors stop proliferation and differentiate into either plasmatocytes or crystal 
cells. Upon maturation in the head mesoderm, the majority of plasmatocytes that account 
for 95% of all embryonic hemocytes migrate out of the head region under the influence of 
chemo-attracting signals along stereotypical routes (Letourneau et al., 2016). In contrast, 
crystal cells that account for 5% of all embryonic hemocytes generally remain localized as 
two groups of cells around the anterior part of the gut, which is near their point of origin in 
the embryo, and they will disperse subsequently during the larval stages. Totally, by the end 
of embryogenesis, the prohemocytes in the head mesoderm give rise to 600-700 
plasmatocytes and approximately 36 crystal cells. 
 
        These embryo-derived hemocytes populate the larvae where they can be found in two 
destinations. One fraction persists as patches of cells attached to the inner epidermis of the 
body cavity, which is designated as sessile hemocytes; the other fraction circulates in the 
hemolymph (the circulating fluid in the body cavity of Arthropods), which is designated as 
circulating hemocytes.  
 
        The molecular control of this embryonic hematopoiesis has been well characterized. 
Briefly, prohemocytes generation requires the pan-hematopoietic Serpent (Srp), a 
Drosophila homolog of human GATA transcription factors, which are also implicated in 
hematopoiesis. The activity of Serpent in the hemocytes is notably controlled by its 
corepressor U-shaped (Ush), a Drosophila homolog of human Friend of GATA (FOG) 
cofactor, which directly binds Srp to inhibit crystal cell fate choice and regulate 
plasmatocytes differentiation (Waltzer et al., 2003; Fossett et al., 2003). The lineage 
commitment of prohemocytes to plasmatocytes or crystal cells depends on the expression of 
the lineage-specific transcription factors Glide/Glial cell missing (Gcm and Gcm2) and the 
RUNX transcription factor Lozenge (Lz), respectively. Specifically, the expression of Gcm 
 18 
factors, together with Srp and Ush, leads to differentiation of prohemocytes into 
plasmatocytes. In contrast, Lz, a runt-domain protein that resembles human AML1/RUNX1, 
is required for the differentiation of hemocyte precursors into crystal cells. When Lz is 
expressed, the expression of Ush is suppressed and Srp and Lz cooperate to induce the 
differentiation of prohemocytes into crystal cells, similar to the cooperation of GATA and 
RUNX in vertebrates that controls several steps of blood cell proliferation and 
differentiation. How Gcm expression is controlled is unknown, but it has been suggested 
that Notch signalling pathway participates in the induction of Lz expression in the 
embryonic crystal cell lineage (Lebestky et al., 2003). 
2.1.2. Larval hematopoiesis 
        The second wave of Drosophila hematopoiesis, is initiated during the larval stages in a 
specialized organ, the lymph gland, which forms during embryogenesis and persists through 
the onset of metamorphosis. During the last two decades, the lymph gland has been a 
prevailing model to investigate the hematopoiesis process under normal conditions or in 
response to immune stress, since it is the dedicated Drosophila larval hematopoietic organ 
(Letourneau et al., 2016). Similar to the hematopoietic stem cell emergence in vertebrates, 
lymph gland cells derive from hemangioblast precursors specified in the late embryo. At 
that stage, the lymph gland precursors form a single pair of lobes that are localized along the 
dorsal vessel. This single pair of lobes only contains about 20 cells each, and they are 
designated as the primary lobes (or the anterior lobes). At the end of the first larval instar, 
additional pairs of posterior lobes also emerge along the dorsal vessel, which are designated 
as the secondary lobes (or the posterior lobes). So in third instar larvae, lymph gland is 
composed of a large pair of primary anterior lobes followed by several small pairs of 
posterior lobes, each separated by a pair of pericardial cells. The posterior lobes are mainly 
composed of prohemocytes, however, the primary lobes are organized into three domains: 
the cortical zone (CZ), the medullary zone (MZ) and the posterior signalling centre (PSC) 
(Figure 6.C). The peripheral cortical zone contains mature and differentiated hemocytes, 
whereas the central medullary zone contains quiescent prohemocytes. At the posterior tip of 
each primary lobe, a cluster of about 30 cells constitutes the posterior signalling centre 
(PSC), which acts as a niche-like structure that controls prohemocyte maintenance and 
lymph gland homeostasis. There is also a population of “intermediate progenitors” between 
the cortical zone and the medullary zone that express both some progenitors and early 
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differentiation markers. During the first two larval stages, lymph gland progenitors divide 
actively before entering quiescence and giving rise to plasmatocytes and crystal cells under 
normal conditions and to lamellocytes in response to immune challenges, such as wasp 
parasitism. During pupariation, the lymph gland disrupts and releases all hemocytes into the 
circulation. 
 
        Besides the lymph gland, there is also another site of hematopoiesis during the larval 
stages, which is called hematopoietic pockets or subepidermal and muscular pockets and 
has only been identified recently. In third instar larvae, sessile hemocytes, which are derived 
from the differentiated hemocytes of the embryo, are prevalent along the posterior region of 
the dorsal vessel and in close association with oenocytes on the lateral sides, where they are 
sandwiched between the epidermal and muscular layers. These so-called hematopoietic 
pockets, provide a specific microenvironment that attracts plasmatocytes and supports their 
survival, proliferation and differentiation (Makhijani et al., 2011). These sessile hemocytes 
can expand through self-renewal in differentiated state in third instar stage and increase 
their accumulation at the site of injury or in circulation under certain circumstances, such as 
starvation, wound inflammation. 
2.1.3. Hematopoiesis in adult Drosophila 
        Although the embryonic and larval hematopoiesis in Drosophila have been studied 
extensively, the current knowledge about adult blood cells is much more limited. Adult 
blood cells are present mostly as sessile hemocytes dispersed under the cuticle and 
associated with different tissues/organs. It has been shown that they are derived from the 
embryonic and larval waves of hematopoiesis and it has long been thought that Drosophila 
adults lack a hematopoietic organ. Hence, it is generally assumed that adult flies only rely 
on a fixed pool of differentiated plasmatocytes and that no blood cell proliferation or 
differentiation takes place during adulthood. However, recently, a study demonstrated the 
presence of active hematopoietic sites in the abdomen of adult flies, which are called 
hematopoietic hubs and can give rise to new blood cells (Figure 6.D) (Ghosh et al., 2015). 
It was shown that these hematopoietic hubs contain some hemocyte progenitors, which 
originate from the posterior lobes of lymph gland, and it was proposed that these cells can 
give rise to plasmatocytes and crystal cells. In addition, whereas the total number of 
hemocytes declines with age in adult flies (Horn et al., 2014), it was shown that adult blood 
cells can proliferate in response to an immune infection. These exciting observations 
 20 
suggest that active hematopoiesis could take place in the hematopoietic hubs of adult flies 
and project this hematopoietic hub as a simple version of the vertebrate bone marrow.
However, these findings need to be confirmed and the extend as well as the functional 
importance of adult blood cell production/differentiation remains unclear. 
2.2. Functions of Drosophila hemocytes 
        As mentioned above, Drosophila hemocyte progenitors can differentiate into three 
mature blood cell types: plasmatocytes and crystal cells (during embryonic, larval and adult 
stages) as well as lamellocytes (during larval stage, in response to specific immune 
challenges).  
 
2.2.1. Prohemocytes 
        Prohemocytes have been described in the embryonic head mesoderm, in embryo-
derived larval hemocytes, in the larval lymph gland and in adult hematopoietic hubs. They 
are generally described as small cells (4-6 um in diameter) with a high nuclear/cytoplasmic 
ratio but few defined characteristics. Although the GATA factor Srp is expressed in all 
prohemocytes, this factor is also expressed in differentiated blood cells and so far there is no 
known specific marker universally labelling Drosophila prohemocytes. For instance, in the 
lymph gland, prohemocytes express tep4 and the reporter gene dome-meso, but these two 
markers do not label embryonic prohemocytes and it is not known if they label adult blood 
cell progenitors. Therefore, further molecular characterization of the prohemocytes is
needed
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Figure 7. Three types of hemocytes in Drosophila melanogaster and their functions 
(A) Plasmatocyte (B) Crystal cell (C) Lamellocyte (From Krzemień PhD thesis) 
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2.2.2. Plasmatocytes 
        Plasmatocytes are relatively round cells with a diameter of 8-10 um and contain 
abundant lysosomes and endoplasmic reticulum (Figure 7.A). Their differentiation from 
prohemocytes requires the expression of transcription factor Glial/Glide cells missing 
(Gcm) in the embryo, and that of the GATA transcription factor Pannier in the lymph gland 
(Minakhina et al., 2007). They are the professional phagocytes of the immune system, 
related to mammalian macrophages, which mediate the cellular immune defence. 
Phagocytosis is an evolutionarily conserved process that is critical for the removal of 
invading pathogens and apoptotic cells. In Drosophila, plasmatocytes are able to engulf 
dead cells and debris as well as invading pathogens, and they are important for bacterial 
clearance and for the resistance to systemic infection. The phagocytic ability of 
plasmatocytes depends on the expression of scavenger and pattern recognition receptors on 
their surfaces. Croquemort (Crq), a member of the CD36 family of receptors, mediates the 
recognition of apoptotic cells (Franc et al., 1996). Eater and NimC1, two members of the 
Nimrod family of cell-surface receptors, recognize both Gram-positive and Gram-negative 
bacteria, leading to rapid engulfment of invading microorganisms (Kocks et al., 2005; 
Kurucz et al., 2007). Draper, the Ced-1 homologue, recognizes lipoteichic acid from 
Staphylococcus aureus and mediates the uptake of this bacterium in adult flies (Hashimoto 
et al., 2009). Additionally, plasmatocytes sculpt various developing tissues and organs 
through the phagocytic removal of cells. For example, the embryonic nervous system 
doesn’t condense properly if the plasmatocyte-mediated phagocytosis is absent. 
 
        Plasmatocytes are also highly motile cells, providing a powerful model to study cell 
migration and chemotaxis in response to developmental cues or tissue damage (Evans et al., 
2014; Ratheesh et al., 2015). This motility requires the expression of PVR (PDGF/VEFG-
related) receptor, Rho GTPase and fascin, and it is essential to ensure the homeostatic 
function of plasmatocytes. Additional functions of plasmatocytes include secretion of 
extracellular matrix (ECM) components required for proper tissue morphogenesis (Bunt et 
al., 2010) and for the maintenance of ovarian stem cells (Van De Bor V et al., 2015), 
controlling the activity of intestinal stem cells during injury-induced regeneration (Ayyaz et 
al., 2015), regulation of glucose metabolism to modulate life span (Woodcock et al., 2015), 
and mediating apoptosis-induced proliferation in the imaginal disks (Fogarty et al., 2016). 
Similar to the mammalian macrophages that have a plethora of functions in addition to their 
 22 
role in immunity, Drosophila plasmatocytes constitute a very helpful model to understand 
how macrophage diversity of function is generated and regulated. 
2.2.3. Crystal cells 
        Crystal cells are megakaryocyte-like cells with the diameter of 10-12 um (Figure 7.B). 
They derive their name owing to the presence of paracrystalline inclusions composed of 
prophenoloxidases (PPO) in the cytoplasm. They are non-phagocytic and function in 
melanization, an important immune response related to clotting and wound healing in 
Arthropods (Evans et al., 2003). Melanization leads to the blackening of wound sites or the 
surface of the invading pathogens, due to the local production and deposition of melanin. 
 
        As described above, crystal cells contain paracrystalline inclusions consisting of mass 
quantities of one or more components of the melanisation enzymatic cascade, which are 
prophenoloxidase enzymes that play a key role in melanin biosynthesis. There are three 
PPOs in Drosophila, which are PPO1 (Black Cell), PPO2 and PPO3. Upon injury, 
activation of the JNK pathway and the TNF homolog Eiger leads to crystal cells rupture and 
release of PPO zymogens into the hemolymph (Bidla et al., 2007). PPOs are then cleaved 
into active phenoloxidase (PO) by a proteolytic cascade (Dudzic et al., 2015), and PO in 
turn catalyses the oxidation of mono- and di-phenols to ortho-quinones, which subsequently 
polymerize into melanin and produce reactive oxygen species (ROS) as by-products 
(Eleftherianos et al., 2011). Although crystal cells are dispensable for fly viability, 
melanization participates in the innate immune response, and the resistance to infection. 
Crystal cell differentiation absolutely requires the induction of Lozenge expression both in 
the embryos and in the larvae (Lebestky et al., 2000; Fossett et al., 2003). The processes 
regulating crystal cell production are described in detail below. 
2.2.4. Lamellocytes 
        Lamellocytes are large, flat and adherent cells (Figure 7.C). They are scarcely present 
in healthy larvae, but their differentiation is massively induced in response to some specific 
immune challenges, such as parasitization by the wasp Leptopilina boulardi (Lanot et al., 
2001). Lamellocytes participate both in the cellular response and in melanisation, and they 
primarily function in the encapsulation and neutralization of pathogens or bodies that are 
too large to be phagocytosed. The encapsulation of parasitic wasp eggs requires the 
cooperation of all three types of larval hemocytes (Mortimer et al., 2013). At the early stage 
of parasitization, circulating plasmatocytes recognize the injected eggs and attach to them, 
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and subsequently form septate junctions to separate the eggs from the hemolymph 
circulation. This detection induces the proliferation and differentiation of sessile hemocytes 
as well as lymph gland hemocytes into lamellocytes. Lamellocytes adhere to the wasp eggs, 
activate the melanisation cascade, and eventually kill the parasites. 
2.3. Genetic control of Drosophila hematopoiesis 
2.3.1. PSC in Drosophila hematopoiesis 
         Similar to the mammalian bone marrow niche controlling the balance between 
hematopoietic stem cells (HSCs) self-renewal and differentiation, the posterior signalling 
centre (PSC) within Drosophila lymph gland, which controls the maintenance and 
differentiation of prohemocytes non-cell-autonomously and could function as a 
hematopoietic niche, represents a helpful and genetically tractable model to study signal 
integration and crosstalk during hemocyte development (Crozatier et al., 2011). It has been 
shown that the specification of PSC cells in the embryo critically requires the expression of 
two transcription factors, which are the homeotic protein Antennapedia (Antp) (Mandal et 
al, 2007) and the Drosophila orthologue of early B-cell factors (EBFs), Collier (Col) 
(Crozatier et al., 2004). Once the Collier activity is absent, the PSC cells are not specified 
and larval prohemocytes differentiate prematurely, which indicates the critical requirement 
for Collier activity in PSC cells specification. Besides transcription factors, the Wingless 
(Wg) signalling pathway also controls both the number of PSC cells and the maintenance of 
prohemocytes (Sinenko et al., 2009). In addition, PSC cells express the signalling molecule 
Hedgehog (Hh), and this Hh signalling pathway is required to maintain hemocyte 
homeostasis in the lymph gland (Mandal et al., 2007). Furthermore, Serrate-mediated Notch 
signalling from the PSC is required to maintain normal levels of Collier transcription 
(Krzemień et al., 2007). All together, these signalling pathways, including Wg, Hh, Notch 
and other signalling pathways, are integrated into PSC cells to control JAK/STAT signalling 
activity in prohemocytes, preventing their premature differentiation. 
2.3.2. ROS in Drosophila hematopoiesis 
        As many transcription regulators and signalling pathways involved in hematopoiesis 
are conserved from humans to Drosophila, a model for reactive oxygen species (ROS) has 
also been established in Drosophila (Owusu-Ansah et al., 2009). This study showed that the 
accumulation of ROS in the lymph gland is tightly controlled during development. 
Specifically, the multipotent hematopoietic progenitors have an increased level of ROS 
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under in vivo physiological conditions. Conversely, once the ROS in the hematopoietic 
progenitors is increased beyond its basal level, it will trigger precocious differentiation of 
these progenitors into all three mature hemocyte types, through a signalling pathway that 
involves JNK and FoxO activation as well as Polycomb down-regulation. In sum, this study 
provides a helpful model that could be extended to reveal the possible role of ROS in the 
differentiation of common myeloid progenitors (CMPs) in the mammalian hematopoiesis 
and oxidative stress response. 
2.3.3. Genetic control of blood cell fate 
        A number of conserved signalling pathways and transcription factors controlling 
Drosophila hematopoiesis have been identified (Letourneau et al., 2016). In particular, 
many publications have focused on the regulation of blood cell progenitor fate in the larval 
lymph gland, showing for instance that the Hedgehog, JAK/STAT, Wnt, Insulin/Target of 
Rapamycin, or Notch signalling pathways, the level of reactive oxygen species (ROS), as 
well as transcription factors, such as the EBF factor Collier, or the GATA factor Serpent 
and Pannier, control lymph gland homeostasis during normal development. In contrast, 
there were fewer studies about the fate of embryo-derived hemocytes that populate the 
larval hemocoel or of the adult blood cells, for which we only have very limited 
information. Similarly, while we have a relatively good understanding of crystal cell fate 
development, how plasmatocyte and lamellocyte differentiation is controlled is less well 
understood. 
 
        Here, I will focus my description on the mechanisms of regulation of crystal cell fate, 
as this is the blood cell lineage in which the gene that I studied during my PhD (MLF, see 
below), which was shown to be required (Bras et al., 2012). As detailed below, the RUNX 
transcription factor Lozenge (LZ) is specifically expressed in the crystal cell lineage and it 
is absolutely required for crystal cell development (Lebestky et al., 2000). The expression of 
Lozenge, and thus the induction of crystal cell fate is dependent on the Notch signaling 
pathway both in circulating larval cells and in lymph gland (Mukherjee et al, 2011; 
Lebestky et al, 2003; Duvic et al., 2002). The activation of the Notch pathway is mediated 
by its ligand Serrate (Ser) and requires the transcription factor Suppressor of Hairless 
(Su(H)). Accordingly, decreasing Notch activity (using for instance a thermo-sensitive allele 
or over-expression of a dominant negative form of Notch) leads to a decrease in the number 
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of crystal cells, while over-expression of Notch induces a strong increase in their number 
(Duvic et al., 2002). 
 
 In the lymph gland, the posterior signaling center (PSC) was first characterized 
thanks to its specific expression of Ser (Lebestky et al., 2003). It was thus initially proposed 
that the PSC is necessary for the induction of crystal cell fate by contacting the neighboring 
hemocytes. However, it was then shown that the PSC is not required for crystal cell 
development, and that it was proposed that some other cells expressing Ser and dispersed in 
the cortical zone could be responsible for the signal that induces crystal cell fate (Crozatier 
et al., 2004). Consistent with this hypothesis, a recent study demonstrated that the 
expression of Yorkie and Scalloped, two components of the Hippo pathway, promotes the 
expression of Ser in these cells of the cortical zone, and is required for the specification of 
the adjacent cells into crystal cells (Ferguson et al., 2014a; 2014b). Another related study 
suggests that the Hippo pathway controls the development of crystal cells in a non-cell-
autonomous manner via Ser and the Notch pathway but also in a cell-autonomous manner 
by directly activating the transcription of lz (Milton et al., 2014). In addition, the 
identification of Notch/Su(H) direct targets in the Kc cells showed that Notch/Su(H) 
cooperates with LZ in the crystal cells to activate the transcription of certain genes, such as 
pebbled/hindsight, which are involved in the endo-replication of crystal cells, and 
klumpfuss, which represses the alternate (plasmatocytes) fate (Terriente-Felix et al., 2013). 
In addition, another study showed both in the lymph gland and in circulating larval blood 
cells that Notch also contributes to crystal cell survival (Mukherjee et al., 2011). 
Interestingly, this study showed that this function of Notch in LZ+ cells does not depend on 
its ligand. Indeed, in LZ+ cells, high level of the HIF-α homolog Sima stabilizes the 
internalisation of activated Notch in the endosome even in the absence of activation by its 
ligand Ser or Delta. This leads to a non-canonical, ligand-independent activation of Notch, 
which acts with Su(H) to permit crystal cell maturation and to prevent crystal cell rupture. 
In addition, the relocation and accumulation of Notch in early endosomes was shown to 
coincide with an increase in the number of crystal cells in the lymph gland in the absence of 
Asrij, a conserved protein involved in endocytosis. Therefore, it was suggested that Asrij 
restricts the number of crystal cells by controlling the intracellular trafficking of Notch 
(Kulkarni et al., 2011). Finally, it has recently been shown that crystal cells can be produced 
by trans-differentiation of plasmatocytes in the sessile islets in response to the activation of 
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the Ser/Notch pathway (Leitão et al., 2015). In sum, it appears that the Notch pathway acts 
at multiple levels in the development of crystal cells. First, Ser is required to activate Notch 
in blood cell progenitors or plasmatocytes to induce the expression of LZ and thus crystal 
cell fate; then, activated Notch cooperates with LZ to lock crystal cell fate and finally ligand 
independent activation of Notch increases crystal cell survival.  
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3. RUNX family of transcription factors in hematopoiesis and leukemia
3.1. The Core-binding factors family  
        As described above, many transcription factors are involved in the regulation of the 
mammalian hematopoiesis and its associated leukemia. Among these transcriptional 
regulators, core-binding factors (CBFs) are a class of transcription factors, which are 
essential for hematopoietic development and are also the frequent targets of mutations or 
gene rearrangements in human leukemia (Speck et al., 2002). They are heterodimeric 
transcription factor complexes composed of α and β subunits (Figure 8.A) (Hart et al., 
2002). The α subunit (CBFα) is the DNA-binding element of the complex, which is able to 
bind to a specific nucleotide sequence motif in vitro even without the β subunit. The β 
subunit (CBFβ) stabilizes the binding of CBFα to the specific DNA sequence motif without 
direct DNA contract (Ogawa et al., 1993a) and can protect the α subunit from proteolysis 
(Huang et al., 2001). Structural analyses have shown that the DNA recognition and binding 
by CBFα is mediated by an allosteric transition in the runt domain, which is further 
stabilized by CBFβ (Tahirov et al., 2001), as well as by the bent-helical conformation of the 
free DNA target (Bartfeld et al., 2002) (Figure 8.A). All CBFα subunits contain an 
evolutionarily conserved 128 amino acid domain called the Runt domain, in reference to 
Drosophila CBFα protein Runt, the founding member of this family. This domain is 
responsible both for DNA binding and heterodimerization with CBFβ (Nimmo et al., 2008; 
Ogawa et al., 1993a). Runt domain proteins are found throughout the metazoan kingdom 
(Rennert et al., 2003) and recognize the PyGPyGGT consensus sequence, which seems to 
be shared by all members of the CBF family. In addition, most RUNX proteins contain a C-
terminal VWRPY motif that functions as a binding site for transcriptional co-repressor of 
the Groucho/TLE family (Ito, 2004) (Figure 8.B). 
 
        In mammals, there are three CBFα subunits encoded by three corresponding genes, 
RUNX1, RUNX2 and RUNX3 (Ito, 2004), and a single ubiquitous ß subunit encoded by 
CBFß. The three RUNX genes are required for the development of various tissues. Because 
they bind the same DNA sequence, their specific role is largely due to their respective 
spatio-temporal expression pattern. In particular, RUNX1 is required for hematopoietic stem 
cell emergence and controls several steps of blood cell maturation, whereas RUNX2 plays a 
key role in osteogenesis and RUNX3 is important for neurogenesis (Bae et al., 2006; de 
Bruijn et al., 2017; Blyth et al., 2010; Lotem et al., 2015). However, these genes also play a 
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critical role in other organs, notably RUNX2 and RUNX3 participate in T cell development 
in the hematopoietic system. Of note, because of a series of aliases for CBFα subunits 
generated in many independent laboratories during the past decades, a unified nomenclature
for this exciting class of transcription factors has been established (van Wijnen et al., 2004), 
as shown in Table 2. 
 
 
 
3.2. Identification of RUNX1 in mammals 
        It has been known that specific chromosomal translocations are closely associated with 
a large number of human blood malignancies. The isolation and subsequent study of many 
A                                                   B 
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Figure 8. Structural representation of the RUNX1-CBFβ and diagrammatic 
representation of three RUNX protein subtypes 
(A). Structures of the RUNX1 runt domain (green) and the CBFβ heterodimerization domain 
(brown) (From Speck et al., 2002). (B). A diagrammatic representation of RUNX1, RUNX2 and 
RUNX3 together with Drosophila Runt. Conserved runt domain and VWRPY sequence at the 
C-terminus of the proteins are indicated (From Ito, 2004). The breakpoints for two major 
translocations affecting RUNX1 are shown. 
Table 2. Synonyms for mammalian RUNX gene subtypes and locus 
(CBFA: Core Binding Factor Alpha; AML: Acute Myeloid Leukemia;  
PEBP2: Polyomavirus Enhancer Binding Protein 2) 
RUNX1 CBFA2 AML1 PEBP2αB 21q22 
RUNX2 CBFA1 AML2 PEBP2αA 6p21 
RUNX3 CBFA3 AML3 PEBP2αC 1p36 
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genes located at the breakpoint regions revealed that they often play critical roles in the 
regulation of proliferation and differentiation of various blood cell lineages. The 
t(8;21)(q22;q22) translocation is one of the most common and frequent translocations in 
acute myeloid leukemia (AML), occurring in 12-15% of all cases, especially in the M2 
AML subtype according to the French-American-British (FAB) classification system 
(Sangle et al., 2011). After the successful isolation of important genes involved in the 
t(8;14) Burkitt lymphoma (c-myc), t(9;22) chronic myeloid leukemia (c-abl), t(15;17) acute 
promyelocytic leukemia (c-erbA), RUNX1/AML1, the first identified mammalian CBF gene, 
was isolated successfully by virtue of its location on human chromosome 21 at the 
t(8;21)(q22;q22) breakpoint (Miyoshi et al., 1991), meanwhile its murine homolog, 
PEBP2α/PEA2, was isolated and cloned successfully very soon after thanks to its capacity 
to bind the enhancer core sites of the polyomavirus (Ogawa et al., 1993b). 
3.2.1. Structure and isoforms of RUNX1 transcription factor 
        Based on the sequence analyses of various forms of RUNX1 cDNA that reflects a 
complex pattern of mRNA species, it was revealed that RUNX1 gene has 12 exons, and two 
alternative promoters: the distal promoter or P1, and the proximal promoter or P2 (Figure 
9.B), which are juxtaposed with their corresponding and specific first coding exons 
(Sroczynska et al., 2009; Bee et al., 2009; Challen et al., 2010). This organization is 
conserved in mammals and the usage of two alternative promoters is also observed in other 
mammalian RUNX genes. So RUNX1 gene could generate more than 12 different mRNA 
isoforms and 3 main protein isoforms (RUNX1a, RUNX1b, RUNX1c) by alternative 
splicing and alternative promoter usage (Miyoshi et al., 1995; Levanon et al., 2001). 
Systematic analyses of RUNX1 P1 and P2 promoter usage during mouse hematopoietic 
development showed that the proximal P2-mediated RUNX1 isoform marks a hemogenic 
endothelium cell population and primitive erythrocytes, whereas the distal P1-mediated 
RUNX1 defines fully committed definitive hematopoietic progenitors (Bee et al., 2009). 
This demonstrates that the differential activities of these 2 RUNX1 promoters define 
milestones of hematopoietic development, and suggests that the proximal RUNX1 isoform is 
a key regulator in the generation of hematopoietic cells from hemogenic endothelium 
(Sroczynska et al., 2009).  
 
        As mentioned above, RUNX1 codes for 3 protein isoforms. The P2 promoter regulates 
the expression of RUNX1a and RUNX1b, whereas the P1 promoter controls RUNX1c 
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expression (Figure 9.B). The two long isoforms, RUNX1b and RUNX1c, contain both the 
DNA-binding Runt domain at their N-terminus followed by a transactivation domain
(Figure 9.A), a nuclear-matrix attachment motif, two putative transcriptional repression 
domains and finally the VWRPY motif. They are generally considered similar in functions
(Challen et al., 2010), although RUNX1c has extra 27 amino acids at the N-terminus as 
compared to RUNX1b. In contrast, RUNX1a lacks the C-terminal transactivation domain 
and VWRPY motif, and it could act as a competitive inhibitor for RUNX1b (Miyoshi et al., 
1995; Zhang et al., 1996). 
 
 
        Expression pattern analyses of these RUNX1 isoforms showed that they have 
differential expression profiles during hematopoietic differentiation in mouse embryos and 
in human embryonic stem cells (hESCs) (Challen et al., 2010). RUNX1a and RUNX1b 
isoforms were expressed consistently throughout hematopoietic differentiation, whereas 
RUNX1c isoform was only expressed at the onset of the emergence of definitive HSCs as 
well as in the AGM region of E10.5 to E11.5 mouse embryo, which suggested that 
RUNX1c isoform could be essential for the specification or function of definitive HSCs. 
However, several other studies indicated that RUNX1a isoform could have more diverse 
roles than the other two isoforms. Enforced expression of RUNX1a in the mouse primitive 
hematopoietic cells resulted in enhanced engraftment upon transplantation, which 
demonstrated that RUNX1a isoform has the capacity to potentiate stem and progenitor cell 
engraftment (Tsuzuki et al., 2007). Another study revealed that ectopic expression of 
RUNX1a isoform in mouse HSCs facilitates their expansion (Tsuzuki et al., 2012) and 
 A                                                                                   B 
              
Figure 9. RUNX1b structure, its post-translational modifications and two 
promoters of RUNX1 gene 
(A) Structure and post-translational modifications of human RUNX1 (From Goyama et al., 
2015). (B) Two promoters (P1 and P2) of the RUNX gene family in human (From Challen et al., 
2010).  
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positively regulates the expression of mesoderm and hematopoietic differentiation-related 
factors. Similarly, RUNX1a over-expression favoured hematopoietic lineage commitment in 
human pluripotent stem cells (Ran et al., 2013). In addition, a higher expression level of 
RUNX1a was found in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia 
(AML)-M2 patients and RUNX1a antagonized with RUNX1b, which indicated that 
RUNX1a over-expression could promote leukemogenesis (Liu et al., 2009). Yet, the 
respective functions of the different RUNX1 isoforms in hematopoiesis and leukemia 
remain to be firmly established. 
3.2.2. RUNX1: a master transcriptional regulator of hematopoietic development 
        RUNX1 is a master transcription factor that plays a critical role in the development and 
differentiation of specific cell lineages from hematopoietic stem cells. Initial studies showed 
that it directly controls the expression of various genes that are essential for blood cell 
survival and differentiation, such the granulocyte/macrophage colony-stimulating factor 
(GM-CSF) or the macrophage colony-stimulating factor receptor (M-CSFR) (Asou, 2003). 
It acts as an activator or repressor of target gene expression depending on the large number 
of transcription factors as well as transcriptional co-activators (Figure 10.A) or co-
repressors (Figure 10.B) that interact with it. For instance, RUNX1 interacts with CCAAT 
enhancer-binding protein (C/EBP) to activate synergistically M-CSFR expression (Zhang et 
al., 1996). It also binds PU.1 (Petrovick et al., 1998), p300 (Kitabayashi et al., 1998), Ets-1 
(Kim et al., 1999), MOZ (Kitabayashi et al., 2001) or GATA-1 (Elagib et al., 2003) to 
activate transcription. In contrast, RUNX1 interacts with transducing-like enhancer of split 
(TLE1), a human homolog of the Groucho family of co-repressors, to repress gene 
expression (Imai et al., 1998). Other RUNX1-associated co-repressors include mSin3A 
(Imai et al., 2004) and histone deacetylase (HDAC) (Reed-Inderbitzin et al., 2006). Hence, 
RUNX1 functions as an organizing protein that facilitates the assembly of transcriptional 
activation or repression complexes, which can be described that it recruits non-DNA-
binding co-activators or co-repressors to initiate the activation or repression of target genes 
transcription under different circumstances. The effect of RUNX1 on target gene expression 
is thus highly context dependent, determined by the composition of the transcriptional 
complexes in which RUNX1 functions at a particular gene. RUNX1 target gene repertoire 
has now been established at the genome-wide level in different cell types(Lichtinger et al., 
2012; Lie-A-Ling et al., 2014; Bevington et al., 2016; Umansky et al., 2015; van Riel et al., 
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2012; Tijssen et al., 2011; Pencovich et al., 2011). These studies notably highlighted the 
role of RUNX1 in remodelling the epigenetic landscape and promoting the association of 
other transcription factors with new set of target genes to induce the hematopoietic fate
(Lichtinger et al., 2012).   
 
3.2.3. Post-translational modifications of RUNX1 
        Besides the physical interactions with various co-activators or co-repressors, RUNX1
can be modified by multiple post-translational modifications (PTMs), including 
phosphorylation, methylation, acetylation, ubiquitination and sumoylation (Figure 9.A), 
which will impact on its activity. 
 
        RUNX1 phosphorylation has been studied extensively, since it can promote the 
transcriptional activation or the degradation of RUNX1. For instance, the extracellular 
signal-regulated kinase (ERK), which is activated by several hematopoietic cytokines or 
phorbol ester treatment, phosphorylates RUNX1 at serine (S)249 and S266, thereby 
potentiating the transactivation and transforming capacities of RUNX1 in fibroblast cells
(Tanaka et al., 1996; Zhang et al., 2004). ERK-dependent phosphorylation of RUNX1 
disrupts RUNX1 association with the transcriptional co-repressor mSin3A and enhances
RUNX1-mediated transactivation but also results in the degradation of RUNX1 by the 
proteasome (Imai et al., 2004). In addition, RUNX1 is phosphorylated on other residues by 
homeodomain-interacting protein kinase 2 (HIPK2), Pim-I kinase (Aho et al., 2006), cyclin-
dependent kinases (Biggs et al., 2006; Zhang et al., 2008; Guo et al., 2011) or Src family 
kinase Shp2 (Huang et al., 2012), resulting in a tight regulation of its activity.  
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Figure 10. Proposed mechanisms to explain the ability of RUNX1 to both activate 
and repress transcription 
(A) RUNX1/AML1 cooperates with activator proteins such as p300/CBP, Ets, Myb on C/EBP to 
activate transcription. (B) RUNX1/AML1 binds to repressor proteins such as mSin3 and TLE to 
repress transcription. (From Lutterbach et al., 2000) 
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        RUNX1 is also modified post-translationally by methylation on arginine residues. For 
example, the protein arginine methyltransferase PRMT1 methylates RUNX1 (Zhao et al., 
2008; Shia et al., 2012), and this methylation on two arginines abrogates the interactions 
between RUNX1 and SIN3A to potentiate the transcriptional activity of RUNX1. 
Conversely, RUNX1 methylation by PRMT4 promotes the assembly of a DPF2-containing 
co-repressive complex that blocks myeloid differentiation by repressing miR-233 
expression in human cord blood cells (Vu et al., 2013).  Similarly, RUNX1 is acetylated on 
lysine residues by the histone acetyltransferase p300, which causes an increase in its DNA-
binding activity and enhances its transcriptional activity (Yamaguchi et al., 2004; 
Kitabayashi et al., 1998). Moreover, RUNX1 (as well as other RUNX proteins) was found 
to be sumoylated by PIAS-1, but the functional impact of this modification remains to be 
determined (Kim et al., 2014).  
 
        Finally, it is important to note that the stability of RUNX1 is controlled by 
ubiquitination, notably by the E3 ubiquitin ligase CHIP (Shang et al., 2009) and the SCF/ 
APC/C complex (Biggs et al., 2006), which target RUNX1 to the proteasome degradation 
pathway. Also CBFß was shown to stabilise RUNX1 by preventing its ubiquitination 
(Huang et al., 2001) whereas RUNX1 phosphorylation promotes its ubiquitination and 
degradation (Biggs et al., 2005; Biggs et al., 2006; Imai et al., 2004). In sum, RUNX1 post-
translational modifications have a profound impact on its activity by controlling its 
interactions with different partner proteins and by regulating its level. 
3.2.4. Role of RUNX1 in hematopoiesis 
        RUNX1 plays a key role in the development of the hematopoietic system.  
Homozygous disruption of RUNX1 in mouse embryo resulted in the developmental defects, 
including lack of fetal liver hematopoiesis and mid-gestation embryonic lethality around 
embryonic day (E) 12.5 (Okuda et al., 1996). These RUNX1-deficient embryos still had 
normal morphogenesis and yolk sac-derived erythropoiesis, but they lacked other yolk-sac 
derived blood cell types as well as definitive hematopoietic progenitors (Okuda et al., 1996) 
and no hematopoietic progenitor/stem cell cluster emerged from their aorta-gonad-
mesonephros (AGM) region (Mukouyama et al., 2000) (Figure 11). So RUNX1 is required 
for the emergence of all definitive hematopoietic cells, but it is not essential for the 
formation of primitive erythrocytes. Of note, primitive erythrocytes in null RUNX1 mice 
displayed abnormal morphology and reduced expression of Ter119 and GATA, which 
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indicates that RUNX1 is also involved in the development of the primitive erythrocytes
(Yokomizo et al., 2008). Interestingly, it was shown that RUNX1 haploinsufficiency 
resulted in the precocious appearance of HSCs in the AGM region and in the yolk sac, 
which suggests that RUNX1 dosage is important for the spatio-temporal control of mouse 
hematopoiesis (Cai et al., 2000). 
 
 Expression pattern analyses showed that RUNX1 is expressed in definitive 
hematopoietic progenitor cells as well as in endothelial cells that reside in the yolk sac, the 
vitelline and umbilical arteries, which contributes directly to the generation of 
hematopoietic cells through the formation of intra-arterial clusters (North et al., 1999). By 
conditional deletion study, it was shown that RUNX1 function in endothelial cells is 
essential for the formation of hematopoietic stem/progenitor cells (HSPCs) from the 
vasculature (Yokomizo et al., 2001; Chen et al., 2009). Furthermore, this transition is
tightly controlled by the sub-aortic mesenchyme, and RUNX1 and the Notch signalling 
pathway are involved in this process (Richard et al., 2013). Altogether, RUNX1 is required 
for the definitive hematopoiesis and the endothelial to hematopoietic cell transition in the 
embryo, as well as involved in the primitive erythropoiesis.  
                  A                                                                    B 
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Figure 11. RUNX1 expression in hematopoiesis sites in the E10.5 embryo 
(A) RUNX1 is expressed (blue) in a small population of endothelial cells and hematopoietic cells 
that are scattered throughout the yolk sac (ys), in endothelial cells lining the vitelline (v) and 
umbilical (u) arteries, and in endothelial cells, mesenchymal cells and intra-aortic hematopoietic 
cluster in the ventral portions of the dorsal aorta within the aorta/gonad/mesonephros (agm) 
region. (B) Detailed view of RUNX1 expression in endothelial cells (e), mesenchymal cells (m) 
and a hematopoietic cluster (hc) in the ventral AGM region. (From Speck et al., 2002) 
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        In adult mice, RUNX1 is expressed in functional hematopoietic stem cells as well as in 
the majority of myeloid cells and a smaller proportion of lymphoid cells, but its expression 
decreases substantially during erythroid differentiation (North et al., 2004). Specifically, 
RUNX1 is expressed in myeloid, B-lymphoid and T-lymphoid cells, and its expression is 
regulated in a cell type- and maturation-specific manner in RUNX1-IRES-GFP knock-in 
mice (Lorsbach et al., 2004). Using conditional knock-out mice, it was shown that RUNX1-
deficient bone marrow exhibited inhibition of megakaryocytic maturation, defective T- and 
B-lymphocyte development and increased hematopoietic progenitor cells, which 
demonstrated that RUNX1 is required for maturation of megakaryocytes and differentiation 
of T- and B-lymphocytes (Ichikawa et al., 2004). RUNX1 transcriptionally regulates 
megakaryocyte development in a cell-autonomous manner (Pencovich et al., 2013) in 
collaboration with the GATA transcription factor GATA1 (Elagib et al., 2003). Notably, it 
promotes the megakaryocyte fate in bi-potent erythroid/megakaryocytic precursors by 
repressing the expression of the erythroid transcription factor KLF1 (Kuvardina et al., 2015) 
or the erythroid miR144/451 cluster (Kohrs et al., 2016), as well as by activating the 
expression of megakaryocyte specific genes (Pencovich et al., 2013; Pencovich et al., 
2011). And as for T-lymphocyte development, RUNX1 is required for active repression in 
CD4-CD8- thymocytes (Taniuchi et al., 2002) and regulates the two transitions of 
developing thymocytes from the CD4-CD8- double-negative stage to the CD4+CD8+ double-
positive stage and from the double-positive stage to the mature single-positive stage (Egawa 
et al., 2007), which indicates that RUNX1 has critical roles at multiple stages of T-
lymphocyte development. Meanwhile, during early B-lymphocyte development, loss of 
RUNX1 resulted in a developmental block that was bypassed following retroviral 
transduction of Ebf1, a key transcription factor regulating early B-lymphocyte development, 
demonstrating that RUNX1 is essential for B-lymphocyte lineage specification in part 
through the epigenetic activation of Ebf1 gene (Seo et al., 2012). In addition, RUNX1 also 
regulates the development of Flt3+ dendritic cell progenitors to facilitate multi-lineage 
hematopoietic differentiation (Satpathy et al., 2014). 
 
        In sum, RUNX1 is not only required for the emergence of the HSCs, but also for the 
differentiation of several blood cell lineages in mice. Of note, the findings obtained in mice 
have been corroborated by studies in human blood cells and RUNX1 is also a key regulator 
of hematopoiesis in Xenopus or zebrafish, suggesting that it plays a conserved role in blood 
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cell development in vertebrates.  
3.2.5. RUNX1 in leukemia 
        The importance of RUNX1 in hematopoiesis is further exemplified by the high number 
of mutations found in RUNX1 in patients with hematological malignancies. Indeed, as 
mentioned above, RUNX1 was originally identified as the target of the t(8;21) translocation 
in human AML (Miyoshi et al., 1991). Since then, a number of translocations or point 
mutations affecting RUNX1 have been identified in diverse blood cell cancers, making 
RUNX1 one of the most frequently altered genes in these malignancies. 
 
 Thus far, more than 50 different chromosomal translocations that involve RUNX1 have 
been discovered in acute leukemia cases (De Braekeleer et al., 2011), among which the best 
studied are the t(8;21)(q22;q22) (Downing et al., 1993; Erickson et al., 1992), 
t(12;21)(p13;q22) (Golub et al., 1995; Romana et al., 1995) and t(3;21)(q26;q21) (Mitani et 
al., 1994; Nucifora et al., 1994) translocations (Figure 12). These translocations are 
associated with the development of either myeloid or lymphoid leukemia. For instance, the 
t(8;21)(q22;q22) is the most frequent chromosomal translocation in AML patients (±12% of 
all cases) whereas t(12;21)(p13;q22) is the most frequent one in ALL patients (±17% of all 
cases). In addition, the inv(16)(p13;q22) that affects RUNX1 dimerization partner CBFβ 
accounts for approximately 15% of all AML cases. Thus modification of RUNX1 activity is 
implicated in a large fraction of human acute leukemia. Generally, these chromosomal 
translocations lead to the production of RUNX1 or CBFβ fusion proteins that act as 
dominant inhibitors of the wild-type RUNX1 to promote blood cell transformation.  
 
        In most cases, the translocations affecting RUNX1 led to the production of a fusion 
protein between RUNX1 DNA-binding domain and (part of) another protein that brings 
along a transcriptional repressor domain. For instance, in the t(8;21) translocation, RUNX1 
C-terminal transactivation domain is replaced by the almost entire ETO (Eight Twenty One) 
protein, which provides an oligomerisation domain as well as a binding interface for 
different co-repressors such as N-CoR (Gelmetti et al., 1998), SMRT (Hildebrand et al., 
2001), Sin3 (Lutterbach et al., 1998) and numerous HDACs (Wang et al., 1998). The 
resulting RUNX1-ETO fusion protein can repress transcription from RUNX1-responsive 
genes by competing with wild type RUNX1 (Miyoshi et al., 1993; Ptasinska et al., 2012). 
Yet, RUNX1-ETO mode of actions is more complex: it was shown that it also forms a 
complex with wild-type RUNX1 on chromatin and it was proposed that the relative binding 
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signals of RUNX1 and RUNX1-ETO determine whether RUNX1-ETO activates or
represses its targets (Li et al., 2016; Minucci, 2016). In addition, RUNX1-ETO also binds 
and regulates other transcription factors such as the myeloid factors C/EBPα or PU.1 (Pabst 
et al., 2001; Vangala et al., 2003). Thus, RUNX1-ETO expression has a profound impact on 
blood cell development by repressing myeloid differentiation and promoting leukemic cell 
self-renewal (Ptasinska et al., 2014). However, it is not sufficient to induce malignant blood 
cell transformation and, as for other translocations affecting RUNX1, other mutations are 
required for the progression towards leukemia. Thus, an important issue is to identify the 
genes that cooperate or interfere with RUNX1 or its oncogenic derivatives during 
hematopoiesis and leukemia. 
  
 
        Besides translocations, a number of point mutations affecting RUNX1 are associated 
with human blood cell diseases. Notably, rare cases of haploinsufficient germ-line 
mutations in RUNX1 lead to the development of familial platelet disorder with 
predisposition to acute myeloid leukemia (Song et al., 1999). There are also numerous 
examples of somatic point mutations of RUNX1 in patients with myelodysplastic 
syndromes, acute myeloid leukemia but also in acute lymphoid leukemia and chronic 
myelomonocytic leukemia (Sood et al., 2017). Rare cases of bi-allelic “null” mutations have 
been found in AML-M0 subtypes, but mutations affecting RUNX1 are mostly mono-allelic
and could affect RUNX1 activity by different mechanisms that remain to be established. 

Figure 12. Structures of CBF fusion genes that are associated with leukemia 
These structures of CBF fusion genes shown here include RUNX1-ETO (t(8;21) translocations), 
CBFβ-SMMHC (inv(16) translocations), TEL-RUNX1 (t(12;21) translocations), RUNX1-EVI1 
(t(3;21) translocations) (From Speck et al., 2002) 
 38 
Nonetheless, these findings highlight the critical role of RUNX1 in normal blood cell 
development in humans and indicate that a tight regulation of its activity and expression 
level is crucial for human health.
3.3. Lozenge in Drosophila hematopoiesis 
        Drosophila genome encodes four RUNX genes: runt, lozenge, RunxA and RunxB.
Lozenge is known to be expressed in Drosophila blood cells and I will thus focus on this 
factor. As a member of the RUNX family, Lozenge (Lz) harbors a highly conserved runt 
domain that is essential for the DNA-binding and protein-protein interactions, and a C-
terminal motif VWRPY that is capable of recruiting Groucho family of co-repressors. It is 
worth mentioning that Drosophila has two CBFß homologs: Brother and Big-Brother that 
can interact with Lozenge (Li et al., 1999; Kaminker et al., 2001), but their function in 
hematopoiesis has not been investigated.  
 
        lozenge gene is located on the X chromosome and it is transcribed from a single 
promoter into two different mRNAs that are generated by alternative splicing of the exon 5. 
There are thus two protein isoforms (Figure 13): Lz (826 amino acids long) and Lz5 (705 
amino acids long), which contain or not an interaction domain for ETS family of 
transcription factors just after the runt homology domain (RHD) (Jackson Behan et al., 
2005). As for mammalian RUNX1, the relative contribution of these two isoforms to 
Drosophila hematopoiesis remains to be determined.  
 

Figure 13. Genomic region and two isoforms of lozenge gene  
(A) lozenge genomic region is shown as well as the two lozenge mRNAs (grey: un-translated 
region, pink: coding sequences). (B) Schematic representation of two Lozenge isoforms. The 
runt domain (RD) is shown in grey, the VWRPY motif is in red and the sequence coded by exon 
5 (E5) is in blue. 
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        Lozenge is involved in several different developmental processes, including the 
development of eye, antennal and tarsal claw, female fertility and hematopoiesis (Canon et
al., 2000). It is known to have a major role in cell fate determination, and the most 
characterized example of this function of lozenge is during eye and crystal cell 
development. 
 
        lozenge mutant alleles were first identified by Morgan and Bridges in 1920 thanks to 
their effects on the morphology of the Drosophila eye (Figure 14).  
 
        Drosophila has a compound eye composed of 800 identical units called ommatidia. In 
each ommatidium, there are eight light-absorbing photoreceptor neurons (R1-R8) and four 
non-neuronal cone cells, which produce the lens (Batterham et al., 1996). A number of 
transcription factors are involved in the cell-specific patterning in the eye, which marks the 
identity of individual cell types. Among such transcription factors are Seven-up (Svp), a 
member of the steroid hormone receptor superfamily expressed in R1, R3, R4 and R6 
(Mlodzik et al., 1990), Bar, a homeobox protein required in R1 and R6 (Higashijima et al., 
1992), and DPax-2, the Drosophila Pax-2 homolog required for the development of the 
cone cells (Fu et al., 1997). Genetic analyses have revealed that lozenge positively or 
negatively regulates all of the known transcription factors required for the cell lineage 
specification. It plays a crucial role in governing the fate of two groups of cells that are born 
in a single round of mitosis in the larval fly eye disc (Daga et al., 1996). By negatively 
regulating seven-up (svp), Lozenge helps to define a subset of these cells as an equipotential 


Figure 14. Scanning electron micrographs of Drosophila adult eyes 
(A) The wild-type Drosophila eye has a regular array of ordered facets. (B) lzts1 flies, when 
reared at 25°C, have wild-type eyes. (C) When lzts1 flies are reared at 29°C, the eye appears 
rough and disorganized. (D) The lzR1 null gives rise to severe eye phenotype. (From Kaminker et 
al., 2001) 
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group that is competent to respond to the EGFR/Sevenless developmental signal. In 
contrast, by positively regulating Bar, Lozenge confers proper photoreceptor identity in a 
second group of cells (Daga et al., 1996). Another study showed that Lozenge directly 
activates argos (which encodes an inhibitor of EGFR) and klumpfuss (the homolog of 
apoptotic regulator WT1), to regulate programmed cell death in Drosophila eye (Wildonger 
et al., 2005). Therefore, Lozenge patterns multiple cell types in the Drosophila eye through 
the control of cell-specific transcription factors (Flores et al., 1998). It is important to note 
that Lozenge can act both as a transcriptional activator and as a transcriptional repressor in 
the same cell. Its capacity to repress transcription of deadpan not only requires the co-
repressor Groucho but also the transcription factor Cut, whose expression is activated by 
Lozenge, and which binds next to Lozenge on deadpan regulatory region to stabilize the 
formation of a repressor complex (Canon et al., 2003). Conversely, it was proposed that 
Lozenge cooperates with the ETS factor Pointed to activate the expression of prospero and 
D-Pax2 (Jackson Behan et al., 2005). This duality of Lozenge function in the eye was 
actually used to show that the human RUNX1-ETO oncogenic fusion protein behaves as a 
constitutive repressor: when RUNX1-ETO is expressed in the fly eye, it represses both 
deadpan and D-Pax2 transcription (Wildonger et al., 2005). 
 
        Lozenge is also absolutely required for crystal cell differentiation both in the embryo 
and in the larva during Drosophila hematopoiesis (Lebestky et al., 2000). It is specifically 
expressed in the crystal cell lineage, and in a lozenge null background no crystal cells is 
formed. Moreover, using a thermo-sensitive allele of lozenge, it was shown that its function 
is continuously required for crystal cell development.  
 
 In the embryo, lozenge is expressed first in the anterior-most row of prohemocytes 
slightly after the onset of Serpent expression (Bataillé et al., 2005). A fraction of these cells 
maintains lozenge expression and differentiates into crystal cells, whereas the remaining 
progenitors give rise to plasmatocytes (Bataillé et al., 2005). In the larvae, lozenge 
expression is activated in scattered cells in response to the Serrate/Notch signaling pathway 
both in the lymph gland and in the sessile hematopoietic pockets (Duvic et al., 2002; 
Lebestky et al., 2003). Recently, it was proposed that the Serrate/Notch signaling in the 
lymph gland leads to the up-regulation of the transcriptional co-factor Yorkie, which acts 
together with its DNA-binding partner Scalloped to directly activate lozenge transcription in 
the crystal cell lineage (Milton et al., 2014). Whether Scalloped and Yorkie are also 
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involved in the activation of lozenge transcription in the embryo and in the larval sessile 
hematopoietic pocket is not known. So, it is still unknown how lozenge expression is 
initiated in the crystal cell precursors. However, it has been shown that Lozenge can activate 
its own transcription, suggesting that its expression in the crystal cell lineage could be 
maintained via an auto-activation loop (Ferjoux et al., 2007).  
 
 At the molecular level, Lozenge can trigger the expression of crystal cell specific 
markers in any tissues that express the GATA factor Serpent, indicating that Lozenge 
synergizes with Serpent to induce crystal cell differentiation (Waltzer et al., 2003; Fossett et 
al., 2003). This functional cooperation is mediated by a direct interaction between Serpent 
and Lozenge (Waltzer et al., 2003) as well as a conserved Serpent/Lozenge-responsive cis-
regulatory module present in many crystal cell specific genes (such as the 
prophenoloxidases PPO1 and PPO2 or lozenge itself), which is composed of at least one 
Serpent and one Lozenge binding site in close association (Ferjoux et al., 2007). 
Furthermore, the interaction between Serpent and Lozenge has been conserved through 
evolution (Waltzer et al., 2003), so the cooperation between Serpent and Lozenge might be 
used as a paradigm to study how GATA/RUNX complexes regulate transcription and blood 
cell development from Drosophila to vertebrates. The Serpent/Lozenge complex notably 
acts with several subunits of the mediator transcription complex to activate gene expression 
(Gobert et al., 2010). In addition, it was shown that Lozenge (and potentially Serpent) 
facilitates the recruitment of the Notch/Su(H) complex to some of its target genes and thus 
collaborates with the Notch signaling pathway during crystal cell differentiation (Terriente-
Felix et al., 2013; Skalska et al., 2015).  
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4. Myeloid Leukemia Factor (MLF) family 
         Myeloid leukemia factors are a novel family of proteins in the course of evolution, and 
MLF1, the founding member, is associated with the emergence of blood cell cancers in 
human (Yoneda-Kato et al., 1996). However, their functions and molecular mechanisms of 
action remain still largely unknown. 
4.1. Human myeloid leukemia factor (hMLF) 
4.1.1. Discovery and structure of hMLF1 and hMLF2 
        Myeloid leukemia factor 1 (MLF1), the founding member of the MLF family, was 
identified by cloning the breakpoints of the t(3;5)(q25.1;q34) translocation, which is a 
chromosomal rearrangement found in rare (less than 0.5%) cases of myelodysplastic 
syndrome (MDS) and acute myeloid leukemia (AML) in human (Yoneda-Kato et al., 1996) 
(Figure 15). It exhibits marked variability in expression, with high levels in testis, ovary, 
skeletal and cardiac muscle, colon and kidney, but low or apparently absent transcription in 
other tissues. Soon after the discovery of MLF1, MLF2 cDNA was cloned, which encodes a 
protein highly homologous to MLF1 (Kuefer et al., 1996). The MLF2 gene locus was 
mapped to chromosome 12q13 in human, which is a chromosomal region involved 
frequently in the translocations and deletions in acute myeloid leukemia or acute lymphoid 
leukemia, although no evidence indicates so far that MLF2 directly participates in blood cell 
cancers and/or hematopoiesis. 
 
        The members of the MLF family appear to be present in all metazoans (Martin-
Lannerée et al., 2006). In human, the MLF family comprises two members, hMLF1 and 
hMLF2, which share nearly 40% of identity between them. At the molecular level, hMLF1 
and hMLF2 are relatively small-sized proteins (about 270 amino acids). hMLF1 has an N-
terminal nuclear export signal (NES) and two C-terminal nuclear localization signals (NLS) 
(Figure 15), which allow hMLF1 to shuttle between the nucleus and the cytoplasm 
(Yoneda-Kato et al., 2008). hMLF1 and hMLF2 do not have specific known functional 
domains that could help ascribe their biochemical activity, and they only have a central 
domain preserved within the MLF family and a 14-3-3 protein binding domain (Gobert et 
al., 2012).  
 
 In addition to the adaptor protein 14-3-3ζ, which can bind MLF1 (Lim et al., 2002; 
Molzan et al., 2012) and regulate its interaction with the apoptotic regulator Bcl-XL (Sun et 
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al., 2015), only a few proteins are known to interact with mammalian MLF proteins, 
including the COP9 signalosome subunit CSN3 which is required for MLF1-induced 
degradation of p53 (Yoneda-Kato et al., 2005), the HOP survival complex components 
Hax1 and HtrA2 (Sun et al., 2017) (see below), the centromere protein CENPU/MLF1IP
(Hanissian et al., 2004), the adaptor protein MADM (Lim et al., 2002), and the hnRNP-U 
like protein MANP (Winteringham et al., 2006). Also, in many cases, the physiological 
relevance of these interactions has not been known, so we only have a limited understanding 
of MLF protein possible mode of action. 
 
4.1.2. Roles of hMLF1 in hematopoiesis 
        So far, the roles of hMLF1 in hematopoiesis in human have still not been 
characterized. However, its expression profile suggests that it regulates blood cell 
progenitor fate. Indeed, hMLF1 is strongly expressed in CD34+ progenitor cells and its 
expression decreases as soon as the specification of these cells towards myeloid and 
erythroid lineage progresses (Matsumoto et al., 2000). 
 

Figure 15. Schematic representation of the members of the MLF family in human 
and in Drosophila 
The fusion protein NPM-MLF1 produced by the t(3;5) chromosomal translocation consists of 
the N-terminal region of NPM (amino acids 1 to 175) fused to the almost entire hMLF1 (amino 
acids 16 to 268). The various domains identified in these proteins are shown. Abbreviations: 
NES (nuclear export signal), NLS (nuclear localization signal), OLIGOM (NPM oligomerization 
domain), 14-3-3 (consensus binding motif for 14-3-3 proteins), MHD (MLF homology domain). 
The percentages of identity between MLF proteins or their MHD regions are indicated. (From 
Gobert et al., 2012) 
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        In a mouse model, MLF1/HLS7 (Hematopoietic Lineage Switch 7) was identified 
during a screening for genes controlling the transition of erythroleukemic cells (J2E)/ 
immature myeloid cells (J2E-m2) (Williams et al., 1999). Indeed, the ectopic expression of 
MLF1 in J2E cells reduces their ability to differentiate into mature erythrocytes in response 
to erythropoietin and causes the acquisition of immature monocyte-type phenotypes. 
Therefore, MLF1 can induce the reprogramming of erythroleukemic cells to monocytes, 
which is called “lineage switching”. In addition, over-expression of MLF1 in primary 
hematopoietic cells of the fetal liver, as well as in different blood cell lines, confirmed that 
MLF1 promotes the differentiation of myeloid cells and inhibits erythropoietin-induced cell 
differentiation (Williams et al., 1999; Winteringham et al., 2004). While the consequences 
of MLF1 invalidation on mice hematopoiesis remains to be established, it was shown that 
MLF1 knock-out lymphocytes are more resistant to apoptotic stimulation than wild-type 
cells, suggesting that MLF1 controls lymphocyte fate (Sun et al., 2015). However, further 
analyses will be required to better characterize MLF1 function and mode of action during 
mammalian blood cell development. 
4.1.3. Roles of hMLF in cancer, cell proliferation and apoptosis. 
        As mentioned above, hMLF1 was identified by cloning the breakpoints of the 
chromosomal translocation t(3;5)(q25.1;q34) associated with MDS and AML (Yoneda-Kato 
et al., 1996). This rare translocation results in the expression of the NPM-MLF1 fusion 
protein, which is composed of the N-terminal portion of nucleophosmin (NPM) containing a 
nuclear localization signal and a dimerization domain, fused to the almost entire protein 
sequence of hMLF1 (Figure 15). NPM is a nucleolar protein with many functions, such as 
control of ribosomal protein transport, regulation of cell cycle progression, maintenance of 
genome stability or assembly/disassembly of nucleosomes (Colombo et al., 2011).  
 
        Many evidences indicate that the NPM-MLF1 fusion protein plays a direct role in 
malignant transformation. In particular, NPM-MLF1 expression increases the proliferative 
potential of hematopoietic progenitors in vitro and facilitates the oncogenic transformation 
induced by RasV12 in murine embryonic fibroblast (Lee et al., 2012). Moreover, NPM is 
very frequently mutated in AML and it is targeted by two other chromosomal translocations 
found in leukemia, to generate fusion proteins with ALK or RAR (Falini et al., 2007). It has 
been proposed that NPM converts its partners into onco-proteins by providing an 
oligomerization domain as well as a nuclear localization signal (NLS) in the case of 
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translocations. In fact, MLF1 is mostly localized in the cytoplasm, but NPM-MLF1 is 
nuclear in cell culture after transfection (Falini et al., 2007; Ohno et al., 2000). It also 
should be noted that the expression of MLF1 is deregulated because it is under the control 
of the regulatory regions of NPM1 in the chromosomal translocation t(3;5). Furthermore, it 
has been observed that the expression of MLF1 increases during the progression of MDS to 
AML and that high expression levels of MLF1 are associated with a poor prognosis in MDS 
patients without the t(3;5) translocation. Thus, deregulation of MLF1 expression could 
participate in the malignant transformation of myeloid cells (Matsumoto et al., 2000). All 
together, the roles and the molecular mechanisms of action of MLF1 in leukemic 
transformation remain rather elusive. 
 
 In addition, MLF1 may have an oncogenic role in other tissues, for instance, MLF1 is 
over-expressed in squamous lung carcinomas (Sun et al., 2004) and esophageal carcinomas 
(Chen et al., 2008). Moreover, MLF2 was shown to contribute to cancer cell metastasis and 
potential gain of function point mutations in MLF2 have been identified in lung and breast 
metastatic cells (Dave et al., 2014). Strikingly, a recent study identified a bi-allelic null 
mutation of MLF1 in infants with T-cell acute lymphoid leukemia (Mansur et al., 2015). 
Therefore, MLF family members could play a role as a tumor suppressor or as an oncogene 
depending on the cell types. 
  
        Along that line, it was shown that MLF1 overexpression impairs cell cycle exit in 
erythrocytes by promoting the degradation of the cell cycle regulator p27Kip1 (Winteringham 
et al., 2004), but inhibits the proliferation of fibroblasts through preventing p53 degradation 
(Yoneda-Kato et al., 2005). More recently, a study showed that MLF1 is a novel modulator 
of neonatal rat cardiomyocyte proliferation (Rangrez et al., 2017). MLF1 overexpression in 
cardiomyocytes inhibited their proliferation and promoted apoptosis, whereas MLF1 
knockdown protected them from apoptosis and hypoxia-induced cell death and promoted 
proliferation. Interestingly, MLF1 is highly expressed in the heart in human, but at 
significantly reduced levels in patients with dilated cardiomyopathy and it is profoundly 
down-regulated in an in vivo mouse model of cardiomyopathy, suggesting that MLF1 could 
be implicated in this pathology. Finally, another recent study showed that MLF1 is a pro-
apoptotic antagonist of HOP complex-mediated survival (Sun et al., 2017). By interacting 
with HAX1 and HtrA2, two components of the HAX1/HtrA2-OMI/PARL (HOP) 
mitochondrial protein complex, MLF1 inhibits HtrA2 cleavage and activation, which leads 
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to apoptotic cell death. Interestingly, mlf1 deletion reverses lymphopenia and significantly 
ameliorates the progressive neurodegeneration observed in Hax null mutant mice. Thus, 
MLF1 could control cell survival in the hematopoietic and nervous system by regulating 
HOP function. However, only a small fraction of MLF1 is present in the mitochondria (Sun 
et al., 2017) and thus its function is probably not restricted to that cell compartment. 
4.2. Drosophila myeloid leukemia factor (dMLF) 
4.2.1. Isoforms and structure of dMLF 
        In Drosophila, there is a single mlf gene, which is located on chromosome II (Ohno et 
al., 2000). dmlf codes for four distinct isoforms that are generated by alternative splicing, 
which are dMLF-A, dMLF-B, dMLF-C and dMLF-D, and these MLF isoforms that range 
from 273 to 376 amino acids long, differ by their N-terminal or C-terminal region (Martin-
Lannerée et al., 2006) (Figure 16). dMLF-A, the most abundant isoform of dMLF, has 28% 
identity with hMLF1 and hMLF2 (Gobert et al., 2012). The central region of dMLF-A 
(amino acids 96 to 202), which corresponds to the MLF homology domain (MHD), has 
about 50% identity with the corresponding domain of hMLF1 or hMLF2 (Figure 15). 
dMLF contains a nuclear export signal (NES) and two nuclear localization signals (NLS), 
and a study showed that these two NLS are required to enable nuclear localization of 
dMLF-A in Drosophila cell culture (Sugano et al., 2007). MLF-C and D also carry these 
NLS but MLF-B does not, and it was reported to be located both in the cytoplasm and in the 
nucleus (Martin-Lannerée et al., 2006). Finally, except a binding site for the 14-3-3 family 
of proteins at the C-terminus, dMLF does not possess any homology with other proteins. 
4.2.2. Expression profile and mutants of dMLF 
        The expression profile of mlf gene reveals that it has a strong maternal contribution and 
it is ubiquitously expressed during the early embryonic stage. At later stage, its expression 
level increases in the central nervous system, gonads, digestive tract and crystal cells 
(Martin-Lannerée et al., 2006; Bras et al., 2012). Furthermore, mlf gene is expressed 
ubiquitously at different larval stages in the imaginal discs. dMLF is localized in both the 
nucleus and the cytoplasm in different ratios depending on the tissues and stages of 
development (Martin-Lannerée et al., 2006). In the larval hemocytes, dMLF is expressed 
predominantly in the crystal cell lineage where it is mainly localized in the nucleus (Bras et 
al., 2012). 
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        The imprecise mobilization of a transposable element located in the first intron of the
mlf gene allowed to generate two mlf null mutant alleles (Martin-Lannerée et al, 2006), and 
both alleles resulted in a deletion of almost entire mlf coding region (Figure 16.A). mlf null 
mutation is associated with a strong lethality during development. Some mlf mutant 
individuals can survive to the adult stage, but they do not exhibit obvious morphological 
defects apart from the loss of some interocellar bristles, frequent shortening of head 
macrochaetes and ectopic vein formation in the wings (Figure 16.B) (Martin-Lannerée et 
al., 2006). Therefore, the phenotypes of these mlf mutants do not provide strong hints 
concerning mlf functions in vivo. 
4.2.3. dMLF partners and involvement in apoptosis 
  Drosophila MLF was first identified in a two-hybrid screen in yeast as a partner of 
the Drosophila transcription factor DREF (DNA Replication Enhancer Factor), which 
regulates the expression of genes involved in DNA replication and cell proliferation (Ohno 
et al., 2000). Moreover, dMLF over-expression was found to induce a reduction in eye and 
  A                                                                           B 
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Figure 16. mlf transcripts and its mutants in Drosophila 
(A) Structures of dmlf transcripts. The four isoforms are depicted and coding exons are shown in 
color, untranslated regions in grey. The extent of dmlf deletion in the two mlf alleles is shown. 
(B) Phenotypes of the adult dmlf mutant flies. Views of the head (A-C) and wings (A’-C’) of 
dmlfR2/dmlfR2 (A and A’; wild type derived from precise excision of the P element), 
dmlfΔC1/dmlfΔC1, act5C-Gal4/+ (B and B’), dmlfΔC1/dmlfΔC1, act5C-Gal4/UAS-hMLF1(22.1). The 
ubiquitous expression of hMLF1 partially rescues mlf mutant phenotypes (C and C’). (From 
Martin-Lannerée et al., 2006) 
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wing size (Sugano et al., 2007; Yanai et al., 2014). Importantly, a recent publication 
showed that MLF is recruited to chromatin on a DREF-responsive enhancer in basket, a 
gene coding for the Jun N-terminal Kinase (JNK) whose activation promotes apoptosis, and 
genetic experiments indicate that gain of MLF causes a reduction in wing size by activating 
the JNK pathway and apoptosis (Yanai et al., 2014). Together with previous findings 
showing that MLF is associated with polytene chromosomes in Drosophila (Fouix et al., 
2003) and that mouse Mlf1 can bind DNA (Winteringham et al., 2006), this report 
demonstrated for the first time that MLF could act directly on chromatin to regulate gene 
expression. This was very recently confirmed at the genome-wide level in S2 cells by 
another study (Dyer et al., 2016) (see Discussion). 
 
        Independently, another two-hybrid screen showed that MLF is a partner of Suppressor 
of Fused, a negative regulator of the Hedgehog signalling pathway, and gain of function 
experiments showed that dMLF genetically interacts with Su(fu) in the eye disc (Fouix et 
al., 2003). In addition, dMLF was shown to physically interact with another negative 
regulator of Hedgehog, dCostal2 (Fouix et al., 2003), and as its mammalian counterpart, 
with the COP9 subunit CSN3 (Sugano et al., 2007). However, the importance of MLF 
interaction with these proteins in vivo remains largely unknown.  
4.2.4. Roles of dMLF in hematopoiesis 
        In Drosophila, dMLF is strongly expressed in crystal cells, one of the three main blood 
cell lineages, at the embryonic stage and the larval stage (Martin-Lannerée et al., 2006; Bras 
et al., 2012). Actually, mlf expression in the crystal cell lineage seems to be directly 
activated by the SRP/LZ complex (Bras et al., 2012; Ferjoux et al., 2007). In addition, mlf 
was identified as a positive regulator of the activity of the SRP/LZ complex in a genome-
wide RNA interference (RNAi) screen in cell culture. Indeed, the down-regulation of dMLF 
expression by RNAi technology in Kc167 cells resulted in a decrease in the transactivation 
activity of a target reporter gene activated by the SRP/LZ complex (Gobert et al., 2010). It 
has been shown that MLF regulates the activity of this complex through ensuring LZ stable 
expression both in Kc167 cells and in crystal cells in vivo (Bras et al., 2012).  
 
       Thanks to its capacity to control transcription factor LZ stability, dMLF also regulates 
the development of the embryonic and the larval LZ+ cell lineage in Drosophila (Bras et al., 
2012). During embryonic hematopoiesis, dMLF is required for the maintenance of LZ+ 
cells. These cells are specified normally, but their number decreases gradually in absence of 
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dMLF. This is probably due to a lack of LZ accumulation/maintenance, which prevents the 
self-regulation of LZ expression and the maintenance of embryonic crystal cells. Indeed, the 
enforced expression of LZ in the LZ+ cells can restore crystal cell number in mlf mutant 
embryos. On the contrary, an increase in the number of circulating LZ+ cells is observed in 
the mlf mutant larvae. This phenotype in the larvae is also associated with a decrease in LZ 
protein level and is rescued by the enforced expression of LZ, suggesting that this 
unexpected increase in larval crystal cell number caused by the loss of dMLF is due to a 
decrease in LZ level. However, the precise mechanism by which dMLF regulates LZ 
stability and why there is an increase in larval crystal cell number still remain unknown. 
During my PhD, I tried to tackle these two important questions to better understand MLF 
function and molecular mechanism of action during hematopoiesis. 
 
        It is worth mentioning that the defects in crystal cell number observed in mlf mutants 
were rescued by re-expressing dMLF specifically in the LZ+ cells using the lz-GAL4 driver, 
demonstrating that these defects are cell autonomous and caused after the induction of LZ 
expression (Bras et al., 2012). In addition, hMLF1 expression also rescued mlf mutant 
defects in crystal cell number, indicating a conservation of MLF function. Finally, RUNX1-
ETO accumulation in Kc167 cells as well as in Drosophila crystal cells or in human 
leukemic cells was also dependent on dMLF or hMLF1, respectively, suggesting that MLF 
factors could regulate the stability of different Runt-domain containing transcription factors. 
This could be particularly relevant for hMLF1 function in the development of MDS and 
AML in human.  
4.2.5. Roles of dMLF in suppression of polyglutamine aggregates and 
neurodegeneration 
 Huntington’s disease (HD), an autosomal dominant neurodegenerative disease, is 
caused by the expansion of normally polymorphic polyglutamine (polyQ) stretches at the N-
terminus of the protein Huntingtin (HTT). If the polyQ stretches in Huntingtin is expanded 
beyond 36, it will lead to misfolding of the protein, which causes the formation of 
cytoplasmic and nuclear/perinuclear aggregates that are also known as intracellular 
inclusions. It has been known that Huntingtin interacts with several proteins and these 
proteins are recruited to the aggregates. However, the contributions of these proteins to the 
pathogenesis of Huntington’s disease have not been identified fully. Several Drosophila 
models have been developed to model Huntington’s disease as well as other polyQ-
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associated neurodegenerative diseases (McGurk et al., 2015). Indeed, the expression of 
polyQ in the Drosophila eye is toxic and produces phenotypes (eye depigmentation and cell 
degeneration) that can be used as readout to screen for enhancers or suppressors of polyQ-
associated neurodegeneration. Thereby, it was shown that over-expression of dMLF can 
ameliorate the cellular toxicity of the polyQ proteins expressed in the eye and in the central 
nervous system (Kazemi-Esfarjani et al., 2000). In particular, the endogenously or 
ectopically expressed dMLF co-localizes with polyQ aggregates in the retina, suggesting 
that dMLF alone or through an intermediary molecular partner sequesters polyQ and/or its 
aggregates to suppress toxicity. Moreover, in transfected primary rat neuronal culture, 
dMLF also co-localizes with the polyQ inclusions and suppresses their toxicity, reducing 
the morphological phenotypes and inclusions (Kim et al., 2005). Interestingly, similar 
suppression was observed with hMLF1 or hMLF2, suggesting that suppression of polyQ 
toxicity is a conserved function of MLF proteins. At the molecular level, dMLF was found 
to reduce the recruitment of the histone acetyltransferase CBP and the chaperone Hsp70 into 
the inclusions, two essential proteins trapped in polyQ aggregates. In addition, hMLF1 and 
hMLF2 were recently found to preferentially interact with the mutated N-terminal 
Huntingtin. Both of them significantly reduced the number of cells containing mutant 
Huntingtin aggregates and subsequent apoptosis in Neuro2A cells model (Banerjee et al., 
2017). In presence of hMLF1 and hMLF2, the mobile fraction of mutant Huntingtin 
aggregates was increased, and hMLF1 could release some transcription factors from mutant 
Huntingtin aggregates. These data suggest that MLF proteins could modulate the formation 
of aggregates as well as the induction of apoptosis, resulting in a decrease in polyQ 
associated toxicity. Thus, beyond their role in hematopoiesis and leukemia, MLF proteins 
could be important regulators in neurodegenerative diseases.
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5. The Hsp40/DnaJ chaperone family 
        The 40kDa heat shock protein (Hsp40/DnaJ) co-chaperones are the largest and the 
most diverse sub-group of the heat shock protein (HSP) family. They are widely accepted as 
regulators of the Hsp70 chaperones, but also have roles as co-chaperones in the Hsp90 
chaperone machine. However, a growing number of evidences show that their biological 
functions may be independent of either of these two chaperone machines. 
5.1. General description of molecular chaperones 
        The successful execution of cellular processes is dependent on the coordinated 
interactions of proteins. After synthesis as linear sequence of amino acids on ribosomes, the 
large majority of proteins must fold into well-defined three-dimensional structures to obtain 
their functions. Although some newly translated proteins are capable of folding 
spontaneously, a large number of proteins are less efficient to fold properly and easy to mis-
fold, leading to the formation of protein aggregates, which can be toxic and cause diseases. 
To settle these problems, cells have a network of molecular chaperones that assist in de 
novo folding and maintain preexisting proteins in their native states (Hartl et al., 2011). 
 
        Molecular chaperones are any proteins that interact with and aid in the folding or 
assembly of another protein without being part of its final structure (Kim et al., 2013). They 
are found in bacteria, plants, insects and other animals, and represent the most preserved 
system of the living kingdom. They are main players of protein homeostasis in cells under 
physiological or stress conditions (Saibil, 2013), modulating the integrity or activity of their 
protein substrates (called clients) with different mechanisms. They participate into many 
biological processes, ranging from folding of newly synthesized proteins or refolding of 
mis-folded protein aggregates to the regulation of their stability and subcellular location 
(Figure 17). Under physiological conditions, they recognize the hydrophobic regions of 
proteins during synthesis, and thus preventing the specific interactions with other proteins as 
well as the formation of lethal insoluble aggregates in cells. Under cellular stress conditions, 
the chaperones interact with denatured or poorly folded proteins and then try to refold their 
substrates properly. If the client protein cannot be refolded properly, it is usually delivered 
to the degradation pathways. As main cyto-protective players, molecular chaperones protect 
cells against different types of stresses and ensure organism survival under adverse 
conditions. 
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5.2. Heat shock proteins 
        Up to now, the largest and best-characterized group of molecular chaperones is 
composed of heat shock proteins (Hsps). The heat shock response (HSR) is an ancient and 
highly conserved molecular response to disruption of protein homeostasis (Morimoto, 
2011), which was discovered in 1962 and characterized with an abnormal transcription of 
certain loci on polytene chromosomes of salivary glands in Drosophila following an 
elevation of temperature (Jamrich et al., 1977). Since then, many studies showed that other 
stresses, including endoplasmic reticulum stress, nutrient deficiencies or viral infections, 
can induce or increase the expression of Hsps. In addition, some Hsps are constitutively 
expressed and have household functions (Vos et al., 2008). Notably, many HSPs are 
chaperones and play an important role in protein homeostasis by binding to newly 


Figure 17. Protein fates in the proteostasis network 
The proteostasis network integrates chaperone pathways for the folding of newly synthesized 
proteins, for the remodeling of misfolded states and for disaggregation with the protein 
degradation mediated by the ubiquitin-proteasome-system (UPS) and the autophagy system. 
(From Kim et al., 2013)  
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synthesized polypeptides, catalyzing their conformational maturation or participating in 
protein quality control. 
 
        In mammals, Hsps are grouped into six main families depending on their molecular 
weight: Hsp100, Hsp90, Hsp70, Hsp60, Hsp40 and the family of small stress proteins (small 
Hsps, or sHsps) (Hartl et al., 2011). These families have some common specificity with 
respect to their subcellular localization (cytoplasm, mitochondria, endoplasmic reticulum), 
their mechanisms of action, their dependence on ATP. Here, it should be noted that, 
historically, the inducible chaperones are denoted as Hsp (Heat shock protein), while the 
constitutively expressed chaperones are denoted as Hsc (Heat shock cognate protein). These 
chaperones form a vast network of molecular chaperones that can be schematically 
subdivided into four families of ATP-dependent chaperones (Hsp60, Hsp70, Hsp90 and 
Hsp100), whose activities are regulated by their respective co-chaperones, for instance, 
Hsp40/DnaJ for the Hsp70 chaperone system. 
 

Figure 18. The proteostasis network for the Hsp70 complex and the Hsp90 complex 
in human cells characterized by mass spectrometry (MS) 
Protein-protein interactions were identified by AP-MS. Proteins are shown as rectangles, and 
lines represent interactions between the proteins (From Taipale et al., 2014). 
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5.3. The DnaJ proteins family 
5.3.1. The Hsp70/DnaJ chaperone system 
        Generally, there are two common chaperone families, the Hsp70 system and the Hsp90 
system, which participate broadly in de novo protein folding and refolding (Figure 18). 
They are multicomponent molecular chaperone machines that promote protein folding 
through ATP- and co-factor-regulated binding and release cycles. 
 
        The founding member of the Hsp40 family, DnaJ, was identified as a regulator of the 
ATPase activity of DnaK, the Hsp70 homolog in E.coli (Yochem et al., 1978). In this 
bacterium, DnaK consists of two domains connected by a highly conserved hydrophobic 
linker region, an N-terminal nucleotide-binding domain (NBD) that binds ATP and carries 
the ATPase activity, and a C-terminal substrate-binding domain (SBD) that binds and fixes 
substrates and then refolds them (Doyle et al., 2013) (Figure 19.A). Its reaction cycle for 
the folding of proteins can be described as follows (Kim et al., 2013) (Figure 19.B): 
following ATP binding to the NBD, DnaK adopts an open conformation with the exposed 
substrate binding domain. In parallel, the co-chaperone DnaJ transiently interacts with a 
particular substrate via its C-terminal substrate-binding domain. Then DnaJ binds to DnaK 
via its N-terminal J domain, presents the substrate to DnaK and stimulates DnaK ATPase 
activity. The hydrolysis of ATP to ADP stimulated by DnaJ induces a change in the 
conformation of the substrate-binding domain, resulting in the closing of DnaK’s α-helical 
lid over the bound substrate peptide, which makes it possible to modify the non-native 
substrate. DnaJ is then released from DnaK as it has a reduced affinity for ADP-bound 
DnaK. The attachment of nucleotide exchange factor (NEF) stimulates the release of ADP 
from the nucleotide-binding domain, and ATP binding induces the opening of DnaK C-
terminal substrate-binding domain, hence the modified substrate is released. The same 
substrate may undergo several successive cycles if necessary, or be delivered to the 
proteasome degradation system if this folding/refolding process fails. In sum, the 
Hsp40/DnaJ co-chaperones are canonically involved in the presentation of the substrate 
peptides to the Hsp70 chaperones as well as in the stimulation of the Hsp70 ATPase 
activity. 
 
        Although the major effect of DnaJ on DnaK reaction cycle is the stimulation of DnaK 
ATPase activity, DnaJ also has a chaperone activity by itself; for example, it is able to 
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renature the denatured luciferase in vitro (Fink, 1999). In addition, some DnaJ proteins 
could be direct or indirect regulators of the Hsp90 chaperones (Sterrenberg et al., 2011).  
A 

B 

Figure 19. Structure and reaction cycle of Hsp70 
(A) Structure of Hsp70. Hsp70 consists of two domains, the nucleotide-binding domain (NBD) 
and the substrate-binding domain (SBD), connected by a conserved linker. 
(B) Reaction cycle. ATP binding to the NBD stabilizes the open state of Hsp70, facilitating the 
binding of substrate protein recruited to Hsp70 by Hsp40 co-chaperone. The open state has fast 
on and off rates for substrate peptide. Hsp40 stimulates ATP hydrolysis on Hsp70, resulting in 
the closing of the SBD α-helical lid over the bound substrate peptide. The closed state has slow 
on and off rates for substrate peptide. NEFs stimulate the release of ADP from the NBD, and 
ATP binding causes substrate release (From Kim et al., 2013). 
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5.3.2. Structure and classification of Hsp40/DnaJ proteins family 
        Generally, members of the Hsp40/DnaJ proteins family possess a common N-terminal 
J-domain allowing them to bind to Hsp70 chaperones and a conserved C-terminal domain 
(Figure 20.A). This J-domain is composed of approximately 70 amino acids that are 
organized into a structure consisting of four helices and a loop located between the helices 
II and III. It also contains a highly conserved HPD (His-Pro-Asp) motif, which is essential 
for the stimulation of the Hsp70 ATPase activity (Sterrenberg et al., 2011) (Figure 20.B). 
      A 

     B 
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Figure 20. Classification and functional domains of DNAJ 
(A) DNAJ proteins are classified into three families. DNAJ may be classified according to the 
presence or absence of three domains, namely the J domain, a glycine/phenylalanine rich region 
(G/F) and the cysteine repeat motif (Cys-repeat) together with a C-terminal domain. 
(B) The three dimensional structure of J-domain (E.coli J-domain; 1BQ0) that is currently used 
to define the DNAJ family. It illustrates that the J-domain structure resembles a “protruding 
finger” (helix 2 and 3) containing the highly conserved HPD (His-Pro-Asp) motif located on the 
loop between helix 2 and 3. This HPD motif is important for stimulation of Hsp70 ATPase 
activity (From Sterrenberg et al., 2011). 
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        The Hsp40/DnaJ proteins family in human is composed of 49 members and 44 
members in Drosophila. These proteins are classified into three types according to the 
presence or absence of two other domains in addition to the N-terminal J-domain and the 
conserved C-terminal domain (Cheetham et al., 1998): Type I (or Type A) has a 
glycine/phenylalanine (G/F) rich domain as well as a cysteine repeat domain, Type II (or 
Type B) has a glycine/phenylalanine (G/F) rich domain and type III (or Type C) does not 
have any of these extra domains (Figure 20.A). Hsp40/DnaJ proteins are found in the 
cytosol, mitochondria, nucleus, endoplasmic reticulum, endosomes or ribosomes, and their 
expression may be ubiquitous or restricted to a particular tissue. Some Hsp40/DnaJ proteins 
of type I and II could interact with unfolded polypeptides and have a chaperone function 
independently of Hsp70 proteins (Hageman et al., 2010). Besides the domains described 
above, some Hsp40/DnaJ proteins possess additional regions that enable them to exert a 
specific function (Lu et al., 2006; Cunnea et al., 2003; Shi et al., 2005).  
 
 Finally, DnaJ-1, the protein that we identified in our proteomic screen as a partner of 
dMLF, belongs to type II (or type B) and its homologs in human are DnaJB1, DnaJB4 and 
DnaJB5. It was first identified in an yeast two-hybrid screen as a partner of the transcription 
factor HSF and it was shown to be a nuclear protein that delays the onset of the heat shock 
response in SL2 cells (Marchler et al., 2001). However, its function during Drosophila 
development and hematopoiesis still remained unknown. 
5.4. Hsp70/DnaJ and hematopoiesis 
        So far, the role of DnaJ proteins in hematopoiesis has barely been studied. However, 
some studies revealed the major role of the Hsp70 chaperones family in erythropoiesis 
(Weiss et al., 2009). Indeed, it has been shown that Hsp70 regulates erythroblast viability 
by preventing their death induced by apoptosis. On the one hand, erythropoietin (Epo) 
treatment induces the translocation of Hsp70 to the nucleus where it binds GATA-1 and 
performs essential functions in erythroid differentiation, since Hsp70 inhibits the cleavage 
of GATA-1 by Caspase 3 (Ribeil et al., 2007). Conversely, during Epo deprivation, Hsp70 
is excluded from the nucleus and GATA-1 is cleaved by Caspase 3. In fact, it has been 
shown that during erythropoiesis, caspases activation results in GATA-1 cleavage and 
cessation of erythrocyte maturation or apoptosis (De Maria et al., 1999). Moreover, the 
phosphorylation of Hsp70 in response to Epo is necessary for its relocation in the nucleus 
and for erythroblast differentiation. On the other hand, AIF (Apoptosis-Inducing Factor) is 
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also involved in erythropoiesis. Following Epo treatment, transient mitochondrial 
depolarization is observed, which leads to the release of procaspases, the caspase activator 
cytochrome C and AIF. AIF can then translocate to the nucleus and induce DNA 
fragmentation independently of the caspases to trigger full-blown apoptotic death (Lui et al., 
2007; Zermati et al., 2001). In this case, it has been proposed that Hsp70 limits the 
apoptotic activity of AIF by sequestering it in the cytoplasm (Lui et al., 2007). In addition, a 
study carried out in zebrafish showed the involvement of a conserved mitochondrial matrix 
chaperone Hspa9b during the development of erythrocytes. Indeed, in this model, the loss of 
the Hspa9b chaperone induces a myelodysplastic phenotype, producing oxidative stress and 
apoptosis in blood cells (Craven et al., 2005). These animals are anemic, and blood cells do 
not differentiate into mature erythrocytes and die by apoptosis. 
 
        The chaperone proteins are also involved at different stages of the hemoglobin 
production (Arlet et al., 2014). In particular, it has recently been shown that the formation 
of hemoglobin aggregates in patients with ß-thalassemia major (ß-TM) causes Hsp70 
sequestration in the cytoplasm, where it binds to the α-chain of the globin. This prevents 
Hsp70 from protecting GATA-1, and leads to a maturation termination of erythrocytes and 
their death by apoptosis (Arlet et al., 2014). 
 
 The role of DnaJ proteins in hematopoiesis remains largely unknown. However, 
DnaJB9/hTid1 was shown to interact with the transcription factor STAT5b and to inhibit its 
expression, thereby suppressing STAT5b-induced hematopoietic cell growth (Dhennin-
Duthille et al., 2011). In addition, a recent study showed that over-expression of the co-
chaperone ERDJ4 (also called DNAJB9), by enhancing the folding of an endoplasmic 
reticulum protein, promotes hematopoietic stem cell survival (van Galen et al., 2014).  
5.5. Molecular chaperones and polyglutamine aggregation 
        In mammals, the importance of molecular chaperones is underlined by the 
consequences of the toxicity of the specific aggregations of poorly folded proteins, which is 
at the origin of large numbers of neurodegenerative diseases (Borrell-Pagès et al., 2006; 
Muchowski et al., 2005). Due to their roles in the fight against aggregated proteins, 
molecular chaperones play a central role in the prevention of neurodegenerative diseases 
that are caused by the aggregation of polyglutamine (polyQ) proteins. Indeed, many studies 
have demonstrated the involvement of the protein quality control systems, like the Hsp70 
chaperones system and the co-chaperones Hsp40/DnaJ, in different neurodegenerative 
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diseases (Bilen et al., 2007; Fernandez-Funez et al., 2000). Moreover, molecular chaperones 
are also involved in some other neurodegenerative diseases, such as Alzheimer's disease 
(Dou et al., 2003) and Parkinson's disease (Huang et al., 2006). Notably, over-expression of 
DnaJ-1 can suppress the polyQ cytotoxicity in different Drosophila neurodegeneration 
models (Fayazi et al., 2006; Kazemi-Esfarjani et al., 2000; Chan et al., 2000), and DnaJ-1 
cooperates with Hsp70 in this process (Chan et al., 2000). In addition, mutations in different 
genes encoding for DnaJ-like proteins are at the origin of pathologies associated with 
proteostasis problems in human, such as neuropathy, muscular dystrophy or Parkinson's 
disease (Koutras et al., 2014). 
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6. Objective of this project 
        MLF factors constitute a small family of poorly characterized proteins and they have 
been implicated in hematopoiesis and in oncogenic blood cell transformation. However, 
their function and molecular mechanism of action still remain elusive. Previous work in 
Drosophila melanogaster showed that dMLF controls the number of crystal cells, one blood 
cell lineage related to megakaryocyte, and stabilizes the RUNX transcription factor Lozenge 
that is indispensable for the development of crystal cells. Moreover, our results suggested 
that regulation of RUNX transcription factor stability and activity is a conserved 
characteristic of MLF factors, which could therefore play a role in many cancers caused by 
a change in RUNX activity in human. During my PhD study, I used Drosophila 
melanogaster as a model to decipher the molecular mechanism of action of MLF on 
Lozenge stability and activity during blood cell development by searching for MLF 
interacting partners and characterizing the role of these MLF partners in the regulation of 
the homeostasis of the hematopoietic system and particularly in the control of proliferation 
and differentiation of LZ+ cell lineage.   
 
 
 

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        During my PhD, I focused my work on the characterization of MLF mode of action in 
relation with the RUNX transcription factor stability and hematopoiesis. To gain insights 
into the possible mechanism of action of MLF proteins, we carried out a proteomic 
approach to identify Drosophila MLF partners in the Drosophila Kc167 blood cell line. 
This allowed us to identify the small chaperone DnaJ-1 as a partner of MLF. We then 
proceeded with the characterization of Drosophila MLF/DnaJ-1 interactions and the 
functional analysis of DnaJ-1 in cell culture and in vivo, as described thereafter. 
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Abstract 
 
A tight regulation of transcription factor activity is critical for proper development. For 
instance, modifications of RUNX transcription factor dosage are associated with several 
diseases, including hematopoietic malignancies. In Drosophila, myeloid leukemia factor 
(MLF) has been shown to control blood cell development by stabilizing the RUNX 
transcription factor Lozenge (LZ). However, the mechanism of action of this conserved 
family of proteins involved in leukemia remains largely unknown. Here, we further 
characterized MLF mode of action in Drosophila blood cells using proteomic, 
transcriptomic and genetic approaches. Our results show that the Hsp40 co-chaperone 
family member DnaJ-1 is a partner of MLF and demonstrate that like MLF, DnaJ-1 binds 
LZ and promotes its expression in cell culture, suggesting that MLF and DnaJ-1 form a 
chaperone complex to regulate LZ level and activity. Importantly, dnaj-1 loss causes an 
accumulation of LZ+ blood cells similar as in mlf mutant larvae, and we find that dnaj-1 
genetically interacts with mlf to control LZ level and LZ+ blood cell development in vivo. In 
addition, we show that mlf or dnaj-1 loss alters LZ+ cell differentiation and causes increased 
Notch expression and over-activation of the Notch signaling pathway. Finally, using 
different conditions to manipulate LZ activity, we show that high levels of LZ are required 
to repress Notch transcription and signaling. Our findings thus establish a functional link 
between MLF and the co-chaperone DnaJ-1 to control RUNX transcription factor activity 
and Notch signaling during blood cell development in vivo. We propose that MLF/DnaJ-1-
dependent increase in RUNX level allows the repression of Notch expression and signaling 
to prevent aberrant blood cell development. 
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Author Summary 
 
A tight regulation of protein expression level is required for proper development. Notably, 
the abnormal expression of key transcription factors or signaling pathway components 
controlling blood cell development contributes to hematological diseases, such as leukemia. 
In this report, we used Drosophila as a model to study the function and mode of action of a 
family of conserved but poorly characterized proteins implicated in leukemia called myeloid 
leukemia factors (MLF). By combining proteomic, transcriptomic and genetic approaches, 
we show that MLF acts in concert with an Hsp40 co-chaperone to control the level and 
activity of a RUNX transcription factor and therefore RUNX+ blood cell number and 
differentiation. Furthermore, we show that RUNX dosage directly impinges on the activity 
of Notch signaling pathway, which is critical for RUNX+ cell survival and differentiation, by 
regulating the transcription of the Notch receptor. These findings shed light on a new mode 
of regulation of RUNX level and Notch activity to prevent abnormal blood cell 
accumulation, which could be involved in leukemogenesis. 
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Introduction 
 
Proper blood cell development requires a fine-tuned regulation of transcription factors and 
signaling pathways activity. Consequently mutations affecting key regulators of 
hematopoiesis such as members of the RUNX transcription factor family or components of 
the Notch signaling pathway are associated with several blood cell disorders including 
leukemia [1, 2]. Also, leukemic cells often present recurrent chromosomal rearrangements 
that participate in malignant transformation by altering the function of these factors [3]. The 
functional characterization of these genes is thus of importance not only to uncover the 
molecular basis of leukemogenesis but also to decipher the regulatory mechanisms 
controlling normal blood cell development. Myeloid leukemia factor 1 (MLF1) was 
identified as a target of the t(3;5)(q25.1;q34) translocation associated with acute myeloid 
leukemia (AML) and myelodysplastic syndrome (MDS) more than 20 years ago [4]. Further 
findings suggested that MLF1 could act as an oncogene [5-8] or a tumor suppressor [9] 
depending on the cell context and it was shown that MLF1 over-expression either impairs 
cell cycle exit and differentiation [10], promotes apoptosis [11, 12] or inhibits proliferation 
[13, 14] in different cell types ex vivo. Yet, its function and mechanism of action remains 
largely unknown. 
 
        MLF1 is the founding member of a small evolutionarily conserved family of nucleo-
cytoplasmic proteins present in all metazoans but lacking recognizable domains that could 
help ascribe their biochemical activity [15]. Whereas vertebrates have two closely related 
MLF paralogs, Drosophila has a single mlf gene encoding a protein that presents around 
50% of identity with human MLF in the central conserved domain [16, 17]. In fly, MLF was 
identified as a partner of the transcription factor DREF (DNA replication-related element-
binding factor) [16], for which it acts as a co-activator to stimulate the JNK pathway and 
cell death in the wing disc [18]. MLF has been shown to bind chromatin [18-20], as its 
mouse homolog [21], and it can either activate or repress gene expression by a still 
unknown mechanism [18, 20]. MLF also interacts with Suppressor of Fused, a negative 
regulator of the Hedgehog signaling pathway [19], and, like its mammalian counterpart 
[13], with CSN3, a component of the COP9 signalosome [22], but the functional 
consequences of these interactions remain elusive. Interestingly, the overexpression of 
Drosophila MLF or that of its mammalian counterparts can suppress polyglutamine-induced 
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cytotoxicity in fly and in cellular models of neurodegenerative diseases [17, 23-25]. 
Moreover phenotypic defects associated with MLF loss in Drosophila can be rescued by 
human MLF1 [17, 26]. Thus MLF function seems conserved through evolution and 
Drosophila appears as a genuine model organism to characterize MLF proteins [15]. 
 
        Along this line, we recently analyzed the role of MLF during Drosophila 
hematopoiesis [26]. Indeed, a number of proteins regulating blood cell development in 
human, such as RUNX and Notch, also controls Drosophila blood cell development [27]. In 
Drosophila, the RUNX factor Lozenge (LZ) is specifically expressed in and required for the 
development of the crystal cells [28], one of the three hematopoietic lineages, which 
accounts for ±4% of the circulating larval blood cells [27]. The Notch pathway also controls 
the development of this lineage: it is required for the induction of LZ expression and it 
contributes then to LZ+ cell survival and differentiation [28-31]. Interestingly, our previous 
analysis revealed a functional and conserved link between MLF and RUNX factors [26]. 
Indeed MLF controls LZ activity and prevents its degradation in cell culture and the 
stabilization of LZ by MLF appears to be critical to control crystal cell number in vivo [26]. 
Intriguingly, though while LZ is required for crystal cell development, mlf mutation caused 
a decrease in LZ expression and an increase in crystal cell number. In humans, deregulation 
of RUNX protein level is associated with several pathologies. For instance, 
haploinsufficient mutations in RUNX1 are associated with MDS/AML in the case of 
somatic mutations, and with familial platelet disorders with associated myeloid malignancy 
for germline mutations [1]. In the opposite, RUNX1 overexpression can promote lymphoid 
leukemia [32, 33]. Understanding how RUNX protein level is regulated and how this affects 
specific developmental processes is thus of particular importance. 
 
        Here, we further studied MLF function and mode of action in Drosophila blood cells 
by using proteomic, transcriptomic and genetic approaches. We show that MLF interacts 
with the Hsp40 co-chaperone protein DnaJ-1 to stabilize LZ as well as to control LZ+ cell 
number and differentiation. In addition, consistent with the analysis of mlf or dnaj-1 mutant, 
it appears that high levels of LZ are required to tune-down Notch expression and signaling 
to prevent aberrant blood cell accumulation. These findings thus establish a functional link 
between the MLF/DnaJ-1 complex and the regulation of a RUNX-Notch axis required for 
blood cell homeostasis in vivo. 
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Results 
MLF interacts with DnaJ-1 
To better characterize MLF molecular mode of action, we sought to identify its partners. 
Accordingly, we established a Drosophila Kc167 cell line expressing a V5-tagged version 
of MLF close to endogenous level of MLF in a copper-inducible manner (Fig 1A). After 
anti-V5 affinity purification from whole cell extracts of control or MLF-V5-expressing 
cells, isolated proteins were identified by mass spectrometry (see M&M for details). Five 
proteins reproducibly co-purified with MLF and were either absent or present at more than 4 
folds lower levels in control purifications (Fig 1B): the Hsp40 co-chaperone DnaJ-1 (also 
known as DROJ1, [34]), the constitutively expressed Hsp70 chaperones Hsc70-4 and 
Hsc70-3, the RNA binding protein Squid (Sqd), and the retrotransposon-encoded protein 
Copia.   
 
        As DnaJ-1 was the strongest hit in our proteomic approach, we focused our analysis on 
this candidate. To confirm the interaction between MLF and DnaJ-1, we performed co-
immunoprecipitation experiments in Kc167 cells transfected with expression plasmids for 
HA-DnaJ-1, GFP or GFP-MLF. We found that GFP-MLF (but not GFP alone) co-
precipitated HA-DnaJ-1 and that conversely HA-DnaJ-1 co-precipitated GFP-MLF as well 
as endogenous MLF (Fig 1C and 1D), indicating that these proteins specifically interacted. 
Moreover, in vitro translated MLF and DnaJ-1interacted with GST-DnaJ-1 and GST-MLF 
respectively but not with GST alone in pull-down assays (Fig 1E and 1F). Of note, 
immunostaining also showed that DnaJ-1 and MLF co-localized in the nuclei of Kc167 
transfected cells (S1A Fig). We then mapped the domains required for their interactions. 
Hsp40/DnaJ co-chaperones play a crucial role in the regulation of protein folding and 
degradation; they chiefly act by delivering client proteins to Hsp70/DnaK chaperones and 
stimulating their ATPase activity [35, 36]. DnaJ-1 belongs to the DnaJB/class II subfamily 
of Hsp40/DnaJ proteins, which are characterized by an N-terminal J domain required to 
stimulate Hsp70 ATPase activity (amino acids 4 to 57 in DnaJ-1), a central 
glycine/phenylalanine (G/F)-rich region (amino acids 64 to 144 in DnaJ-1), and a conserved 
C-terminal region (amino acids 157 to 320 in DnaJ-1) that contains the client binding 
domain followed by a dimerization interface [36]. Immunoprecipitations of GFP-MLF 
expressed with different HA-tagged DnaJ-1 variants indicated that DnaJ-1 C-terminal 
region mediates MLF binding (Fig 1G). In contrast, a point mutation in the highly 
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conserved HPD loop (P32S) crucial for Hsc70 activation [36], deletion of the J-domain or 
deletion of the J and G/F domains did not affect DnaJ-1 binding to GFP-MLF. MLF does 
not harbor characteristic domains besides a central “MLF homology domain” (MHD, amino 
acids 96 to 202) conserved between MLF family members [15]. Using GFP-DnaJ-1 as bait 
and deletion mutants in MLF as preys, we found that the MHD was sufficient for binding to 
DnaJ-1, while MLF N and C-terminal regions were dispensable (Fig 1H). Finally, consistent 
with the above results, the C terminal region (amino acids 157 to 334) of DnaJ-1 fused to 
GFP but not the GFP moiety alone co-precipitated the HA-tagged MHD (S1B Fig). In sum, 
these data indicate that MLF and DnaJ-1 specifically bind to each other through their 
conserved central and C-terminal region, respectively. 
 
 
MLF acts in a chaperone complex with DnaJ-1 to control LZ activity and stability 
We have previously shown that MLF is required for LZ-induced transactivation and stable 
expression [26]. We thus asked whether DnaJ-1 also controlled LZ function. As shown in 
Fig 2A, transfection of LZ expression plasmid in Kc167 cells induced a robust activation of 
the 4xPPO2-Fluc reporter gene [37], which was significantly decreased when either MLF or 
DnaJ-1 expression was knocked down by dsRNA treatment. Furthermore, Western blot 
analyses revealed that, like mlf, dnaj-1 knockdown caused a drop in LZ protein expression 
(Fig 2B). Importantly RT-qPCR experiments showed that mlf and dnaj-1 knockdown did 
not affect the expression of each other or decrease lz transcript level, while they caused a 
significant reduction in the expression of LZ target gene ppo2 (Fig 2C-F). Hence, like MLF, 
DnaJ-1 controls LZ protein activity by regulating its stability. 
 
        We then asked whether MLF or DnaJ-1 could bind LZ. Upon transfection of the 
corresponding expression plasmids, both HA-MLF and HA-DnaJ-1 were co-
immunoprecipitated by GFP-tagged LZ but not by GFP alone (Fig 2G and 2H). 
Furthermore, in vitro translated LZ bound to E. coli-purified GST-MLF and GST-DnaJ-1 
but not to GST alone in pull down assays (S2A Fig). These results strongly suggest that 
MLF and DnaJ-1 specifically interact with LZ. Using different MLF variants in co-
immunoprecipiation assays, we found that the N-terminal part of MLF homology domain 
(amino acids 96 to 147) was crucial for the interaction with LZ (S2B Fig). Similarly, DnaJ-1 
C-terminal domain was required for binding LZ, while its J domain was dispensable (S2C 
Fig). Therefore it appears that LZ interacts with conserved domains of MLF and DnaJ-1 and 
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our results suggest that the MLF/DnaJ-1 complex regulates LZ stability by interacting with 
it.  
 
        Reminiscent of our previous results with MLF [26], we observed that DnaJ-1 over- 
expression was associated with an increase in LZ-induced transactivation and LZ expression 
level (Fig 2I and 2J). The over-expression of C-terminus-truncated DnaJ-1 proteins did not 
affect LZ-induced transcription or LZ expression. In contrast, the over-expression of DnaJ-1 
carrying the P32S point mutation or deleted of its J domain caused a decrease in LZ-induced 
transactivation and a drop in LZ level (Fig. 2I and 2J), suggesting that Hsc70 activation by 
DnaJ-1 is required for LZ stable expression. Since we identified Hsc70-4 as a potential 
partner of MLF, we further tested this hypothesis. Immunoprecipitation experiments 
confirmed that MLF and DnaJ-1 interacted with Hsc70-4 (S3A and S3B Fig). Moreover, 
knocking down hsc70-4 by dsRNA caused a strong decrease in LZ-induced transactivation 
of the 4xPPO2-Fluc reporter gene and a concomitant reduction in LZ expression (S3C and 
S3D Fig). In sum, our results support the idea that MLF acts in a chaperone complex with 
DnaJ-1 and Hsc70-4 to control LZ stability and activity. 
 
 
DnaJ-1 cell-autonomously controls LZ+ cell number and differentiation in vivo 
Since DnaJ-1 interacts with MLF and controls LZ level ex vivo, we sought to analyze DnaJ-
1 function during larval crystal cell development, using the lz-GAL4/+ driver and the UAS-
mCD8GFP reporter to monitor this LZ+ blood cell lineage. Given that no mutant for dnaj-1, 
we used a CRIPR/Cas9 strategy to generate dnaj-1 null alleles (See Materials and Methods 
and S4 Fig) [38]. In the following experiments, we used an allelic combination between two 
mutant lines obtained from independent founder flies (dnaj-1A and dnaj-1C), which harbor a 
complete deletion of dnaj-1 coding sequence (S4 Fig). Around 65% of the dnaj-1A/C mutants 
reached larval stage and 15% emerged as adult flies, but they did not show obvious 
morphological defect. Notwithstanding and reminiscent of mlf phenotypes, bleeding of third 
instar larvae revealed that dnaj-1 mutants exhibited a ±1.8-fold increase in circulating 
lz>GFP+ cells as compared to wild type (Fig 3A). In addition, as in mlf mutants, crystal 
cells from dnaj-1 mutant larvae still expressed the differentiation marker PPO1 and were 
capable of melanization upon heat treatment (Fig 3C-H). A closer examination also revealed 
the presence of unusually large lz>GFP+ cells in dnaj-1 mutants and quantitative analyses 
confirmed that dnaj-1 loss caused a significant increase in lz>GFP+ cell size whereas 
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lz>GFP- cells were unaffected (Fig 3B). Interestingly, a similar phenotype is observed in 
mlf mutant larvae, suggesting that both genes not only control crystal cell number but also 
their differentiation (see below). Importantly, lz>GFP+ cell number and size was restored to 
wild-type when DnaJ-1 was re-expressed in the crystal cell lineage of dnaj-1A/C mutant 
larvae using the lz-GAL4 driver (Fig 3A and 3B), demonstrating that these phenotypes are 
specifically caused by dnaj-1 mutation and that DnaJ-1 acts cell autonomously after the 
onset of lz expression in the crystal cell lineage. Furthermore, the increase in crystal cell 
number and size was also observed when we monitored crystal cell presence by 
immunostaining against PPO1 in larvae carrying dnaj-1A or dnaj-1C homozygous mutation 
or over a deficiency covering dnaj-1 locus (Def(3L)BSC844) (S4 Fig). Overall, these results 
demonstrate that, like mlf, dnaj-1 controls larval crystal cell number and size. 
 
        We then assessed whether DnaJ-1 affected LZ stability in vivo as it does in cell culture. 
Unexpectedly, immunostaining against LZ did not reveal a decrease in LZ expression in 
dnaj-1 mutant crystal cells, while LZ level was clearly lower in mlf mutant (Fig 3I-K). 
Actually, quantitative analyses revealed a slight (30%) but significant (p=0.006) increase in 
LZ level in dnaj-1 mutant as compared to wild type, whereas LZ level dropped by more 
than 2 folds in mlf mutant (Fig 3L). Thus, unlike mlf, dnaj-1 loss is not sufficient to 
destabilize LZ in vivo. 
 
 
DnaJ-1 and MLF act together to control LZ accumulation and crystal cell 
development 
One potentially important difference between Kc167 cells, in which DnaJ-1 is required to 
stabilize LZ, and crystal cells, in which it is not, is MLF expression. Indeed, in Kc167 cells, 
MLF is chiefly detected in the cytoplasm and is expressed at low levels in the nucleus (S5A 
Fig). In contrast, MLF is present at high levels in the nucleus of larval crystal cells (S5B 
Fig). Moreover, its expression in this lineage is not affected by dnaj-1 loss (S5C and 5D 
Fig). We thus supposed that the presence of high levels of nuclear MLF might prevent LZ 
degradation in the absence of DnaJ-1. 
 
        To test this hypothesis, we designed two complementary experiments. On the one 
hand, we assessed whether MLF over-expression in Kc167 cells could protect LZ from 
degradation following dnaj-1 knockdown. On the other hand, we asked whether LZ protein 
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would still be stable in dnaj-1 mutant crystal cells if MLF level is decreased. As shown in 
Figure 4, LZ expression was reduced when Kc167 cells were treated with a dsRNA 
targeting dnaj-1 and increased upon over-expression of MLF. Strikingly though, and 
reminiscent of the above observations in dnaj-1 mutant crystal cells, LZ level was not 
reduced but further increased when dnaj-1 was knocked down in MLF overexpressing cells 
(Fig 4D and 4E). Conversely, in vivo, the expression of a dsRNA against mlf in lz>GFP+ 
cells caused a drop in LZ expression that was significantly enhanced in dnaj-1 deficient 
larvae, while dnaj-1 mutation alone increased LZ level (Fig 4F-J). Hence, it appears that 
high levels of MLF can prevent LZ degradation in the absence of DnaJ-1. 
 
        Then, since chaperones are important for proper protein folding [35, 36], we postulated 
that LZ protein accumulating in crystal cells in the absence of DnaJ-1 might be less active. 
Thus increasing LZ expression should be sufficient to rescue lz>GFP+ cell number and 
size. Consistent with this hypothesis, and as observed in mlf mutant larvae, lz>GFP+ cell 
number and size was restored to wild-type when we enforced LZ expression in this lineage 
(Fig 5A and 5B). Finally, since MLF and DnaJ-1 bind to each other and jointly control LZ 
stability, we tested whether they genetically interacted to regulate crystal cell development. 
While heterozygous mutation in either mlf or dnaj-1 did not efficiently alter circulating 
lz>GFP+ cell number or size, mlfΔC1/+, dnaj-1A/+ transheterozygote larvae displayed a 
significant increase of both parameters (Fig 5C and 5D). We thus conclude that DnaJ-1 and 
MLF act together to control LZ expression and crystal cell development in vivo. 
 
 
MLF and DnaJ-1 control crystal cell differentiation 
In parallel, to gain further insights into the function of MLF in the control of crystal cell 
development, we established the transcriptome of circulating LZ+ blood cells in wild type 
and mlf mutant larvae. Heterozygous lz-GAL4, UAS-mCD8GFP L3 larvae carrying or not 
mlf null mutation were bled, lz>GFP+ cells were collected by FACS and their gene 
expression profile was determined by RNA sequencing (RNAseq) from biological 
triplicates (see M&M for details). Using Drosophila reference genome dm3, we detected the 
expression of 7399 genes (47% of the total fly genes) in each of the 6 samples (Fig 6B and 
S6 Table). Consistent with the role of the crystal cells as the main source of phenoloxidases 
[39], the two most strongly expressed genes were PPO1 and PPO2. In addition, lz 
expression as well as that of several other crystal cell markers (see below) was readily 
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detected. It was recently shown that larval circulating LZ+ cells derive from plasmatocytes, 
which express Hemolectin (Hml) and Nimrod C1 (NimC1) and transdifferentiate into 
mature crystal cells [40]. Accordingly, we detected the expression of these genes as well as 
other “plasmatocytes” markers such peroxidasin and croquemort (which were actually 
shown to be also expressed in crystal cells [41, 42]) in lz>GFP+ cells. 
 
        Using DESeq2 to identify differentially expressed genes between wild type and mlf 
mutant lz>GFP+ cells, we found 779 genes with significantly altered expression (adjusted 
p-value <0.01): the transcript level of 469 genes was decreased and that of 310 genes was 
increased in the absence of MLF (Fig 6A, 6B and S7 Table). In line with our previous in 
situ hybridization results [26], RNAseq analysis did not reveal a significant modification of 
PPO1 or PPO2 expression in the absence of mlf. However, lz transcript level was reduced 
by ±2 folds (p-value=0.0018), which could be due to defective maintenance of lz auto-
activation loop [43]. To assess whether other crystal cell markers were affected by mlf loss, 
we established a compilation of genes expressed in (embryonic or larval) crystal cells based 
on Flybase data mining and re-examination of Berkeley Drosophila Genome Project in situ 
hybridizations (http://insitu.fruitfly.org/cgi303bin/ex/insitu.pl) (S8 Table). Among these 129 
genes (i.e. excluding mlf itself), 44 (34%) were differentially expressed in the absence of mlf 
(19 repressed and 25 activated) (Fig 6C), indicating a strong over-representation of 
deregulated genes in the “crystal cell” gene set as compared to all expressed genes (p-
value=2.6x10-13, hypergeometric test) and showing that mlf plays a crucial role in proper 
crystal cell differentiation. 
 
        To substantiate these results, we assessed by in situ hybridization the expression of 4 
genes that were either down-regulated (CG7860 and Oscillin) or up-regulated (CG6733 and 
Jafrac1) in mlf mutant. CG7860 and Oscillin were specifically expressed in lz>GFP+ but 
not in the surrounding lz>GFP- hemocytes in wild-type conditions (Fig 6D and 6G). 
Consistent with our RNAseq data, the expression of CG7860 and Oscillin was strongly 
reduced in mlf mutant larvae. Although it is expressed in embryonic crystal cells [43], 
CG6733 was not detectably expressed by in situ hybridization in circulating hemocytes of 
wild-type larvae, but it was expressed in the lz>GFP+ lineage in mlf mutant larvae (Fig 6J 
and 6K). Finally, Jafrac1 expression increased in lz>GFP+ cells of mlf mutant larvae as 
compared to wild-type, whereas its (lower) expression in lz>GFP- blood cells seemed 
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similar (Fig 6M and 6N). These data thus confirm the RNAseq results and demonstrate that 
MLF controls the expression of several crystal cell markers. Since MLF acts together with 
DnaJ-1, we also tested whether these four genes were deregulated in dnaj-1 mutant larvae. 
As for mlf, we observed that dnaj-1 mutation caused a down-regulation of CG7860 and 
Oscillin expression and an up-regulation of CG6733 and Jafrac1 expression in lz>GFP+ 
blood cells (Fig 6F, 6I, 6L and 6O). Therefore, the loss of mlf or dnaj-1 leads to the 
deregulation of crystal cell gene marker expression, indicating that both genes are required 
for proper differentiation of the LZ+ blood cell lineage. 
 
 
MLF and DnaJ-1 repress Notch signaling 
Interestingly, the levels of Notch receptor transcripts were significantly higher in mlf mutant 
(p=1.3x10-6) (Fig 6C). Notch signaling plays a key role in crystal cell development [27]: 
Notch is first activated by its ligand Serrate to specify crystal cell precursors and 
subsequently Notch activation is maintained in LZ+ cells in a ligand independent manner to 
promote crystal cell growth and survival [29-31, 40, 44]. The rise in lz>GFP+ cell number 
and size observed in mlf and dnaj-1 mutants could thus be due to increased ligand-
independent Notch signaling [30, 31]. Hence, we further investigated the level of Notch 
expression and activation. Immunostaining using an antibody against Notch extracellular 
domain (NECD) showed that Notch was expressed at higher levels in lz>GFP+ cells of mlf 
and dnaj-1 mutant larvae than in wild-type condition (Fig 7A-C). Quantitative analyses 
confirmed that mlf loss caused a significant increase of Notch expression in lz>GFP+ cell, 
whereas the (lower) expression of Notch in lz>GFP- blood cells was not affected (Fig 7D). 
Similar results were obtained when we measured Notch protein levels using an antibody 
directed against its intra-cellular domain (NICD) (Fig 7E). These data strongly suggest that 
Notch expression is specifically increased in lz>GFP+ cells of mlf and dnaj-1 mutants. We 
then tested whether this resulted in increased signaling by monitoring the expression of two 
Notch signaling pathway reporter genes expressed in larval crystal cells: Klumpfuss-Cherry 
[31] and NRE-GFP [45]. Both mlf and dnaj-1 loss were associated with a strong increase in 
the expression of these reporters (Fig 7F-J). Thus mlf and dnaj-1 are required to tune down 
Notch signaling in the crystal cell lineage. 
 
        Crystal cells tend to increase their size as they mature in response to Notch signaling 
[31, 40]. To better characterize the defects associated with mlf or dnaj-1 loss, we analyzed 
 76 
the distribution of lz>GFP+ cells as well as Notch expression level according to lz>GFP+ 
cell size category. Whereas cells more than 1.3-fold larger than the mean wild-type cell size 
represented a small fraction (±10%) of the lz>GFP+ population in wild-type larvae, they 
constituted the prevalent population in mlf or dnaj-1 mutant (respectively 49.6% and 37%) 
(Fig7K). In addition, while Notch expression was maximum in the population of lz>GFP+ 
cells of mean cell size and lower in larger cells of wild-type larvae, it was maintained at 
higher levels in the larger cell populations of mlf or dnaj-1 mutants (Fig 7L-N). 
 
        All together, these results show that MLF/DnaJ-1 loss causes the accumulation of large 
and mis-differentiated crystal cells exhibiting abnormal Notch signaling activation. 
 
 
High levels of LZ are required to prevent accumulation of lz>GFP+ cells and to repress 
Notch expression/signaling 
LZ is absolutely required for crystal cell formation and differentiation [27]. The above data 
show that the increase in crystal cell number and size observed in mlf or dnaj-1 mutant is 
rescued by enforcing LZ expression. This is intriguing since it suggests that decreasing LZ 
activity causes an expansion of the crystal cell population associated with aberrant 
differentiation. We thus tested what happens when LZ activity is reduced. Accordingly, we 
introduced the lzr1 null allele in the lzGAL4 context. This hypomorphic allelic combination 
caused a decrease in LZ expression (Fig 8B) and resulted in an increase in lz>GFP+ cell 
number and size (Fig 8E and 8F). Interestingly, lzGAL4/Y hemizygote larvae displayed similar 
phenotypes (Fig 8C, 8E and 8F), indicating that this P{GAL4} insertion in lz alters its 
expression in the crystal cell lineage. As an alternate strategy, we interfered with LZ activity 
by expressing a fusion protein between LZ partner Brother (Drosophila CBFß homolog) 
and the non-muscular myosin heavy chain SMMHC [46]. This chimera mimics the CBFß-
MYH11 fusion protein generated by the inv(16) translocation in human AML and can 
sequester RUNX factors in the cytoplasm [1, 47]. Bro-SMMHC expression in lz>GFP+ 
cells titrated LZ from the nucleus and also caused an increase in lz>GFP+ cell number and 
size (Fig 8D-F). Furthermore, consistent with the analyses of mlf and dnaj-1 mutants, the 
expression of the Notch signaling pathway reporters NRE-GFP and Klu-Cherry was 
strongly increased in lzGAL4/lzR1 mutant or upon Bro-SMHCC expression in the LZ+ blood 
cell lineage (Fig 8G, H). 
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        In contrast to Notch (Fig 7L), we observed that LZ expression increased with lz>GFP+ 
cell size (S9 Fig). This suggested that LZ level rises as crystal cells mature and, in view of 
the above results, we surmised that this increase might down-regulate Notch signaling by 
repressing Notch receptor expression. Accordingly, we found that Notch level significantly 
augmented in lz>GFP+ cells of hypomorphic lzGAL4/Y hemizygote larvae whereas it was 
reduced when LZ was over-expressed (Fig 9 A-E). In addition, the increase in Notch 
expression observed in lzGAL4/Y larvae was suppressed by enforcing LZ expression. We 
hypothesized that Notch might be a transcriptional target of LZ. By analyzing the 
expression of different GAL4 lines that cover potential Notch regulatory regions [48], we 
identified two lines that drive expression in circulating LZ+ blood cells (Fig 9F and S10 
Fig). Interestingly, the regulatory elements carried by these two lines (GMR30A01 and 
GMR30C06) overlapped on a 668bp DNA segment that contains two consensus binding 
sites for RUNX transcription factors conserved in other Drosophila species (S10A Fig), 
suggesting that Notch might be a direct target gene of LZ. We thus tested the effect of LZ 
dosage manipulation on the activity of this enhancer-GAL4 line. Strikingly, a hypomorphic 
lozenge mutation (lzg/Y) [49] or the expression of Bro-SMMHC caused an increase in the 
expression of this enhancer, whereas the over-expression of LZ resulted in its down-
regulation (Fig 9G-K). These findings strongly argue that LZ directly represses Notch 
expression 
 
        All together, these results demonstrate that high levels of LZ are required to prevent 
the accumulation of over-grown lz>GFP+ cells as well as over-activation of the Notch 
pathway and we propose that LZ-mediated repression of Notch transcription is critical for 
this process. 
 
 
Discussion 
Members of the RUNX and MLF families have been implicated in the control of blood cell 
development in mammals and Drosophila and deregulation of their expression is associated 
with human hemopathies including leukemia [1, 9, 15, 50]. Our results establish the first 
link between MLF, DnaJ-1 and the regulation of RUNX transcription factor in vivo. In 
addition, our data suggest that the stabilization of LZ by the MLF/DnaJ-1 complex is critical 
to control Notch signaling and thus blood cell growth and survival. These findings pinpoint 
the specific function of the Hsp40 chaperone DnaJ-1 in hematopoiesis, reveal a potentially 
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conserved mechanism of regulation of RUNX activity and highlight a new layer of control 
of Notch signaling at the transcriptional level. 
 
        In line with results published as this manuscript was in preparation [20], we found that 
MLF binds DnaJ-1 and Hsc70-4 and that these two proteins, like MLF, are required for LZ 
stable expression in Kc cells. In addition, we show that MLF and DnaJ-1 bind to each other 
via evolutionarily conserved domains and also interact with LZ, suggesting that LZ is a 
direct target of a chaperone complex formed by MLF, DnaJ-1 and Hsc70-4. Of note, a 
systematic characterization of Hsp70 chaperone complexes in human cells identified MLF1 
and MLF2 as potential partners of DnaJ-1 homologs, DNAJB1, B4 and B6 [51], a finding 
corroborated by Dyer et al. [20]. Therefore, the MLF/DnaJ-1/Hsc70 complex could play a 
conserved role in mammals, notably in the regulation of RUNX transcription factors 
stability. How MLF acts within this chaperone complex remains to be determined. In vivo, 
we demonstrate that dnaj-1 mutation leads to defects in crystal cell development strikingly 
similar to those observed in mlf mutant larvae and we show that these two genes act together 
to control LZ+ cell development by impinging on LZ activity. Our data suggest that in the 
absence of DnaJ-1, high levels of MLF lead to the accumulation of defective LZ proteins, 
whereas lower levels of MLF allow its degradation. We thus propose that MLF stabilizes 
LZ and, together with DnaJ-1, promotes its proper folding/conformation. In human, DnaJB4 
stabilizes wild-type E-cadherin but induces the degradation of mutant E-cadherin variants 
associated with hereditary diffuse gastric cancer [52]. Thus the fate of DnaJ client proteins 
is controlled at different levels and MLF might be an important regulator in this process. 
 
        In this work, we present the first null mutant for a gene of the DnaJB family in 
metazoans and our results demonstrate that a DnaJ protein is required in vivo to control 
hematopoiesis. There are 16 DnaJB and in total 49 DnaJ encoding genes in mammals and 
the expansion of this family has likely played an important role in the diversification of their 
functions [53, 54]. DnaJB9 overexpression was found to increase hematopoietic stem cell 
repopulation capacity [55] and Hsp70 inhibitors have anti-leukemic activity [56], but the 
participation of other DnaJ proteins in hematopoiesis or leukemia has not been explored. 
Actually DnaJ molecular mechanism of action has been fairly well studied but we only have 
limited insights as to their role in vivo. Interestingly though both DnaJ-1 and MLF suppress 
polyglutamine protein aggregation and cytotoxicity in Drosophila models of 
neurodegenerative diseases [17, 23, 24, 33, 57-61], and this function is conserved in 
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mammals [24, 25, 62, 63]. It is tempting to speculate that MLF and DnaJB proteins act 
together in this process as well as in leukemogenesis and thus a better characterization of 
their mechanism of action may help develop new therapeutic approaches for these diseases. 
 
        As shown here, mlf or dnaj-1 mutant larvae harbor more crystal cells than wild type 
larvae and display a higher fraction of the largest lz>GFP+ cell population, which likely 
corresponds to the more mature crystal cells [31, 40]. It is thus tempting to speculate that 
mlf or dnaj-1 loss promotes the survival of fully differentiated crystal cells. Our RNAseq 
data demonstrate that mlf is critical for expression of crystal cell associated genes, but we 
observed both up-regulation and down-regulation of crystal cell differentiation markers in 
mlf or dnaj-1 mutant LZ+ cells. In addition, our transcriptome did not reveal a particular bias 
toward decreased expression for “plasmatocyte” markers in LZ+ cells from mlf mutant 
larvae (for instance, hml, peroxidasin, viking or Cg25C expression was unaffected, 
croquemort was down-regulated and NimC1 was up-regulated). Thus, it appears that MLF 
and DnaJ-1 loss do lead to the abnormal accumulation of mis-differentiated crystal cells. 
 
        Our data support a model whereby MLF and DnaJ-1 act together to promote LZ 
expression, which in turn represses Notch transcription and signaling pathway to control 
crystal cell size and number. Indeed, we observe an over-activation of the Notch pathway in 
LZ+ blood cells of mlf or dnaj-1 mutant larvae as well as when we interfere with LZ activity, 
and it has been shown that Notch activation increases crystal cell growth and survival [30, 
31, 40]. Our results suggest that LZ directly represses Notch transcription as we identified a 
LZ-responsive Notch cis-element that contains a conserved RUNX binding site. Activation 
of Notch pathway in circulating LZ+ cells is ligand-independent and mediated through 
stabilization of the full length Notch protein in endocytic vesicles [30, 64]. Hence, a tight 
control of Notch expression is of particular importance to keep Notch pathway activation in 
check and prevent abnormal development of the LZ+ blood cell lineage. By stabilizing LZ, 
MLF and DnaJ-1 thus provide a cell-autonomous mechanism to inhibit Notch signaling. 
Further experiments will now be required to establish how LZ represses Notch transcription. 
RUNX factors can act as transcriptional repressors by recruiting co-repressors such as 
members of the Groucho family [65]. Whether MLF and DnaJ-1 directly contribute to LZ-
induced repression in addition to regulating its stability is an open question. MLF and DnaJ-
1 were recently found to bind and regulate a common set of genes in cell culture [20]. They 
may thus provide a favorable chromatin environment for LZ binding or be recruited with LZ 
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and/or favor a conformational change in LZ that allows its interaction with co-repressors. 
The scarcity of lz>GFP+ cells precludes a biochemical characterization of LZ, MLF and 
DnaJ-1 mode of action notably at the chromatin level, but further genetic studies should 
help decipher their mode of action. While the post-translational control of Notch has been 
extensively studied, its transcriptional regulation seems largely overlooked [66]. Our 
findings indicate that this is nonetheless an alternative entry point to control the activity of 
this pathway. Given the importance of RUNX transcription factor and Notch signaling in 
hematopoiesis and blood cell malignancy [1, 2], it will be of particular interest to further 
study whether RUNX factors can regulate Notch expression and signaling during these 
processes in mammals. 
 
        In conclusion, our study shows that MLF and DnaJ-1 act together to regulate RUNX 
transcription factor activity, which in turn controls Notch signaling during hematopoiesis in 
vivo. We anticipate that the extraordinary genetic toolbox available in Drosophila will help 
shed new light on the mechanism of action of these evolutionarily conserved proteins and 
will bring valuable insights into the control of protein homeostasis by MLF and DnaJ-1 
during normal or pathological situations. 
 
 
Materials and Methods 
Fly strains 
The following Drosophila melanogaster lines were used: mlfΔC1, UAS-mlf [17], UAS-ds-mlf 
(National Institute of Genetics, NIG), UAS-lz, lzGAL4, UAS-mCD8-GFP, lzg, lzr1, 
P{EPgy2}DnaJ-1EY04359, UAS-dnaj-1, Def(3L)BSC884, vas-Cas9, UAS-GFPnls, NRE-
GFP, GMR30C06, GMR30A01 (Bloomington Drosophila Stock Center), Bc-GFP [67], Klu-
mCherry [31], UAS-Bro-SMMHC [46]. To generate dnaj-1 deficient flies, we designed two 
guide RNA targeting dnaj-1 locus (S4 Fig) and the corresponding DNA oligonucleotides 
(g2: GTCGACCACAACGCGCCGGATCAA; g3: GTCGCATCACAGTCACGCTTTCCT) 
were cloned in pCFD3 (Addgene, [68]). vas-cas9 females were crossed to P{EPgy2}DnaJ-
1EY04359 males and the resulting embryos were injected using standard procedures with 
both pCFD3-g2 and pCFD3-g3 plasmids (500ng/μl). Deletion of the P{EPgy2}EY04359 
transposon, as revealed by loss of the w+ marker, was screened for at the F2 generation, and 
deletion of dnaj-1 locus was assessed by PCR and sequencing. All crosses were conducted 
on standard food medium as described in [69]. 
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Immunostainings and in situ hybridizations 
For each sample, four third instar larvae were bled (or 5.0x103 Kc167 cells were dispensed) 
in 1ml of PBS in 24-well-plate containing a glass coverslip. Unless mentioned otherwise, 
only female larvae were used. The hemocytes were centrifuged for 2 min at 900g, fixed for 
20 min with 4% paraformaldehyde in PBS and washed twice in PBS. For immunostainings: 
cells were permeabilized in PBS-0.3% Triton (PBST) and blocked in PBST-1% Bovine 
Serum Albumin (BSA). The cells were incubated with primary antibodies at 4°C over-night 
in PBST-BSA, washed in PBST, incubated for 2h at room temperature with corresponding 
Alexa Fluor-labeled secondary antibodies (Molecular Probes), washed in PBST and 
mounted in Vectashield medium (Eurobio-Vector) following incubation with Topro3 
(ThermoFisher). The following antibodies were used: anti-LZ, anti-Notch intracellular 
domain, anti-Notch extracellular domain (Developmental Studies Hybridoma Bank, 
DSHB), anti-MLF [19], anti-PPO1 [70], anti-GFP (Fisher Scientific), anti-HA (Sigma). 
 
        For in situ hybridizations: after fixation, the cells were washed and permeabilized in 
PBS-0.1% Tween20 (PBSTw), pre-incubated for 1h at 65°C in HB buffer (50% formamide, 
2xSSC, 1 mg/ml Torula RNA, 0.05 mg/ml Heparin, 2% Roche blocking reagent, 0.1% 
CHAPS, 5 mM EDTA, 0.1% Tween 20) and 535 incubated over-night with anti-sense DIG-
labeled RNA probes (against CG6733, CG7860, Jafrac or Oscillin) diluted in HB. The 
samples were washed in HB for 1h at 65°C, in 50% HB- 50% PBSTw for 30 min at 65°C 
and three times in PBSTw for 20 min at room temperature. Then the cells were incubated 
for 30 min in PBSTw- 1% BSA before being incubated with anti-DIG antibody conjugated 
to alkaline phosphatase (Roche, 1/2000 in PBSTw) for 3h. After 4 washes in PBSTw, in situ 
hybridization signals were revealed with FastRed (Roche). The cells were then processed 
for immunostaining against GFP as described above, incubated in Topro3, washed in PBS 
and mounted in Vectashield medium for analysis. 
 
        Experiments were performed using at least biological triplicates. Samples were imaged 
with laser scanning confocal microscopes (Leica) and images were analyzed with ImageJ. 
Cell size and protein expression levels were measured on maximal intensity projections of 
Z-sections through the whole cell on a minimum of 25 cells per genotype. Crystal cell 
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counts were performed as described in [25]. Most statistical tests and graphs were 
performed using Prism v5 (GraphPad Software). 
 
 
Plasmids 
The following previously described plasmids were used: pAc-LZ-V5, 4xPPO2-Firefly 
luciferase (originally named 4xPO45-Fluc, [37]), pET-3c-LZ [71], pAc-MLF [17]. We 
generated the following Drosophila expression plasmids for C-terminally tagged or N-
terminally tagged proteins using standard cloning techniques: pAc-LZ-EGFP, pAc-MLF-
EGFP, pMT-MLF-V5-His, pAc-DnaJ-1-EGFP, pAc-Hsc70-4-EGFP, pAc-3xHA-DnaJ-1(2-
334), pAc-3xHA-DnaJ-1(P32S), pAc-3xHA-DnaJ-1(58-334), pAc-3xHA-DnaJ-1(2-156), 
pAc-3xHA-DnaJ-1(2-191), pAc-3xHA-DnaJ-1(2-269), pAc-3xHA-DnaJ-1(157-334), pAc-
3xHA-MLF(2-309), pAc-3xHA-MLF(2-147), pAc-3xHA-MLF(2-202), pAc-3xHA-
MLF(202-309), pAc-3xHA-MLF(148-309), pAc-3xHA-MLF(96-309), pAc-3xHA-MLF 
(96-202). DnaJ-1 and MLF cDNA were also cloned into pBlueScript II to generate pBS-
DnaJ-1 and pBS-MLF and in pGEX-2T to generate pGEX-DnaJ-1 and pGEX-MLF. All 
constructs were verified by sequencing. 
 
 
Cell culture, dsRNA treatments and transfections 
Drosophila Kc167 cells were grown at 25°C in Schneider medium (Invitrogen) 
supplemented with 5% fetal bovine serum (FBS) and 50 μg/ml of penicillin/streptomycin 
(Invitrogen). For RNAi experiments, double stranded RNA duplexes (dsRNA) 
corresponding to 400-600bp exonic regions were produced using T7 promoter containing 
primers and MEGAscript T7 transcription kit (Ambion). After an annealing step, dsRNA 
probes were purified using the RNeasy clean-up protocol (Qiagen). Independent dsRNA 
targeting different regions of dnaj-1 and hsc70-4 were produced. Cells were seeded at 
2x106/ml on dsRNA (16 μg/well for 6-well-plate, 8 μg for 12-well plate and 1 ug for 96-
well-plate) and incubated in Schneider medium without FBS for 40min before being 
transferred to 5% FBS containing medium. 24h later, cells were transfected with the 
plasmids of interest using Effectene (Qiagen) and they were collected 72h later for 
subsequent analyses. 
Luciferase reporter assays 
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For luciferase assays, 50 ng of 4xPPO2-Firefly luciferase reporter plasmid [37] were co-
transfected with 20 ng of pAc-Renilla luciferase plasmid, 10 ng of pAc-LZ-V5 and/or 10 ng 
of pAc expression plasmid for the protein of interest in 96-well plate. Firefly and Renilla 
luciferases activities were measured 72h after transfection using Promege Dual luciferase 
reporter assay. Three biological replicates were performed for each transfection assay. 
 
 
Real-time quantitative PCR 
For RT-qPCR, RNA was from Kc167 cells using RNeasy kit (Qiagen) with an additional 
on-column DNAse treatment step. 1 μg of total RNA was used for reverse transcription 
using Superscript II and random primers (Invitrogen). 10 μl of a 1/300 dilution of cDNA 
was used as template for real time PCR using HOT Pol Evagreen qPCR mix (Bio-rad) to 
analyse dnaj-1, mlf, lz, PPO2, renilla luciferase and rp49 expression. All experiments were 
performed using biological triplicates or quadruplicates. 
 
 
In vitro pull down assays 
pET-3c-LZ, pBS-MLF and pBS-DnaJ-1 plasmids were used as template to produce 35S-
methionine-labeled proteins in vitro using Rabbit Reticulocyte Lysate coupled transcription-
translation system (Promega). pGEX-2T, pGEX-MLF and pGEX-DnaJ-1 were used to 
produce GST, GST-MLF and GST-DnaJ-1 in Escherichia coli (BL21). Equivalent amounts 
of GST purified proteins immobilized on Glutathione-Sepharose beads were used to pull 
down LZ, MLF or DnaJ-1. Proteins were incubated for 2h at 4°C in buffer A (20 mM Tris–
HCl, pH 8.0, 150 mM NaCl, 10 mM KCl, 1 mM EDTA, 0.1 mg/ml BSA, 1 mM DTT, 
0.05% NP40). After extensive washing in buffer B (20 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, 1 mM EDTA, 1 mM DTT, 0.05% NP40), bound proteins were eluted in SDS-loading 
buffer, separated by SDS–PAGE and visualized by autoradiography. 
 
 
Protein extraction, immunoprecipitations and western blots 
Kc167 cells were collected, washed in PBS and incubated for 30 min on IP buffer (150 mM 
NaCl, 0.5% NP40, 50 mM Tris-HCl, pH8.0, 1mM EGTA) supplemented with protease 
inhibitor cocktail (Roche). The extracts were cleared by centrifugation at 13 000g for 15 
min at 4°C and subjected to SDS-PAGE (50 μg of proteins par lane) or immunoprecipitation 
(1 mg per point). For immunoprecipitation, proteins were pre-absorbed with 100 μl of 
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Sepharose beads slurry for 1h at 4°C before being incubated with 20 μl of anti-GFP 
(Chromotek), anti-V5 (Sigma-Aldrich) or anti-HA (Covance) antibody coupled to 
Sepharose beads for 4h at 4°C. The beads were spun down and washed in IP buffer and 
immunoprecipitated proteins were processed for SDS-PAGE and Western Blot analyses. 
Western blots were performed using standard techniques and the blots were developed by 
photoluminescence procedure using Lumi-LightPLUS Western Blotting Substrate (Roche) 
and Amersham HyperfilmTM ECL (GE Healthcare) or ChemidocTM Touch Imaging System 
(BioRad). The following antibodies were used for western blots: anti-V5 (Invitrogen), anti-
HA (BioLegend), anti-GFP, anti-tubulin (Sigma-Aldrich), anti-Renilla luciferase (MBL) 
and anti-MLF [19]. 
 
 
Affinity purification and mass spectrometry analysis 
Stable Kc167 cells carrying an inducible expression vector for MLF were obtained by co-
transfecting pMT-MLF-V5-His and pCoBlast (Thermo Fisher Scientific) expression 
plasmids and selecting individual clones with 25μg/ml blasticidin. For affinity purification, 
MLF-inducible or parental Kc167 cells were seeded at 106/ml and cultivated for 24h in the 
presence of 50 mM CuSO4 to induce MLF expression. 20 mg of proteins extracted in IP 
buffer were then incubated on 200 μl of anti-V5 coupled Sepharose beads (Sigma-Aldrich) 
or 400 μl of anti-V5 coupled magnetic beads (MBL). After several washes in IP buffer, 
affinity purified proteins were eluted in Laemmli buffer, reduced in 30 mM DTT and 
alkylated with 90 mM Iodoacetamide before being loaded on 12% SDS-PAGE. The single 
band of proteins was cut and digested overnight at 37°C with 1 μg of Trypsin (Promega) in 
50 mM NH4CO3. Digested peptides were extracted from the gel by incubating 15 min at 
37°C in 50 mM NH4CO3 and twice for 15 min at 37°C in 5% formic acid/acetonitrile (1:1). 
The dried peptide extracts were dissolved in 17 μl of 2% acetonitrile, 0.05% trifluoroacetic 
acid and the peptide mixtures were analysed by nanoLC-MS/MS using an Ultimate3000-RS 
system (Dionex) coupled to an LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher 
Scientific). 5μl of each peptide extract were loaded on a 300 μm ID x 5 mm PepMap C18 
precolumn (LC Packings, Dionex,) at 20 μl/min in 5% acetonitrile, 0.05% trifluoroacetic 
acid. After 5 minutes desalting, peptides were online separated on a 75μm IDx50 cm C18 
Reprosil C18 column. The flow rate was set at 300 nl/min. Peptides were eluted using a 0 to 
50% linear gradient of solvent B (solvent A: 0.2% formic acid in 5% acetonitrile, solvent B: 
0.2% formic acid in 80% acetonitrile) for 80 min at 300 nl/min. The LTQ Orbitrap was 
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operated in data-dependent acquisition mode with the XCalibur software (version 2.0 SR2, 
Thermo Fisher Scientific), on the 350-1800 m/z mass range with the resolution set to a 
value of 60 000. The twenty most intense ions per survey scan were selected for CID-
MS/MS fragmentation and the resulting fragments were analyzed in the linear ion trap 
(parallel mode). A 60 s dynamic exclusion window was used to prevent repetitive selection 
of the same peptide. The Mascot Daemon software (version 2.2.0, Matrix Science, London, 
UK) was used for protein identification against a non-redundant SwissProt database. Mascot 
results were parsed with Mascot File Parsing and Quantification (MFPaQ) version 4.0 [72]. 
Quantification of proteins was performed using the label-free module of the MFPaQ 
software, where a protein abundance index based on the average of peak area values for the 
three most intense tryptic peptides of the protein was calculated [73]. Triplicate injections 
were performed. 
 
 
RNA-seq experiments 
RNAseq experiments were performed using independent biological triplicates. For each 
sample, around 150 third instar larvae of control (lz-GAL4, UAS-mCD8GFP/+) or mlf 
mutant (lz-GAL4, UAS-mCD8GFP/+, mlfΔC1/mlfΔC1) genotypes were bled in ice-cold PBS. 
The hemocytes were centrifuged through a 40 μm mesh at 1000 rpm for 1 min and lz>GFP+ 
cells were collected by FACS (FacsAria II) under a pressure of 20 psi. A fraction of the 
collected cells were used to control GFP+ cell purification specificity by examination under 
an epifluorescent microscope after fixation and mounting in Vectashield medium with 
DAPI. RNA was extracted from sorted cells using Arcturus PicoPure RNA kit (Applied 
Biosystems). RNA samples were run on Agilent Bioanalyzer to assess RNA integrity and 
concentration. The NuGEN Ovation RNA-Seq system with Ribo-SPIA technology was used 
to prepare the cDNA according to the manufacturer instruction. Library preparation was 
performed using the Illumina TruSeq RNA-Seq library preparation kit. The resulting 
libraries were sequenced using a 1x50-bp on Illumina HiSeq 2500. Initial sequence data QC 
was done using FASTQC. Reads were filtered and trimmed to remove adapter-derived or 
low quality bases using Trimmomatic and checked again with FASTQC. Illumina reads 
were aligned to Drosophila reference genome (BDGP R5/dm3) with TopHat and Bowtie2. 
Read counts 679 were generated for each annotated gene using HTSeq-Count. RPKM 
(Reads Per Kilobase of exon per Megabase of library size) values were calculated using 
Cufflinks. Read normalization, variance estimation and pair-wise differential expression 
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analysis with multiple testing correction was conducted using the R Bioconductor DESeq2 
package. Heatmaps and hierarchical clustering were generated with R Bioconductor. The 
RNAseq data were deposited on GEO under the accession number GSE93823. 
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FIG 1. MLF interacts with the co-chaperone DnaJ-1. 
(A) Western blots showing MLF and MLF-V5 expression in Kc167 cells stably transfected with the copper-inducible 
pMT-MLF-V5 expression vector and treated or not with 50 μm CuSO4 for 24h. Tubulin (Tub) was used as an internal 
loading control. (B) Proteins identified by mass spectrometry from CuSO4-induced Kc167-pMT-MLF-V5 cells using 
anti-V5 antibody coupled to Sepharose (IP1) or magnetic (IP2) beads for purification. The number of quantified peptides 
(#Qpep), sequence coverage and fold enrichment in comparison to control (parental Kc167 cells) are indicated for each 
experiment. Spe IP: not detected in control condition. (C, D) Western blots showing the results of immunoprecipitation 
experiments against GFP (C) or HA (D) performed in Kc167 cells transfected with expression vectors for the indicated 
proteins. (E, F) Autoradiograms showing the results of pull down assays between in vitro translated 35S methionine 
labeled MLF (E) or DnaJ-1 (F) and the indicated GST fusion proteins produced in E. coli. (G, H) Schematic 
representation of DnaJ-1 (G) and MLF protein domains (H) and western blots showing the results of immunoprecipitation 
experiments against GFP performed in Kc167 cells transfected with expression vectors for GFP-MLF and various HA-
DnaJ-1 mutants (G) or GFP-DnaJ-1 and different HA-MLF mutants (H). Conserved domains are highlighted in grey. J: J 
domain. G/F: glycine/phenylalanine-rich region. C-ter: C-terminal domain. MHD: MLF homology domain.
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FIG 2. MLF and DnaJ-1 bind LZ and control its stability and activity. 
(A) Luciferase assays in Kc167 cells treated with the indicated dsRNA and transfected with 4xPPO2-Fluc 
reported plasmid in the presence or not (ctr) of pAc-LZ-V5 expression plasmid. pAc-Rluc was used as an 
internal normalization control. (B) Western blots showing LZ-V5, MLF, Renilla luciferase (R luc) and 
Tubulin (Tub) expression in Kc167 cells treated with the indicated dsRNA and cotransfected with pAc-LZ-
V5 and pAc-Rluc expression vectors. (C-F) Results of RT-qPCR assays showing the relative expression of 
mlf, dnaj-1, lz and ppo2 transcripts in Kc167 cells transfected with pAc-LZ-V5 and pAc-Rluc and treated 
with the indicated dsRNA. (G, H) Western blots showing the results of immunoprecipitation experiments 
against GFP performed in Kc167 cells transfected with expression vectors for HA-MLF (G) or HA-DnaJ-1 
(H) and GFP or GFP-LZ as indicated in the upper part of the panels. (I, J) Luciferase assays (I) and western 
blots (J) performed on Kc167 cells transfected with 4xPPO2-Fluc reported plasmid and pAc-based 
expression plasmids for LZ and for different DnaJ-1 variants as indicated. pAc-Rluc and Tubulin were used 
as internal controls. (A-F): dsDnaJ-1 (a) and (b) correspond to two distinct dsRNA targeting dnaj-1. (A, C-F 
and I) For luciferase assays and RT-qPCR, means and standard deviations of results from biological 
triplicates are shown. ***: p-value<0.001, **: p-value<0.01 (Students t-tests) as compared to LZ with dsGFP 
condition. 
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FIG 3. dnaj-1 controls crystal cell development. 
(A, B) Quantification of circulating lz>GFP+ cell number (A) and lz>GFP+ or lz>GFP- cell size (B) in lz-
GAL4, UAS-mCD8GFP/+ third instar larvae of the indicated genotypes. (C-E) Fluorescent immunostainings 
against the crystal cell differentiation marker PPO1 in third instar lz>GFP+ hemocytes. (F-H) Bright field 
images of the posterior segments of third instar larvae heat-treated at 65°C for 10 min to induce crystal cell 
melanization. (I-K) Fluorescent immunostainings against LZ in lz>GFP+ blood cells of third instar larvae 
from the indicated genotypes. LZ expression alone is shown on the right panels. (L) Corresponding 
quantification of LZ expression level. (A, B, L) **: p-value<0.01 and ***: p-value<0.001 compared to 
control. (C-E, I-K): nuclei were stained with Topro3. Scale bar: 10 μm. 
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FIG 4. High levels of MLF prevent LZ degradation in the absence of DnaJ-1. 
(A-D) Immunostainings against LZ (red) and HA-MLF (green) in Kc167 cells treated with the indicated 
dsRNA and transfected with pAc-LZ-V5 alone (A, C) or in combination with pAc-3HA-MLF (B, D). (E) 
Quantification of LZ expression level in Kc167 cells transfected with pAc-LZ-V5 alone or in combination 
with pAc-3HA-MLF and treated with the indicated dsRNA. (F-I) Immunostainings against LZ in circulating 
blood cells from lz-GAL4, UAS-mCD8GFP/+ control (F), UAS-dsMLF (G), dnaj-1-/- (H) and UAS-dsMLF; 
dnaj-1-/- (I) third instar larvae. (J) Quantification of LZ expression level in lz>GFP+ circulating blood cell 
from third instar larvae of the indicated genotypes. (A-D, F-I) Nuclei were stained with Topro3. LZ 
expression only is shown in the lower panels. Scale bar: 10 μm. (E, J) *: p-value<0.05, **: p-value<0.01, 
***: p-value<0.001. 
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FIG 5. DnaJ-1 and MLF interfere with LZ activity and act together to control LZ+ 
blood cell development 
Relative lz>GFP+ blood cell number (A, C) and size (B, D) in lz-GAL4, UAS-mCD8GFP/+ third instar 
larvae of the indicated genotypes. *: p-value<0.05, ***: p-value<0.001. 
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FIG 6. MLF and DnaJ-1 control crystal cell differentiation. 
(A) MA-plot of DESeq2 results for RNAseq data comparison between control and mlf-/- , lz>GFP+ blood 
cells sorted by FACS from third instar larvae. Genes that are significantly (adjusted p-value<0.01) up-
regulated or down-regulated in mlf mutant are highlighted in red or blue, respectively. Red triangles: genes 
with log2 fold change >5. (B) Pie chart showing the number of expressed genes in lz>GFP+ cells and the 
number of up-regulated (red) or down-regulated (blue) genes in mlf mutant. (C) Heat map of differentially 
expressed (p-value<0.01) “crystal cell”-associated genes between control and mlf mutant lz>GFP+ cells. 
Differential gene expression as per comparison to the mean of 6 samples is displayed as log2 scale. 
Hierarchical clustering was performed using R-Bioconductor. (D-O) Immunostainings against GFP and in 
situ hybridization against CG7860 (D-F), Oscillin (G-I), CG6733 (J-L) and Jafrac1 (M-O) in blood cells 
from lz-GAL4, UAS-mCD8GFP/+ control (D, G, J, M), mlf-/- (E, H, K, N) or dnaj-1-/- (F, I, L, O) third instar 
larvae. RNA expression only is shown in the lower panels. Nuclei were stained with Topro3. Scale bar: 10 
μm. 
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FIG 7. MLF and DnaJ-1 are required to prevent Notch overexpression and 
overactivation of Notch signaling in the crystal cell lineage. 
(A-C) Immunostainings against Notch (NECD: Notch extracellular domain) in blood cells from lz-GAL4, 
UAS-mCD8GFP/+ control (A) mlf-/- (B) and dnaj-1-/- (C) larvae. The expression of Notch protein only is 
shown in the lower panels. Nuclei were stained with Topro3. (D) Quantification of NECD immunostainings 
in lz>GFP+ and lz>GFP- blood cells from control, mlf-/- and dnaj-1-/- larvae. (E) Quantification of NICD 
(Notch intracellular domain) immunostainings in lz>GFP+ blood cells from control, mlf-/- and dnaj-1-/- 
larvae. (F-H) Expression of the Notch pathway reporter Klu-Cherry in lz>GFP+ blood cells from control, 
mlf-/- or dnaj-1-/- larvae. Klu-Cherry expression only is shown in the lower panels. (I) Corresponding 
quantification of Klu-Cherry expression levels. (J) Quantification of the expression level of the Notch 
pathway reporter NRE-GFP in PPO1-expressing cells from control, mlf-/- or dnaj-1-/- larvae. (A-C, F-H) 
Scale bar: 10μm. (K) Quantification of the proportion of lz>GFP+ cells according to their size in control, 
mlf-/- or dnaj-1-/- larvae. Cells were grouped into 5 categories as compared to the mean size of lz>GFP+ cells 
in wild type condition. (L-N) Quantification of NICD expression level (relative to control) in each of the five 
lz>GFP+ cell size categories in control (L), mlf-/- (M) and dnaj-1-/- (N) larvae. 
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FIG 8. High levels of LZ prevent accumulation of lz>GFP+ cells and overactivation of 
Notch signaling. 
(A-D) Fluorescent immunostainings against LZ in circulating blood cells from lz-GAL4, UAS-mCD8GFP/+ 
(A, control), lz-GAL4, UAS-mCD8GFP/lzr1 (B), lz-GAL4, UAS-mCD8GFP/Y (C) and lz-GAL4, UAS-
mCD8GFP/+, UAS-BroSMMHC (D) third instar larvae. Nuclei were stained with Topro3. Scale bar: 10μm. 
(A’-D’): LZ expression only is shown. (E-H) Relative quantification of lz>GFP+ cell number (E) and size 
(F) as well as NRE-GFP (G) and Klu-Cherry (H) expression levels in third instar larvae of the indicated 
genotypes. **: p-value<0.01, *** p-value<0.001. 
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Fig 9. LZ represses Notch expression. 
(A-D) Immunostainings against NECD (Notch extracellular domain) in blood cells from lz-GAL4, UAS-
mCD8GFP/+ (A), lz-GAL4, UAS-mCD8GFP/Y (B), lz-GAL4, UAS-mCD8GFP/Y; UAS-lz (C) and lz-GAL4, 
UAS-mCD8GFP/+; UAS-lz (D) third instar larvae. The expression of Notch protein only is shown in the 
lower panels. Nuclei were stained with Topro3. (E) Corresponding quantification of NECD level in lz>GFP+ 
blood cells. (F-F’’’) Immunostaining against LZ in circulating blood cells from Notch GMR30A01-GAL4, 
UAS-GFPnls third instar larvae. Nuclei were stained with Topro3. (F’-F”’): single channel images. (G-J) 
Notch GMR30A01-GAL4-driven expression of GFP in circulating blood cells from larvae of the indicated 
genotypes. (K) Corresponding quantification of GFP expression level. (A-D, F-J) Scale bar: 10μm. (E, K) *: 
p-value<0.05, *** p-value<0.001. 
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S1 Fig. DnaJ-1 and MLF interact in Kc167 cells.  
(A) Confocal images of fluorescent immunostainings against GFP (green) and HA (red) in 
Kc167 cells transfected with expression plasmids for GFP-DnaJ-1 and HA-MLF. Nuclei were 
stained with Topro3. Merged and individual channels are displayed. Scale bar: 10 μm.  
(B) Western blots showing the results of an immunoprecipitation experiment against GFP in 
Kc167 cells transfected with expression plasmids for the indicated proteins. 
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S2 Fig. LZ interacts with MLF and DnaJ-1. 
(A) Autoradiogram showing the results of pull down assays between in vitro translated 35S-
methionine-labeled LZ and the indicated GST fusion proteins produced in E. coli.  
(B, C). Western blots showing the results of immunoprecipitation experiments against GFP 
performed in Kc167 cells transfected with expression vectors for GFP-LZ and various HA-MLF 
(B) or HA-DnaJ-1 (C) mutants. 
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S3 Fig. Hsc70-4 interacts with MLF and DnaJ-1 and controls LZ activity and 
expression. 
(A, B) Western blots showing the results of immunoprecipitation experiments against GFP performed in 
Kc167 cells transfected with expression vectors for GFP or GFP-Hsc70-4 and either HA-MLF (A) or 
HA-DnaJ-1 (B).  
(C) Luciferase assays in Kc167 cells treated with the indicated dsRNA and transfected with 4xPPO2-Fluc 
reported plasmid in the presence or not (ctr) of pAc-LZ-V5 expression plasmid. pAc-Rluc was used as an 
internal normalization control. Means and standard deviations from biological triplicates are represented. 
***: p-value<0.001 as compared to pAc-LZ-V5+dsGFP.  
(D) Western blots showing LZ-V5, Renilla luciferase (Rluc) and Tubulin (Tub) expression in Kc167 cells 
treated with the indicated dsRNA and cotransfected with pAc-LZ-V5 and pAc-Rluc expression vectors. 
(B, C) dsHsc70-4 (a) and (b) correspond to two distinct dsRNA targeting Hsc70-4. 
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S4 Fig. Generation and characterization of dnaj-1 mutants. 
(A) Schematic representation of dnaj-1 locus. dnaj-1 transcripts and coding sequence(orange) 
are shown. The location of the sequences targeted by the 2 guide RNAs (gRNA2 and gRNA3), 
of the P(EPgy2) element used to select CRISPR/Cas9-mediated deletion events, and of the 
primers (F and R) used for PCR validation are indicated. Part of the region covered by the 
deletion Def(3L)BSC884 is also indicated.  
(B) Results of PCR amplification on genomic DNA from wild-type (wt) and putative dnaj-1 
deletion mutants (A, C, D, E and F) using the F and R primers displayed in (A). The mutant lines 
A and C exhibit a complete deletion of the region located between the two gRNAs, as confirmed 
by sequencing. Other mutants carried deletion of dnaj-1 associated with more complex 
rearrangements.  
(C-D) Immunostaining against the crystal cell differentiation marker PPO1 was used to assess 
crystal cell size and number in different dnaj-1 mutant backgrounds. (C) Relative size of the 
PPO1+ blood cells in bleeds from third instar larvae of the indicated genotypes. (D) Relative 
number of PPO1+ blood cells in bleeds from third instar larvae of the indicated genotypes. **: p-
value<0.01; ***: p-value<0.001. 
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S5 Fig. MLF expression in Kc167 cells and in larval crystal cells. 
(A-C) Fluorescent immunostainings against MLF in Kc167 cells (A) or in circulating blood cells 
from Bc-GFP/+ control (B) or dnaj-1-/- (C) third instar larvae. Nuclei were stained with Topro3. 
Only MLF staining is shown in the lower panels. Scale bar: 10 μm. 
(D) Quantification of MLF expression level in lz>GFP+ circulating blood cells from control or 
dnaj-1-/- third instar larvae. 
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S9 Fig. LZ expression increases with lz>GFP+ cell size.  
Quantification of LZ and NICD expression levels in lz>GFP+ circulating blood cells of lz-GAL4, 
UAS-mCD8GFP/+ third instar larvae. Cells were pooled into 5 categories according to their size 
(% of the mean cell size) and LZ or NICD expression level in each pool was plotted. 
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S10 Fig. Characterization of Notch-Gal4 lines 
(A) Schematic representation of Notch locus with the position of the two GMR lines that drive 
expression in LZ+ blood cells. The putative RUNX binding site and their conservation in 
different Drosophila species are indicated.  
(B) LZ and GFP expression in NotchGMR30C06-GAL4, UAS-GFPnls circulating blood cells 
from third instar larvae. Nuclei were stained with Topro3. 
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2. Supplementary results (not present in the article) 
2.1. Endogenous MLF interacts with DnaJ-1   
        Our results show that MLF and DnaJ-1 interact with each other specifically in co-
immunoprecipitation experiments following co-transfection of epitope-tagged version of 
these two proteins as well as in in vitro GST pull-down assays, suggesting that the 
interaction between them is direct. In addition, we found that 3HA-DnaJ-1 co-precipitated 
GFP-MLF as well as the endogenous MLF (see above; Figure 1.D of the submitted
manuscript). To strengthen our conclusions, we asked whether the endogenous MLF could 
also co-precipitate 3HA-DnaJ-1 in Kc167 cells. So we performed a co-immunoprecipitation 
experiment with extracts of Kc167 cells transfected with pAc-3HA-DnaJ-1 expression 
plasmid by using rabbit anti-MLF antibody to precipitate the endogenous MLF and rabbit 
anti-GFP antibody as a negative control. Western blot analysis showed that MLF antibody 
precipitated the endogenous MLF and co-precipitated 3HA-DnaJ-1, while GFP antibody did 
not precipitate either protein (Figure 21), which further confirmed the interaction between 
MLF and DnaJ-1. Of note, since we do not have the antibody against DnaJ-1, we could not 
test the interaction between both endogenous DnaJ-1 and MLF. 
 
2.2. MLF or DnaJ-1 can form a dimer 
        DnaJ-1 is a member of the DnaJB/class II subfamily of Hsp40/DnaJ proteins, which 
contains an N-terminal J-domain required for the stimulation of Hsp70 ATPase activity, a 


Figure 21. Endogenous MLF interacts with DnaJ-1 
Western blotting results of co-immunoprecipitation experiment by using GFP or MLF antibody 
performed in Kc167 cells transfected with HA-DnaJ-1 expression plasmid. 
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central glycine/phenylalanine (G/F) rich region, and a conserved C-terminal region that 
contains a client binding domain followed by a dimerization interface (Kampinga et al., 
2010). Interestingly, when we performed in vitro GST pull-down assays, we found that in 
vitro translated 35S-labeled DnaJ-1 weakly interacted with GST-DnaJ-1, but not with GST 
alone (Figure 22.B), suggesting that DnaJ-1 can directly interact with itself, probably due to 
the existence of a dimerization interface in its conserved C-terminal region. Similarly, we 
also found that in vitro translated MLF strongly interacted with GST-MLF, but not with 
GST alone (Figure 22.A), indicating that MLF interacts with itself. 
 
2.3. Hsc70-5 interacts with MLF and DnaJ-1
        Previous work has revealed that Hsc70-4 interacts specifically with MLF and DnaJ-1
(see above and Dyer et al., 2016). Hsc70-4 belongs to the family of constitutively expressed 
Hsp70 chaperones, which are composed of 5 paralogs in Drosophila melanogaster (Hsc70-
1 to Hsc70-5). Considering the similarity in protein structure of the various Hsc70s (the 5 
Hsc70 proteins exhibit ±60% of identity), it is interesting to know whether the interaction 
between Hsc70-4 and MLF or between Hsc70-4 and DnaJ-1 is conserved among other 
Hsc70s. Actually, we also identified Hsc70-3 as a potential partner of MLF in our 
proteomic analysis (see above; Figure 1.B of the submitted manuscript). To further test this 
hypothesis, we expressed a GFP-tagged version of Hsc70-5 (the most divergent Hsc70 
family member, which is 52% identical to Hsc70-4) together with HA-MLF or HA-DnaJ-1 
in Kc167 cells and we performed immunoprecipitation using GFP-Trap resin. Our results             
showed that GFP-tagged Hsc70-5, but not GFP alone, co-precipitated both MLF (Figure 
  A                                                                      B 
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Figure 22. MLF or DnaJ-1 forms a dimer 
(A, B) Autoradiograms of pull-down assays between in vitro translated 35S-methionine labeled 
MLF (A) or DnaJ-1 (B) and the indicated GST fusion proteins produced in E. coli. 
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23.A) and DnaJ-1 (Figure 23.B), suggesting that Hsc70-5 specifically interacts with MLF 
and DnaJ-1. These data suggest that the interactions between Hsc70s and MLF or DnaJ-1 
are conserved across members of the Hsc70 family and support the idea that MLF acts 
within the Hsp70 chaperone system. 
 
2.4. Hsp83 does not interact with MLF or DnaJ-1 
        There are two main chaperone systems, the Hsp70 system and the Hsp90 system, both 
of which participate broadly in de novo protein folding and refolding (Hartl et al., 2011). 
Our data show that MLF can act through DnaJ-1 and the Hsp70 system to control Lozenge 
stability and activity. However, it is still unknown whether MLF or DnaJ-1 might also
interact with the Hsp90 chaperone machinery. To answer this question, we cloned Hsp83, a 
Drosophila homolog of human Hsp90 chaperones, and performed immunoprecipitation 
experiments between Hsp83 and MLF or DnaJ-1 after co-transfection of the corresponding 
expression plasmids in Kc167 cells. As Western blotting results showed, Hsp83 co-
precipitated neither MLF (Figure 24.A) nor DnaJ-1 (Figure 24.B), suggesting that MLF 
and DnaJ-1 do not act in the Hsp90 chaperone system. These data also further confirm the 
specificity of the interactions that we observed between MLF, DnaJ-1 and Hsc70 proteins.
  A                                                                  B 
    
Figure 23. Hsc70-5 interacts with MLF and DnaJ-1 
Western blotting results of immunoprecipitation experiments against GFP performed in Kc167 
cells co-transfected with GFP or Hsc70-5-GFP and 3HA-MLF (A) or 3HA-DnaJ-1 (B) 
expression plasmids, as indicated in the upper part of each panel. 
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2.5. High levels of MLF rescue Lozenge stability and activity when DnaJ-1 is knocked 
down 
        DnaJ-1 was identified as a partner of MLF. When it was knocked down in Kc167 cells,
we observed a decrease in Lozenge protein level and a reduction in Lozenge transactivation 
activity (Figure 2.A-F of the submitted manuscript). In contrast, a slight but significant 
increase in Lozenge protein level was observed in dnaj-1-/- mutant larvae (Figure 3.I-L of 
the submitted manuscript). Yet, the endogenous MLF level in Kc167 cells is much lower 
than that in larval crystal cells (Figure 4 of the submitted manuscript), and our data suggest
that the level of MLF could explain the differences in Lozenge sensitivity to DnaJ-1 
knockdown between Kc167 cells and larval crystal cells. To further test this hypothesis, we 
performed Western blotting and transactivation assays in Kc167 cells over-expressing MLF 
or not following DnaJ-1 knockdown. Our results showed that knockdown of DnaJ-1 caused 
a decrease in Lozenge level that was rescued when MLF was over-expressed (Figure 25.A).
Of note, knockdown of DnaJ-1 had no effects on the expression of MLF, indicating that it 
does not impact on Lozenge level by modifying MLF level (Figure 25.A). Moreover, DnaJ-
1 knockdown caused a reduction in Lozenge-induced activation of the 4xPPO2-Fluc
reporter gene and this drop was rescued upon MLF over-expression (Figure 25.B). All
  A                                                                      B 
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Figure 24. Hsp83 does not interact with MLF or DnaJ-1 
(A, B) Western blotting results of immunoprecipitation experiments against GFP performed in 
Kc167 cells co-transfected with GFP or Hsp83-GFP and 3HA-MLF (A) or 3HA-DnaJ-1 (B) 
expression plasmids. 
3HA-MLF 
Hsp83-EGFP 
EGFP 
3HA-MLF 
Hsp83-EGFP 
EGFP 
+ + 
- 
+ 
+ 
- 
+ + 
- 
+ 
+ 
- 
input α-GFP IP 
3HA-DnaJ-1 
Hsp83-EGFP 
EGFP 
3HA-DnaJ-1 
Hsp83-EGFP 
EGFP 
+ + 
- 
+ 
+ 
- 
+ + 
- 
+ 
+ 
- 
input α-GFP IP 
 115 
together, these data indicate that high levels of MLF can rescue Lozenge stability and 
activity when DnaJ-1 is knocked down. 
2.6. High levels of DnaJ-1 do not rescue Lozenge stability or activity when MLF is 
knocked down 
        Similarly, it was shown that MLF knockdown caused a dramatic decrease in Lozenge 
level and a concomitant reduction in transactivation activity in Kc167 cells (Bras et al., 
2012). As described above, high levels of MLF rescue Lozenge stability and transactivation 
activity in the absence of DnaJ-1 in Kc167 cells. Here, we asked whether the converse is 
true. Our results showed that DnaJ-1 over-expression didn’t increase Lozenge level 
following MLF knockdown (Figure 26.A), and similar results were observed in the 
luciferase assays (Figure 26.B). In addition, knockdown of MLF had no effects on DnaJ-1 
level in Kc167 cells (Figure 26.A). Taken together, these data indicate that high levels of 
 A                                                         B 
               
Figure 25. High levels of MLF rescue Lozenge stability and activity when DnaJ-1 is 
knocked down
(A) Western blotting showing LZ-V5, MLF, Renilla luciferase (R luc) and Tubulin (Tub) 
expression in Kc167 cells treated with the indicated dsRNA. 
(B) Luciferase assays in Kc167 cells treated with the indicated dsRNA and transfected with 
4xPPO2-Fluc reporter plasmid in the presence or not of pAc-LZ-V5 and pAc-MLF expression 
plasmids as indicated in the lower part of the panel. pAc-Rluc was used as an internal 
normalization control. 
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DnaJ-1 are not sufficient to rescue Lozenge stability or activity when MLF is knocked 
down. 
 
2.7. MLF, DnaJ-1 and Hsc70-4 control human RUNX1 stability 
        As we know, members of the RUNX family of proteins contain a highly evolutionarily 
conserved 128 amino acid domain at their N-terminus, which is designated as the runt 
homology domain (RHD) and mediates the interactions between RUNX family proteins
with DNA but also with some other proteins. We have demonstrated that Lozenge, a 
Drosophila homolog of human RUNX1 transcription factor, interacts with MLF, DnaJ-1 
and Hsc70-4, and that its activity and stability are regulated by these three proteins to 
control Drosophila blood cell development. Here, we asked that whether the MLF/DnaJ-
1/Hsc70-4 chaperone complex might also regulate other RUNX factors. First, we tested 
whether human RUNX1 interacts with MLF, DnaJ-1 or Hsc70-4. Accordingly, we 
expressed RUNX1 in Kc167 cells together with GFP-tagged versions of MLF, DnaJ-1 or 
Hsc70-4 and we performed co-immunoprecipitation experiments. Our results showed that 
A                                                                   B 
                 
Figure 26. High levels of DnaJ-1 do not rescue Lozenge stability or activity when 
MLF is knocked down 
(A) Western blotting results of LZ-V5, DnaJ-1, and Tubulin (Tub) expression in Kc167 cells 
treated with the indicated dsRNA. 
(B) Luciferase assays in Kc167 cells treated with the indicated dsRNA and transfected with 
4xPPO2-Fluc reporter plasmid in the presence or not of pAc-LZ-V5 expression plasmid with or 
without DnaJ-1 expression. pAc-Rluc was used as an internal normalization control.  
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MLF and Hsc70-4 co-precipitated RUNX1. However, we did not observe a co-
immunoprecipiation of RUNX1 with GFP-DnaJ-1 (Figure 27.A). Then we asked whether 
these proteins are required for the stable expression of RUNX1 in Kc167 cells.
Interestingly, the knockdown of MLF, or DnaJ-1 or Hsc70-4 caused a decrease in the level 
of RUNX1 (Figure 27.B). Thus, even though we could not detect yet a physical interaction 
between DnaJ-1 and RUNX1 in our assays, these data indicate that RUNX1 stability can be 
regulated by MLF, DnaJ-1 and Hsc70-4 from Drosophila, and we propose that RUNX1 
stability might also be controlled by the homologs of these proteins in human. These data 
also suggest that the runt homology domain, which is conserved between Lozenge and 
RUNX1, is an important determinant of the regulation by the MLF/DnaJ/Hsc70 chaperone
machinery. In line with this hypothesis, co-immunoprecipitation results showed that 
Lozenge RHD is sufficient for the interaction between Lozenge and MLF as MLF co-
precipitated the runt domain, but DnaJ-1 didn’t (Figure 28). Thus, other RUNX proteins 
might also be regulated by these factors. 
 A                                                                                B
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Figure 27. MLF, DnaJ-1 and Hsc70-4 control human RUNX1 stability in Drosophila 
cell culture 
(A) Western blotting of co-immunoprecipitation experiments against GFP performed in Kc167 
cells co-transfected with GFP or GFP-MLF, GFP-DnaJ-1, GFP-Hsc70-4 and 6myc-RUNX1 
expression plasmids. 
(B) Western blotting showing the expression of RUNX1, Renilla luciferase (R luc), Tubulin 
(Tub) and endogenous MLF expressed in Kc167 cells transfected with 6myc-RUNX1 expression 
plasmid and treated with the indicated dsRNA. 
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Figure 28. MLF interacts with Lozenge runt domain 
Western blotting of co-immunoprecipitation experiments against GFP performed in Kc167 cells 
co-transfected with GFP or GFP-MLF, GFP-DnaJ-1 and 3HA-LZ-Runt expression plasmids.
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1. The interactions between LZ, MLF, DnaJ-1 and Hsc70-4 
1.1. MLF/DnaJ-1 complex 
        MLF is known to be a conserved regulator of RUNX transcription factor Lozenge (LZ) 
stability and activity, but the molecular mechanism of action of MLF on LZ stability has not 
been well understood (Bras et al., 2012). To answer this key question, an affinity 
purification approach followed by mass spectrometry was applied to search for MLF 
interacting partners, which could provide some valuable clues to this mystery. This 
approach allowed us to discover that MLF interacts with DnaJ-1 in Kc167 cells, which is in 
accordance with the results published by Dyer et al. who used a similar strategy in 
Drosophila S2 cells. We confirmed these results by co-immunoprecipitation experiments in 
Kc167 cells and our in vitro GST pull-down assay results further suggest that the interaction 
between MLF and DnaJ-1 is direct, which is consistent with the findings using purified 
recombinant proteins (Dyer et al., 2016). Furthermore, our domain mapping experiments 
show that MLF homology domain (MHD) interacts with DnaJ-1’s conserved C-terminus, 
suggesting that the interaction between MLF and DnaJ-1 is conserved. In line with this idea, 
Dyer et al. showed that over-expressed hMLF1 or hMLF2 interacts with DnaJB6, a 
homolog of DnaJ-1, in human 293T cells. This provides a possible mechanism for MLF-
directed transcription factor stabilization, since DnaJ-1 co-chaperone plays a crucial role in 
the regulation of protein folding and degradation, and MLF is likely to participate in the 
chaperone complex and exerts its function in the regulation process of a particular 
molecular chaperone complex. These findings open a new direction to decipher MLF 
molecular mode of action in the Drosophila model organism. However, it is still difficult to 
assess the interaction between MLF and DnaJ-1 in vivo, due to the small amount of crystal 
cells and the technical difficulties of their successful isolation from Drosophila. 
Technologies like BiFc (Bimolecular Fluorescence Complementation) (Hudry et al., 2011) 
using transgenically expressed MLF and DnaJ-1 proteins fused to the N- or C-terminal 
domain of GFP, or Proximity Ligation Assays (Weibrecht et al., 2010) using antibody 
directed against each protein, could be an alternative option to try to validate MLF/DnaJ-1 
physical interaction in vivo. 
1.2. MLF/Hsc70-4 complex 
        DnaJ-1, a member of the Hsp40/DnaJ co-chaperone family, chiefly acts by delivering 
client proteins to the Hsp70 chaperones and stimulating the Hsp70 ATPase activity by 
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interacting with them via their N-terminal J-domain. Interestingly, we also recovered 
Hsc70-4 and Hsc70-3 as potential MLF partners in our proteomic approach, two Hsp70 
paralogs in Drosophila. Our co-immunoprecipitation experiments confirmed that MLF and 
DnaJ-1 interact with Hsc70-4, respectively. Similarly, Dyer et al. also found that MLF 
interacts with Hsc70-4. In addition, our co-immunoprecipitation results showed that MLF 
(and DnaJ-1) can also interact with Hsc70-5, which is only ±50% identical to Hsc70-4, 
suggesting that MLF very probably interacts with several Hsc70 proteins and participates in 
diverse Hsp70 chaperone complexes in association with DnaJ-1. Yet, whether MLF directly 
interacts with Hsc70 proteins or indirectly interacts with them via DnaJ-1 remains to be 
determined. In in vitro GST pull-down assays, I only observed a weak interaction between 
in vitro translated Hsc70-4 and GST-MLF, but a strong interaction with GST-DnaJ-1 (data 
not shown). However, these results need to be confirmed. In addition, there is another 
common chaperone complex, the Hsp90 system, which participates broadly in de novo 
protein folding and refolding (Hartl et al., 2011). So we tested whether MLF or DnaJ-1 
could also interact with this Hsp90 chaperone. Our co-immunoprecipitation results showed 
that neither MLF nor DnaJ-1 interacts with Hsp83, a Drosophila homologue of human 
Hsp90 chaperones, indicating that MLF and DnaJ-1 are not part of the Hsp90 chaperone 
system.  
 
 Of note, Dyer et al. also identified the nucleotide exchange factor (NEF) BAG2, 
which stimulates the release of client proteins from the Hsp70 chaperones, as one of the 
main partners of MLF. However, we did not retrieve this protein in our proteomic approach, 
which could be due to its weak association with the MLF/DnaJ-1/Hsc70-4 complex. 
Furthermore, a systematic characterization of Hsp70 chaperone complexes in human cells 
has identified hMLF1 and hMLF2 as potential partners of DnaJ-1 homologs, DnaJB1, 
DnaJB4 and DnaJB6 (Taipale et al., 2014). All together, these publications and our work 
strongly support the conclusion that MLF is a conserved component of the Hsp70 chaperone 
system that interacts with DnaJB co-chaperones.  
1.3. MLF/DnaJ-1/Hsc70-4 complex and LZ 
        Results from our team suggested that MLF proteins act as a conserved regulator of 
RUNX transcription factor stability and activity. In particular, Drosophila MLF controls LZ 
activity and prevents its degradation by the proteasome in cell culture (Bras et al., 2012). 
However, it was unknown whether MLF physically interacts with LZ to control its stability. 
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Our co-immunoprecipitation results showed that MLF interacts specifically with LZ and our 
in vitro GST pull-down assays suggested that the interaction between MLF and LZ is direct. 
In addition, we demonstrated that DnaJ-1 and Hsc70-4 also interact specifically with LZ, 
respectively, suggesting that LZ is a direct target of the chaperone complex formed by MLF, 
DnaJ-1 and Hsc70-4. Importantly, we found that knockdown of DnaJ-1 or Hsc70-4 
expression by RNAi in Kc167 cells leads to a reduction in LZ protein level and activity 
without affecting its mRNA level, similar to what was observed following MLF 
knockdown. Dyer et al. also observed similar results on LZ protein level in S2 cells. In 
addition, we found that over-expression of DnaJ-1 mutants unable to stimulate Hsp70 
chaperone activity also causes a reduction in LZ level and activity, suggesting that the effect 
of DnaJ-1 on LZ is strictly dependent on its capacity to activate Hsc70-4. Thus, the 
MLF/DnaJ-1/Hsc70-4 chaperone complex is required for the stable expression of LZ in cell 
culture. Yet, how each component acts within this chaperone complex still remains to be 
determined.  
2. MLF in the Hsp70 chaperone complex: a chaperone or a co-chaperone? 
        Many studies have shown that over-expression of MLF, DnaJ-1 and some Hsp70s can 
suppress the cytotoxicity associated with polyglutamine (polyQ) protein aggregations in 
Drosophila (Kuo et al., 2013; Kim et al., 2005). In view of these publications and our 
results, it is tempting to speculate that the chaperone complex formed by MLF, DnaJ-1 and 
Hsc70-4 could play a role in the progression of neurodegenerative pathologies due to 
protein aggregation. This also further provides clues concerning the possible mode of action 
of MLF. 
 
         DnaJ-1 is known to act as a co-chaperone to assist the Hsp70 chaperones by delivering 
client proteins to their C-terminal substrate binding domain and stimulating their ATPase 
activity, but also as a chaperone by itself to mediate protein folding and refolding 
(Kampinga et al., 2010). On one hand, given the strong interaction between MLF and DnaJ-
1, MLF could act as a chaperone when DnaJ-1 acts as a co-chaperone, or MLF could act as 
a co-chaperone when DnaJ-1 acts as a chaperone by itself. On the other hand, MLF interacts 
with Hsc70-4 (directly or via DnaJ-1), an Hsp70 chaperone involved in a wide range of 
protein quality control functions, including de novo protein folding and protein degradation. 
So it would be interesting to test whether (1) MLF holds an intrinsic chaperone activity, (2) 
MLF modulates DnaJ-1 chaperone activity, (3) MLF modulates the activity of the 
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DnaJ/Hsc70 complexes. In that sense, we tried to produce highly purified MLF, DnaJ-1 and 
Hsc70-4 recombinant proteins in E. coli to assess the effects of MLF on the stimulation of 
Hsc70-4 ATPase activity and on Hsc70-4 dependent refolding of a denatured model 
substrate protein (i.e., firefly luciferase), as well as the effects of MLF on DnaJ-1 intrinsic 
chaperone activity in an assay based on the prevention of luciferase aggregation (Perrody et 
al., 2012). However, MLF was highly insoluble and we could not produce enough proteins 
to perform these experiments. MLF could also act by regulating the client specificity of 
DnaJ proteins, and it would be interesting to identify other factors whose stability is 
regulated by MLF and/or DnaJ-1. According to the reaction cycle of the Hsp70 chaperone 
system, MLF could bind to LZ to prevent it from forming aggregates and then, together 
with DnaJ-1, present LZ to Hsc70-4 for proper protein folding. Our preliminary data 
suggest that an important fraction of LZ is not soluble when expressed in Kc167 cells and 
might form aggregates. In this model, MLF could act as a co-chaperone to prevent LZ but 
also polyglutamine (polyQ) protein aggregations. It would be interesting to further 
investigate the impacts of MLF, DnaJ-1 or Hsc70-4 knockdown on LZ soluble and 
insoluble fractions.  
3. Regulation of LZ stability and activity by MLF and DnaJ-1 
        It has been demonstrated that MLF stabilizes RUNX transcription factor Lozenge, as 
the endogenous nuclear Lozenge is degraded in LZ+ cells from mlf null mutant larvae and 
the Lozenge expressed in Kc167 cells is decreased when the endogenous MLF is knocked 
down (Bras et al., 2012). Due to loss of Lozenge, a key transcription factor for crystal cell 
development, phenotypic defects in LZ+ cells emerge, such as changes in the number and 
the size of LZ+ cells, indicating that the regulation of Lozenge stability by MLF is vital for 
the normal development of LZ+ cells (Bras et al., 2012). However, how MLF regulates 
Lozenge stability remains largely unknown. Understanding this process might provide 
valuable information as to MLF functions and mode of action but also concerning the 
regulation of RUNX transcription factors. Both MLF and RUNX are implicated in 
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in human, and thus 
our findings might be of interest in terms of human health. Based on our findings and those 
of Dyer et al., the prevailing hypothesis is that MLF acts together with the chaperone 
complex DnaJ-1/Hsc70-4 to control Lozenge level post-translationally by preventing its 
degradation. 
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        The human homolog of Lozenge, RUNX1 is essential for hematopoiesis and it is 
subjected to proteolytic degradation by the ubiquitin-proteasome pathway in absence of 
CBFβ subunit (Huang et al., 2001), suggesting that RUNX1 could be unstable in the 
nucleus without its β subunit and this instability could be an intrinsic property of RUNX1. It 
has been shown that RUNX1 is modified by a chain of ubiquitin and then the 70S 
proteasome can recognize this ubiquitylated RUNX1 to degrade it (Huang et al., 2001). 
However, when we tested whether Lozenge could be ubiquitylated, we didn’t detect 
ubiquitylation of Lozenge in Kc167 cells (data not shown). Nonetheless, Lozenge is 
degraded in the absence of mlf in LZ+ cells as well as in Kc167 cells and its degradation in 
Kc167 cells is partly inhibited by MG132 treatment, suggesting that the proteasome is 
implicated in Lozenge degradation (Bras et al., 2012). There is also a proteasome pathway 
independent of ubiquitylation (Erales et al., 2014), and it could be interesting to check 
whether Lozenge is degraded by this pathway. Besides degradation mediated by 
proteasome, some specific proteases and certain lysosomes also cause the degradation of 
particular proteins. We propose that MLF might act at three different levels. Firstly, MLF 
binding to Lozenge could block its interaction with the proteolytic chamber of the 20S 
proteasome or interfere with its recognition by the 70S proteasome. Secondly, MLF could 
block Lozenge ubiquitylation and its subsequent targeting to the proteasome, even though 
we have not obtained direct evidence that Lozenge can be ubiquitylated. Thirdly, MLF 
could inhibit the proteasome-independent degradation of Lozenge. An important challenge 
will be to further define MLF mode of action and the pathway that mediates Lozenge 
degradation. 
 
        We have demonstrated that MLF is involved in the Hsp70 chaperone system, and 
Hsp70 chaperones can also mediate the degradation of some proteins that are not refolded 
by Hsp70 chaperones through chaperone mediated autophagy (CMA) or chaperone-assistant 
selective autophagy (CASA), both of which are dependent or independent on ubiquitylation 
(Kettern et al., 2010). So, even though our results argue that Hsc70-4 is required for 
Lozenge stability, it could be interesting to test whether Lozenge degradation is caused by 
Hsp70 chaperones-mediated autophagy in the absence of MLF. 
 
 Intriguingly, we found that in the presence of high levels of MLF (LZ+ larval blood 
cells or Kc167 cells over-expressing MLF), the absence or the knockdown of DnaJ-1 does 
not result in a decrease in Lozenge level, in contrast to what we observed in the presence of 
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low level of MLF (naive Kc167 cells or LZ+ larval blood cells with MLF knockdown) 
(Figure 2 and 4 in the manuscript). It is possible that MLF and DnaJ-1 somehow compete 
for binding to Lozenge or, alternatively, that the association of MLF with DnaJ-1 changes 
the fate of Lozenge protein. MLF could act first to stabilize Lozenge (prevent its 
degradation), and then the MLF/DnaJ-1 complex could favor proper Lozenge folding and 
thus its activity. In view of our results, we propose that in the absence of MLF, Lozenge is 
degraded whereas in the absence of DnaJ-1, Lozenge is not properly folded and either it is 
degraded if there is a low level of MLF or it accumulates in a unfolded/inactive state if there 
is enough MLF to prevent its degradation (Figure 29). 
 
        Our preliminary results indicate that an important fraction of Lozenge is insoluble 
when it is expressed in Kc167 cells (data not shown). This suggests that Lozenge is prone to 
form aggregates and that MLF or DnaJ-1, which has been involved in the regulation of 
polyQ aggregates, might participate in the solubilization of Lozenge. It would be interesting 
to further test this hypothesis by systemically assessing the effects of MLF, DnaJ-1 and 
Hsc70-4 knockdown or over-expression on the soluble and insoluble fraction of Lozenge as 
well as by testing in vitro whether these factors modify the solubility of purified 
recombinant Lozenge protein. 
 
 Finally, since DnaJ-1 and MLF can also bind chromatin and regulate transcription 
(Dyer et al., 2016), it would be interesting to test whether Lozenge recruits these proteins to 
chromatin or whether these two proteins are also involved in the recruitment of Lozenge to 
chromatin. Indeed, even though our data show that the defects caused by MLF or DnaJ-1 
loss can be rescued by the re-expression of Lozenge in vivo, we can not exclude the 


Figure 29. Model for regulation of Lozenge protein fate by MLF and DnaJ-1
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possibility that these two protein somehow participate directly in the regulation of Lozenge 
capacity to regulate gene expression. However, the limited amount of crystal cells present in 
the larva precludes our possibility to perform ChIP experiments in vivo to test these 
hypotheses. 
4. MLF, DnaJ-1, LZ and the control of crystal cell size and number 
        Based on the data collected from the dnaj-1-/- mutant larvae, we showed that this gene 
is required for the normal development of the circulating crystal cells and that it genetically 
interacts with mlf during this process. The loss of DnaJ-1 notably caused an increase in the 
number and the size of LZ+ blood cells, which was rescued by the re-expression of DnaJ-1 
in this lineage. This demonstrates that these phenotypes are specifically due to the absence 
of DnaJ-1 and that DnaJ-1 acts after the induction of crystal cell fate and in a cell-
autonomous way. So far, the function of DnaJB proteins in hematopoiesis has barely been 
studied and thus our results provide the first evidence that this conserved family of co-
chaperones controls blood cell development in vivo. Besides the circulating larval blood 
cells, it would be interesting now to study the role of DnaJ-1 in the development of the 
crystal cells in the embryo, the lymph gland and the adult but also to assess its function in 
other blood cell types during Drosophila hematopoiesis. 
 
        In addition, like in mlf-/- mutant larvae, we found that the increase in LZ+ blood cell 
size and number observed in dnaj-1-/- larvae is rescued when we enforced the expression of 
Lozenge in this lineage. Together with our results in Kc167 cells, this strongly suggests that 
MLF and DnaJ-1 to control LZ+ cell development by promoting Lozenge activity. 
Consistent with this hypothesis, we found that reducing Lozenge expression or interfering 
with its activity causes an increase in the number and the size of LZ+ cells, a phenotype that 
could be described as “preleukemic”. This not only reinforces our conclusion but also 
establishes an interesting parallel with the situation in mammals where a reduction in 
RUNX1 activity has been associated with oncogenic blood cell transformation.  
 
        Moreover, we could link the decrease in Lozenge level/activity with an over-activation 
of the Notch signaling pathway and our data suggest that high levels of Lozenge directly 
repress Notch expression and thus activation of the Notch pathway to control LZ+ blood 
cells number and size. It will be interesting to decipher how Lozenge represses Notch 
transcription and to explore further how the Notch pathway controls LZ+ cells growth and 
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survival. Again, this could be particularly interesting to study the role of Notch pathway 
activation in human leukemia.  
5. Conservation of regulation of RUNX transcription factor stability and activity 
by MLF/DnaJ-1 
 Given the conservation of the RUNX, MLF, DnaJ and Hsp70 families through 
evolution, it will be particularly interesting to study the relationships between the 
MLF/DnaJ/Hsc70 complex and RUNX factors in other species. RUNX1 and Lozenge share 
a highly conserved runt domain, and we showed that RUNX1 stability is regulated by MLF, 
DnaJ-1 as well as Hsc70-4 in Kc167 cells. In addition, we found that MLF and Hsc70-4 
(but not DnaJ-1) bind to RUNX1. Moreover, it was shown previously in the lab that 
RUNX1-ETO protein level is also regulated by MLF both in Drosophila and in human 
leukemia cells (Bras et al., 2012). Thus, the MLF/DnaJ/Hsc70 complex could play a 
conserved role in the regulation of RUNX transcription factors stability and it would be 
worth investigating whether homologs of MLF, DnaJ-1 and Hsc70-4 also control the level 
and/or the activity of RUNX transcription factors in human, particularly in normal and 
leukemic blood cells. One limitation of these study is that mammals could have the high 
level of gene redundancy between members of the DnaJ family, Thus, studies in simpler 
model organisms like Drosophila still offer a good opportunity to study in vivo the function 
of these factors.  
6. Perspectives 
        We have demonstrated that MLF, DnaJ-1 and Hsc70-4 interact with Lozenge, and 
regulate the stability as well as the activity of this RUNX transcription factor. Yet, we still 
don’t know whether all these proteins can be in the same complex and how they organize 
topologically. Therefore, more biochemical approaches are needed to gain insights into the 
relationships among these proteins and to decipher how MLF and DnaJ-1/Hsc70-4 control 
Lozenge stability. 
 
        In our study, biochemical experiments were carried out in Kc167 cells, an embryonic 
blood cell line. These cells have lower levels of endogenous MLF than crystal cells, which 
lead to differences in Lozenge expression and regulation between these two cell types.  
Notably, a reduction in Lozenge expression was observed in Kc167 cells when DnaJ-1 was 
knocked down, while Lozenge accumulation was present (and stronger) in LZ+ cells in 
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dnaj-1 null mutant larvae. In addition, we cannot exclude the possibility that other important 
proteins implicated in Lozenge regulation by the MLF/DnaJ/Hsc70 complex are 
differentially expressed between Kc167 cells and LZ+ larval blood cells. Thus Kc167 cells 
are not ideal to characterize the regulation of Lozenge stability by MLF and DnaJ-1. It 
would be best if we could isolate and purify sufficient amounts of LZ+ cells from 
Drosophila embryos or larvae to perform these experiments, or if we could obtain a cell line 
that contains endogenous MLF level equivalent to those observed in vivo in crystal cells. 
 
        We have revealed that MLF and DnaJ-1 interact with each other via their highly 
evolutionarily conserved domains and that Lozenge also associates with each one of them, 
establishing a functional link between RUNX transcription factors and the Hsp70 chaperone 
complex formed by MLF, DnaJ-1 and Hsc70-4. Based on our study of RUNX1 regulation 
in Kc167 cells, we propose that a complex homologous to the MLF/DnaJB/Hsc70 complex 
could regulate the stability of RUNX in human. More generally, it seems that MLF1 and 
MLF2 could regulate the Hsp70 chaperone machinery in human. Hence, besides their 
impact on RUNX transcription factors, it will be interesting to identify other proteins whose 
stability/activity is regulated by MLF and DnaJ and that could be implicated for instance in 
neurodegenerative diseases, in which these two families of proteins are involved. This 
would provide valuable insights into the molecular mechanism of action of MLF and DnaJ 
protein families in normal development and in pathological situations.  
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